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EPIDITHIODIOXOPIPERAZINES: SYNTHETIC STUDIES OF 
(+)-CHETOMIN AND (–)-SPORIDESMIN A  
 
 This dissertation documents efforts toward the asymmetric total syntheses of the 
natural products (+)-chetomin and (–)-sporidesmin A. Synthetic methods have been 
developed to efficiently construct the dioxopiperazine core of both molecules. 
Additionally, a simple epidithiodioxopiperazine has been synthesized to demonstrate a 
general method for the addition of a sulfur bridge to a dioxopiperazine ring. The work 
described herein, while not totally successful, provides a basis for future completion of 
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Nearly twenty distinct families of epidithiodioxopiperazine fungal metabolites 
have been characterized since the seminal discovery of gliotoxin in 1936. This unique 
class of natural products is characterized by a sulfur-bridged dioxopiperazine (1.1), a 
feature generally requisite for the potent biological activity prevalent among the class.1-5  
 
All natural epidithiodioxopiperazines discovered to date contain at least one 
aromatic amino acid. Representative molecules from each family to be discussed are 
shown in Figure 1.1 (tyrosine- and/or phenylalanine-derived) and Figure 1.2 
(tryptophan-derived). In this chapter, we present an overview of the structures of 
naturally occurring epidithiodioxopiperazines, relevant physiological properties, and 














Figure 1.1. Epidithiodioxopiperazines derived from tyrosine and/or 
phenylalanine. 
 
 Figure 1.2. Tryptophan-derived epidithiodioxopiperazines. 



















































































































































































































1.2: Epidithiodioxopiperazines Derived from Phenylalanine or Tyrosine 
 In 1936, a novel substance with substantial antifungal and antiviral activity was 
isolated from the wood fungus Gliocladium fimbriatum by Weindling and Emerson.6 A 
putative structure (1.16, Figure 1.3) was proposed for the metabolite based on 
degradation studies. This structure, however, could not account for some experimental 
observations, leading Johnson and Woodward to propose a revised structure for gliotoxin 
(1.2) in 1958.7 Absolute stereochemistry was later determined by x-ray analysis.8 
Gliotoxin and related metabolites (Figure 1.3) have since been isolated from a variety of 
fungi—including several Penicillium and Aspergillus species, Gliocladium, 
Thermoascus, and Candida—and have been the focus of numerous synthetic and 
biosynthetic studies that have formed the basis for much of the research discussed 
herein.2,3 
 
 Figure 1.3. Gliotoxins. 
 The initial interest in the chemotherapeutic potential of gliotoxin as an antifungal 
or antiviral agent waned as in vivo studies revealed gliotoxin to be generally cytotoxic.9 




















































the main source of invasive aspergillosis and leading cause of death in 
immunocompromised patients.10 However, interest in the molecule was renewed when it 
was discovered that gliotoxin displayed selective toxicity to cells of the hematopoietic 
system.11,12 Specifically, gliotoxin exhibits antiproliferative activity against T and B cells 
and inhibits phagocytic activity with considerable selectivity toward immune system 
cells, leading to promising studies that have demonstrated that gliotoxin prevents graft-
versus-host disease after bone marrow transplantation.13  
 Generally, the toxicity of gliotoxin and other epidithiodioxopiperazines can be 
attributed to two mechanisms: generation of reactive oxygen species (Figure 1.4) and 
mixed disulfide formation (Figure 1.5). In the presence of a suitable reducing agent such 
as glutathione or dithiothreitol, epidithiodioxopiperazines are reduced to the 
corresponding dithiols (1.23). Autooxidation back to the disulfide (1.1) occurs with the 
production of superoxide ions and hydrogen peroxide, known to cause oxidative damage 
to cells.14,15 Gliotoxin has specifically been shown to induce single- and double-stranded 
DNA damage in the presence of glutathione, presumably by hydroxyl radicals generated 
in this redox process.16  
 
Figure 1.4. Redox cycling of epidithiodioxopiperazines. 
 Evidence suggests that gliotoxin and other epidithiodioxopiperazines are also 




























incubation with radiolabelled gliotoxin, cells were shown to contain protein-bound [35S]-
gliotoxin (1.24).3 This result could be reversed if cells were treated with both gliotoxin 
and excess reducing agent (dithiothreitol), suggesting a covalent interaction. Moreover, 
the antiviral activity of gliotoxin is lost in the presence of excess dithiothreitol. This 
evidence supports a mechanism of toxicity resulting from mixed disulfide formation 
between gliotoxin and protein.19 
 
 Figure 1.5. Mixed disulfide formation. 
 Toxicity of epidithiodioxopiperazines would seem to rely on an intact disulfide 
ring or the reduced dithiol. Indeed, dethiogliotoxin lacks the antibacterial activity of 
gliotoxin. Reduction and methylation of the disulfide bridge 
(bisdethiodi(methylthio)gliotoxin, 1.19) also results in a loss of antiviral activity.4,20 Not 
surprisingly, the simple disulfide 1.25 and dithiol 1.26 exhibit potent biological activity, 
highlighting the importance of the fragment to the observed toxicity of 
epidithiodioxopiperazines.21 The great structural diversity in epidithiodioxopiperazines 
may have evolved only to mask the core disulfide moiety to prevent degradation by target 




















 Figure 1.6. Simple biologically active epidithiodioxopiperazines. 
 Like gliotoxin, the hyalodendrins (Figure 1.7) are derived naturally from 
phenylalanine and serine. Hyalodendrin (1.3) was originally isolated by Strunz in 1974 
from Hyalodendron sp.22 The same fungus was later shown to produce the 
bis(methylthio) derivative (1.29)23 and epitetrasulfide 1.28.24 Epitrithiohyalodendrin 
(1.27) has only been observed as a product of the unidentified fungus NRRL 3888, along 
with 1.3 and 1.29.25 Not surprisingly, hyalodendrin and the epitri- and epitetrasulfide 
derivatives exhibit antibacterial activity, while the bisdethiodi(methylthio) analogue is 
inactive against fungi and bacteria and relatively non-toxic to mice.22-25 Interestingly, it 
was observed that hyalodendrin could be converted to epitetrasulfide 1.28 in the presence 
of HCl with heating in methanol and the culture medium. Racemic tetrasulfide was 
isolated when HCl was omitted from the same conditions.  
Enantiomers of the hyalodendrins (except for epitrisulfide 1.27) have been 
isolated from both terrestrial and marine sources. Gliovictin (1.32) was first isolated from 
Helminthosporium victoriae in 1974,26 the same year that researchers at Eli Lilly reported 
the isolation of the same structure (named A26771E) along with the disulfide (A26771A, 
1.30) and epitetrasulfide (A26771C, 1.31) from Penicillium turbatum.27 Fenical has also 
isolated gliovictin from the marine deuteromycete Asteromyces cruciatus.28 Predictably, 
1.30 and 1.31 both showed antiviral and antibacterial activity, while gliovictin–lacking 





















 Figure 1.7. Hyalodendrins and related compounds. 
 Kawahara and coworkers reported the isolation of dithiosilvatin (1.4) and 
silvathione (1.33) in 1987 from Apergillus silvaticus (Figure 1.8).29 
Dioxopiperazinethiones such as 1.33 are rare and are possible intermediates in the 
formation of trioxopiperazines from epidithiodioxopiperazines. The authors reported the 
conversion of 1.4 to the bisdethiodi(methylthio) derivative (1.34) by reductive 
methylation (NaBH4, MeI), a compound previously isolated by Hanson and O’Leary 
from Gliocladium deliquescens.30 
 
 Figure 1.8. Silvatins. 
 The next subgroup of epidithiodioxopiperazines to be discussed is characterized 












































































aranotins (Figure 1.9), emethallicins (Figure 1.10), and emestrins (Figure 1.11). 
Aranotin (1.5) and acetylaranotin (1.35) have been isolated from Arachniotus aureus and 
Aspergillus terreus and exhibit antiviral activity that is apparently selective for RNA 
viruses such as the polio, Coxsackie (A21), rhino-, and parainfluenza viruses through 
inhibition of viral RNA synthesis.31-37 Structurally, the aranotins are related to gliotoxin, 
with the similarities most evident in apoaranotin (1.37). Apoaranotin can be considered a 
chimera of gliotoxin and aranotin, containing the cyclohexadienol of gliotoxin and the 
dihydrooxepine ring of aranotin. Asteroxepin (1.39) was the first monooxepine derivative 
to be isolated and is further unique in that it contains one unsubstituted amide. This 
dioxopiperazine may provide evidence for the sequence of steps in the biosynthesis of the 
more complex aranotins. 
 
 Figure 1.9. Aranotins. 
 Closely related to the aranotins are the emethallicins (Figure 1.10). Both families 
share the same absolute stereochemistry, and emethallicin A (1.6) differs apoaranotin 
(1.37) only in the ester moieties. This observation was experimentally confirmed by 





































































occurring apoaranotin.38 Emethallicins B, D, and F (1.40, 1.42, and 1.44) share this same 
monooxepine core and differ apoaranotin only in ester substitution and sulfur content of 
the epipolythiodioxopiperazine ring. Emethallicin C (1.41) is symmetrical and the only 
emethallicin to contain two dihydrooxepine rings, more closely resembling aranotin and 
acetylaranotin. 
 
 Figure 1.10. Emethallicins. 
Emethallicin A (1.6) was first isolated from Emericella heterothallica in 1989 by 
Kawai and coworkers, who later reported the isolation of emethallicins B-F (1.40-1.44) 
from the same fungus.38-41 Interestingly, Kawai was unable to convert synthetic 
emethallicin D monoacetate (1.42, R=Ac) to the naturally occurring metabolite (1.42, 













































































tetrasulfide monoacetates of 1.6 and 1.40, respectively.39 This disproportionation of the 
trisulfide is similar to a result obtained by Waring and coworkers, who similarly 
converted trisulfide gliotoxin E (1.21) to the disulfide, gliotoxin (1.2), and the 
tetrasulfide, gliotoxin G (1.22).42  
All of the emethallicins exhibit fairly strong inhibitory activities upon histamine 
release from mast cells, with IC50 values ranging from 1.0 x 10-6 to 2.0 x 10-8 M. 
Generally, activity is stronger for the original emethallicins than for the acetate 
derivatives. Micromolar inhibition of 5-lipoxygenase has also been reported.43 
The final class of known epipolythiodioxopiperazine metabolites known to 
contain at least one dihydrooxepine ring is the macrocyclic emestrins (Figure 1.11). 
Emestrin (1.7) was isolated in 1985 from the fungus Emericella striata, and later from E. 
quadrilineata, E. foveolata, E. acristata, and E. parvathecia.44-46 Trisulfide emestrin B 
(1.45), piperazinethione aurantioemestrin (1.47), and trioxopiperazine dethiosecoemestrin 
(1.48) were later isolated from E. striata.46-49 It has been postulated that the latter two 
compounds are derived biosynthetically from emestrin. Emestrin displays potent 
antifungal and antibacterial activity, but is also very toxic to mammals. 
Recently, Kanda and coworkers reported the isolation of MPC1001 (1.46) and its 
analogues (not shown) from Cladorrhinum sp. KY4922, contributing eight new members 
to the emestrin family of natural products.50 MPC1001 contains a methoxy group rather 
than the free phenol found in emestrin, but is otherwise structurally and stereochemically 
identical. MPC1001 and its epipolysulfide analogues all showed antiproliferative activity 
in the DU145 human prostate cancer cell line.50 
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 Figure 1.11. Emestrins and related metabolites. 
 Epicorazines (Figure 1.12) have been isolated from several organisms, including 
Epicoccum nigrum (epicorazine A and B, 1.8 and 1.49),51-53 E. purpurascens (epicorazine 
B),54 and Stereum hirsutum (epicorazine C, 1.50).55 The only difference between 1.8 and 
1.49 is the absolute stereochemistry at C6. This cis configuration is shared between 1.49 
and 1.50. 
 
 Figure 1.12. Epicorazines. 
 Epicorazine A, B, and C display only marginal activity against Gram-positive 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and 
















































































































negative organisms. All three exhibit antiproliferative effects against L929 mouse 
fibroblast cells and K562 human leukemia cells, as well as cytotoxicity toward the HeLa 
human cervical carcinoma cell line.55 
 The scabrosin esters were originally isolated from the lichen Xanthoparmelia 
scabrosa in 1978, but it was not until 1999 that the correct structures were determined 
(Figure 1.13).56,57 The isolation of these compounds was of particular interest, as this 
report marked the first epidithiodioxopiperazine to be isolated from lichenized fungi. 
Submicromolar activity, similar to that of gliotoxin (1.2), was observed for the scabrosins 
against the murine P815 mastocytomia cell line, as well as low nanomolar activity in 
MCF7 human breast carcinoma cell line. Scabrosin esters have also been shown to induce 
apoptosis concomitantly with a large increase in mitochondrial membrane potential and 
significant decrease in total cellular ATP. Mitochondrial ATP synthase is the proposed 
cellular target of the scabrosins.58 
 
 Figure 1.13. Scabrosin esters. 
 The sirodesmins (Figure 1.14) were first discovered in 1977 as metabolites of 
Sirodesmium diversum59 and later from the unrelated fungus Phoma lingam.60 
Sirodesmins A-H (1.10, 1.56-1.60) are characterized by a spirofused tetrahydrofuran 
cyclopentylpyrrolidine skeleton. Sirodesmins A-C are epimers of G and H at the 








scabrosin ester 1 (R1=CH3,   R2=CH3,     1.9)
scabrosin ester 2 (R1=CH3,   R2=C3H7,   1.52)
scabrosin ester 3 (R1=C3H7, R2=C3H7,   1.53)
scabrosin ester 4 (R1=CH3,   R2=C5H11, 1.54)












 Figure 1.14. Sirodesmins. 
Sirodesmins are potent antiviral agents, particularly against the rhinovirus.59 
Sirodesmin G (originally named sirodesmin PL, 1.58) has specifically been shown to 
exhibit activity against Gram-positive bacteria,61 although it has also been implicated as 
the causative agent of blackleg disease in canola crops (along with phomalirazine, 1.61). 
Metabolites 1.58 and 1.61 have both been isolated from the ascomycetous fungus 
Leptosphaeria maculans, the organism known to be responsible for blackleg disease.62 
 
1.3: Tryptophan–Derived Epidithiodioxopiperazines 
 The remaining epidithiodioxopiperazine alkaloids to be discussed are all derived 
from tryptophan (Figure 1.2). Of this subset, the sporidesmins (Figure 1.15) are the most 






















































































desacetyl-sirodesmin PL (1.59)sirodesmin G 
(sirodesmin PL, 1.58)





















Sporidesmin was discovered by researchers investigating the source of the disease facial 
eczema that plagued sheep in New Zealand and Australia. The disease caused extensive 
liver damage in infected sheep and ultimately resulted in death. Thornton and Percival 
eventually established that ingestion of pasture grasses on which the fungus Pithomyces 
chartarum (previously known as Sporidesmium bakeri) was growing was the cause of the 
serious disease.63,64 Sporidesmin (1.11) was isolated and implicated as the main toxic 
agent produced by P. chartarum.65 The structure and absolute configuration were 
subsequently determined by crystallographic means.8,66,67  
 As an interesting aside, veterinarians discovered that zinc sulfate doses gave 
sheep protection from the effects of sporidesmin.68 Transition metals such as zinc are 
now known to inhibit generation of the superoxide anion radical, with 
epidithiodioxopiperazines shown to form a 2:1 complex with zinc ion.69,70 
Extensive amounts of research have focused on the sporidesmins, producing the 
complete characterization of all nine derivatives (1.11, 1.62-1.69). All contain a densely 
functionalized, tryptophan–derived pyrroloindoline core coupled to an alanine residue. 
Sporidesmin C (1.63)71 is the most unusual, containing a novel trisulfide [4.3.3] ring 
system.  
 A great deal of chemistry applicable to most of the epipolythiodioxopiperazines 
was discovered through investigations of the sporidesmins. For example, the trisulfide 
sporidesmin E (1.65) is readily converted to the disulfide (1.11) upon treatment with 
triphenyl phosphine. Alternatively, di- and trisulfides can be converted to tetrasulfides, 
achieved using hydrogen polysulfide or dihydrogen disulfide. This was demonstrated by 
the conversion of sporidesmins A (1.11) and E (1.65) into sporidesmin G (1.67). 
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 Figure 1.15. Sporidesmins. 
In 1944, Waksman and Bugie reported the isolation of a new antibiotic metabolite 
of the fungus Chaetomium cochliodes that they named chetomin.72 It was not until 30 
years later that Walter and coworkers determined the structure of chetomin (1.12), 
revealing a nearly dimeric core likely formed from two molecules each of tryptophan and 
serine.73 The two fragments are joined by a bond between the β-pyrrolidinoindoline 
carbon and the indole nitrogen, a common feature of all five chaetocins (Figure 1.16).74 
Chetomin is the only molecule in the family to contain a disulfide bridge within both 
dioxopiperazine rings. Dethio-tetra(methylthio)chetomin (1.70) and chaetocochin C 
(1.73) differ only in the oxidation state of the sulfurs, while chaetocochins A (1.71) and B 























































































































sporidesmin J (1.69)sporidesmin H (1.68)
sporidesmin F (1.66)sporidesmin D (1.64)
sporidesmin C (1.63)sporidesmin B (1.62)sporidesmin A (1.11)
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 Figure 1.16. Metabolites of the fungus Chaetomium cochliodes. 
 Chetomin was recently isolated from Chaetomium seminudum by Fujimoto and 
coworkers in 2004, along with three new metabolites named the chetoseminudins (Figure 
1.17).75 Chetoseminudin A (1.74) is merely the pentasulfide homolog of chetomin. From 
a biosynthetic viewpoint, the more interesting discoveries are chetoseminudins B-D 
(1.75-1.77), monomeric bisdethiodi(methylthio) structures that potentially provide insight 
as to the biosynthetic sequence that produces chetomin, the chaetocochins, and other 
related epipolythiodioxopiperazines derived from tryptophan and serine. 
 
 Figure 1.17. Chetoseminudins. 
Chetomin (1.12) has an unprecedented mechanism of action as a cancer 
























































































































chetoseminudin B (1.75) chetoseminudin C (R=H, 1.76)
chetoseminudin D (R=Ac, 1.77)
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induction of the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1) in 
order to survive. Overexpression of HIF-1 is associated with radioresistance in tumors, 
increased risk of metastasis, and a poor prognosis for patients.76-78 In normal cells, the !-
subunit of HIF-1 (HIF-1!) is hydroxylated and degraded by vHL proteosome (Figure 
1.18). As oxygen levels decrease and become the rate-limiting reagent in the 
hydroxylation reaction, HIF-1! accumulates and binds to transcriptional coactivators 
p300 and CREB binding protein (CBP). Consequent to this binding is the transcription of 
proteins requisite to the survival of hypoxic cancer cells, facilitating tumor growth and 
progression.79  
Figure 1.18. HIF-1 hypoxia response pathway. 
Chetomin has been shown to inhibit the interaction between HIF-1 and p300 both 
in vitro and in cells, despite extensive surface interactions between the two proteins. 
Specifically, Kung and coworkers have shown that chetomin disrupts the tertiary 
structure of p300, inhibiting the transcriptional activity of HIF-1.76 No other small 
molecule has been identified to mediate an antitumor response through this mechanism of 


























epidithiodioxopiperazines bind zinc at the CH1 domain of p300, ultimately resulting in 
ejection of a stable zinc–epidithiodioxopiperazine complex. Loss of zinc from the CH1 
domain causes the previously observed disruption of the p300 tertiary structure.1,80    
 Chaetocin A (1.13, Figure 1.19) is a dimeric epidithiodioxopiperazine also 
derived from two molecules each of tryptophan and serine. It was isolated from 
Chaetomium minutum in 1970.81,82 Fifteen years passed before the penta- and hexasulfide 
homologs chaetocin B and C (1.78 and 1.79) were isolated from Chaetomium spp., along 
with the novel tetrasulfide chetracin A (1.80).83 In 2012, several related metabolites were 
isolated from Oidiodendron truncatum, including the tetra-, penta- and hexasulfide 
homologs melinacidin IV, chetracins B and C (1.82, 1.83, and 1.84), and the 
dethiotetra(methylthio) derivative chetracin D (1.81).84  
The three chaetocin metabolites (and likely the chetracins) can be interconverted 
through either desulfurization of 1.78 and 1.79 with triphenyl phosphine to generate 
chaetocin (1.13), or by sulfurization of chaetocin with phosphorus pentasulfide in carbon 
disulfide to afford a mixture of chaetocins B and C.83  
Recently, chaetocin A was identified as the first known inhibitor of lysine-specific 
histone methyltransferases.85 Histone methylation is an important process in controlling 
gene expression patterns, especially during cellular differentiation and embryonic 
development. The activity of histone methyltransferases is disregulated in some tumors, 
making chaetocin an attractive tool for the study of the molecular mechanism of histone 
methylation.85 Additionally, melinacidin IV and chetracin B display nanomolar (3 – 54 




 Figure 1.19. Chaetocins and related metabolites. 
 Several metabolites related to the chaetocins have recently been reported, 
possessing a C3-C3’ linkage to indole rather than the additional monomer found in the 
chaetocins (Figure 1.20). T988 A, B, and C (1.86-1.88) were originally isolated from 
Tilachlidium sp., although recently it was shown that Oidiodendron truncatum also 
produces the same metabolites, in addition to oidioperazine A (1.89) and the chetracins 
(1.83-1.85).75,86 Chetoseminudin C (1.76) was also isolated from O. truncatum, 
suggesting that it may be a common intermediate to all of the tryptophan- and serine-
derived epipolythiodioxopiperazines discussed thus far. T988 A and B are cytotoxic to 




























































































melinacidin IV (x=y=2, 1.82)
chetracin B (x=2, y=3, 1.83)



































 Figure 1.20. Fungal metabolites related to the chaetocins. 
 Verticillin A (1.14, Figure 1.21) is quite similar to chaetocin A (1.13), derived 
from two molecules of alanine rather than serine. Only verticillins A, D and E (1.14, 1.92 
and 1.93) are symmetrical, while the two tryptophan residues of the remaining verticillins 
are coupled to different amino acids on the two halves (either alanine, serine, or tyrosine). 
Verticillin B (1.90), for instance, contains alanine and serine residues on the northern and 
southern halves of the molecule, respectively. Verticillins A-C were isolated from 
Verticillium sp., while the remaining compounds in Figure 1.21 are produced by 
Gliocladium sp.87-89 
 
 Figure 1.21. Verticillin A and related metabolites. 
 Gliocladines A-E (Figure 1.22, 1.97-1.101) were isolated in 2005 from 
Gliocladium roseum, along with verticillin A, Sch52900, and Sch52901 (1.14, 1.95, and 
1.96).90 Gliocaldines A and B are simply the penta- and hexasulfide homologs of 
verticillin A, thus it is not surprising that the same organism produces all three 



















































































NH verticillin B (R1=CH3, R2=CH2OH, 1.90)
verticillin C (R1=CH3, R2=CH2OH, S5 homolog 1.91)
verticillin D (R1=CH(OH)CH3, R2=CH(OH)CH3, 1.92)
verticillin E (R1=COCH3, R2=COCH3, 1.93)
verticillin F (R1=COCH3, R2=CH(OH)CH3, 1.94)
Sch52900 (R1=CH(OH)CH3, R2=CH3, 1.95)




familiar, as they are the alanine derivatives of T988 A and C (Figure 1.20). Bionectra 
byssicola F120 has also been shown to produce bionectins A and B (1.102, 1.103), the 
glycine and tyrosine derivatives of T988C.91 
 
 Figure 1.22. Verticillin-type epipolythiodioxopiperazines. 
 The dimeric subset of epipolythiodioxopiperazines increased greatly in number 
with the discovery of the leptosins (Figure 1.23) from a strain of Leptosphaeria sp. 
attached to the marine alga Sargassum tortile.92-94 Leptosins A-K (1.104-1.118) all 
contain at least one valine residue, a feature unique among all 
epipolythiodioxopiperazines to this family. Leptosins A-C, G, H, and K (1.104-1.113) 
share the 12,12’-dihydroxylated, octacyclic core of the verticillins, gliocladines, and 
chetracins. The C3-C3’ linkage to indole is once again produced in leptosins D-F (1.114-
1.116), the valine derivatives of the T988s, gliocladines C-E, and the bionectins. In 1994, 
two remarkable additions to this family were discovered, the epimers leptosin I and J 
(1.117 and 1.118).94 These two compounds are characterized by a C12-C11’ ether 
linkage, introducing an additional ring to the structure that prohibits the possibility of 



















gliocladine A (x=3, 1.97)
gliocladine B (x=4, 1.98)












gliocladine C (x=2, 1.99)
gliocladine D (x=3, 1.100)












bionectin A (R=H, 1.102)






 Figure 1.23. Leptosins. 
 In summary, over 100 epipolythiodioxopiperazine alkaloids have been isolated 
and characterized to date. While this was intended to be a comprehensive review of all 
known members of this class of natural products, some were undoubtedly and 
inadvertently omitted. One cannot help but marvel at the remarkable biological activity of 
the class as a whole, although it is unlikely that any epipolythiodioxopiperazine will ever 
achieve therapeutic utility in the clinic due to the general cytotoxicity inherent in the 
disulfide through mechanisms discussed above. Certainly others have and will continue 
to argue otherwise, but it is our opinion that the true contribution to medicine will be 
realized by employing epipolythiodioxopiperazines as tools for the study of novel 
biological pathways. To date, the natural products chetomin (1.12), gliotoxin (1.2), and 
chaetocin A (1.13) have already contributed to our understanding of the respective 
















leptosin A   (x=4, y=2, 1.104)
leptosin B   (x=3, y=2, 1.105)
leptosin C   (x=2, y=2, 1.106)
leptosin G   (x=4, y=3, 1.107)
leptosin G1 (x=3, y=3, 1.108)
leptosin G2 (x=2, y=3, 1.109)





















leptosin K   (x=2, 1.111)
leptosin K1 (x=3, 1.112)




















leptosin I  (R1=CH2OH, R2=H, 1.117)













leptosin D (x=2, 1.114)
leptosin E (x=3, 1.115)






 Many of the families (particularly those containing a C3-C3’ indoline linkage) 
share a great deal of structural similarity beyond the epipolythiodioxopiperazine moiety 
that defines the class. It is likely that hundreds of additional variants exist in nature and 
have yet to be discovered. While numerous biosynthetic studies have been conducted, we 
still have only a limited understanding of the ease with which nature is able to assemble 
epipolythiodioxopiperazines, molecules that have for over fifty years taunted synthetic 
chemists. In the last section of this chapter, we present the notable biosynthetic 
discoveries reported to date. 
 
1.4: Biosynthetic Investigations of Epidithiodioxopiperazines 
 Researchers have investigated the biosynthesis of gliotoxin (1.2) for nearly forty-
five years, but still very little experimental evidence exists to support the numerous 
proposals. In 1958 and 1960, Suhadolnik reported the only undisputed incorporation 
study, demonstrating that Trichoderma viride incorporates isotopically labeled 
phenylalanine (1.119) and serine (1.120) into gliotoxin (Scheme 1.1).95,96 Walsh recently 
implicated the nonribosomal peptide synthetase GliP in the catalysis of the peptide 
coupling and dioxopiperazine cyclization reactions.97 Some debate has occurred as to 
whether cyclo-Phe-Ser (1.121) is a biosynthetic intermediate to gliotoxin. Although 
doubly labeled 1.121 is incorporated into gliotoxin by T. viride, the fungus Penicillium 
terlikowskii poorly incorporates the same compound.98-100 Walsh observed that release of 
the dioxopiperazine from the enzyme is slow, allowing for some speculation that further 
transformations may occur to the enzyme bound compound prior to release. 
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  Scheme 1.1. Proposed biosynthesis of gliotoxin. 
 Arene oxide 1.122 was proposed as a biosynthetic intermediate to both the 
gliotoxins and aranotins by Neuss in 1968. Cyclization at the ortho position provides the 
tricyclic core of gliotoxin (1.123), whereas a ring enlarging tautomerization of the arene 
oxide could give the oxepine ring (1.129) characteristic of the aranotins (Scheme 
1.2).33,34 
 






































































































































 The incorporation of sulfur into epidithiodioxopiperazines was until recently 
poorly understood. Sulfur transfer readily occurs among various potential donors, 
including methionine, cysteine, and sodium sulfate, complicating [35S] feeding 
studies.2,101 In 2011, two groups independently provided evidence supporting a GliC–
mediated bishydroxylation of a dioxopiperazine (i.e. 1.123 to 1.124).102,103 Elimination of 
water to generate diiminium 1.125 could be followed by nucleophilic attack of the 
cysteine thiolate residues of two glutathione (GSH) molecules, catalyzed by the 
specialized glutathione S-transferase GliG.102-104 Sequential GliJ peptidase and GliI 
thioesterase activity is proposed to reveal the free dithiol.102 Scharf and coworkers have 
unequivocally shown that GliT catalyzes the oxidation to the disulfide (i.e. 1.128), 
leaving N-methylation to complete the biosynthesis of gliotoxin.105 The order of tailoring 
events is up for debate, but recent advances in genomics and proteomics tools to study 
and manipulate secondary metabolite production will certainly produce much more 
accurate insight as to the formation of gliotoxin in nature. 
 Recall that the toxicity of epidithiodioxopiperazines generally arises from redox 
cycling or mixed disulfide formation (Figures 1.4 and 1.5). How is it then that producing 
fungi, such as Aspergillus fumigatus, are immune to toxicity inherent in the structure of 
gliotoxin? Several studies published in the last two years have provided convincing 
evidence that GliT is responsible for the self-resistance of A. fumigatus to gliotoxin.105,106 
Deletion of the gliT gene renders A. fumigatus mutants highly sensitive to gliotoxin, 
toxicity that can be reversed by addition of glutathione. Moreover, concentrations of 
reduced gliotoxin increase with the concomitant depletion of intracellular glutathione 
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levels. It is likely that alterations of the cellular redox status and mixed disulfide 
formation contributes to the growth inhibition observed in the absence of gliT.  
Perhaps the cytotoxicity of gliotoxin is an indirect consequence of the true role of 
gliotoxin and other epidithiodioxopiperazines produced by fungi. The same redox cycling 
that produces deleterious consequences in naïve organisms may, in Aspergillus 
fumigatus, serve as a buffer against cellular oxidative stress.106 Gliotoxin and other 
epidithiodioxopiperazines may have evolved as simple antioxidants, with the host 
protected from unwanted redox cycling and mixed disulfide formation by GliT. 
Sirodesmin PL (1.58) is the only other epidithiodioxopiperazine to have been 
extensively studied from a biosynthetic perspective. Putative biosynthetic gene clusters 
for sirodesmin and gliotoxin identified from Leptosphaeria maculans and Aspergillus 
fumigatus, respectively, are given in Figure 1.24.107-109 Based on recent advances to our 
understanding of gliotoxin biosynthesis and the identification of homologs in the 
sirodesmin gene cluster, we are able to predict many of the experimentally unverified 
steps in the biosynthesis of sirodesmin PL (Scheme 1.3). 
Figure 1.24. Putative epidithiodioxopiperazine gene clusters for sirodemsin PL 
(A) and gliotoxin (B).109 
Feeding studies have shown that Leptosphaeria maculans incorporate labeled 
tyrosine and serine into both sirodesmin PL (1.58) and presumed intermediate 
phomamide (1.132).59,110-112 We propose the incorporation of sulfur to proceed 
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analogously to the gliotoxin biosynthesis, through dihydroxylation (1.133), imine 
formation, and glutathione addition (1.134). Unmasking of the dithiol (1.135) and 
oxidation to the disulfide (1.136) could be followed by oxidation and Claisen 
rearrangement to give 1.137, which after cyclization and oxidation provides known L. 
maculans metabolite phomalirazine (1.61).59,111 Oxidative spirorearrangement, N-
methylation, and ketone reduction would lead to another known metabolite, desacetyl-
sirodemin PL (1.59). Acetylation by SirH would complete the biosynthesis of sirodesmin 
PL (1.58).2,65,107,109  
 



























































































































1.5: Concluding Remarks 
 Epidithiodioxopiperazine alkaloids possess an astonishing array of molecular 
architecture that has for decades challenged and inspired synthetic chemists. Biosynthetic 
studies presented in this chapter provide a glimpse at the efficiency and elegance with 
which Nature is able to assemble these compounds. Synthetic chemists strive to mimic 
and in turn better understand the mechanisms by which microorganisms are able to 
produce such complexity, hoping to channel some of Nature’s efficiency into novel 
synthetic pathways. In the next chapter, we present many of the synthetic advances made 




Total Syntheses of Epidithiodioxopiperazines 
 
2.1: Introduction  
 Over 100 naturally occurring epidithiodioxopiperazines have been isolated. 
However, relatively few have succumbed to total synthesis despite decades of effort, 
highlighting the challenging synthetic nature of the class of molecules. Initial interest in 
the biological activity of epidithiodioxopiperazines sparked the synthetic interest of 
several groups, with six different naturally occurring members of the class yielding to 
synthetic chemists between 1973 and 1981. Three decades passed before renewed interest 
in epidithiodioxopiperazines arose, sparked by isolation reports of new metabolites, 
exciting results from the biological community detailing novel mechanisms of action in 
cells, and advances in genomics that invigorated interest in elucidating the biosynthesis 
of these secondary metabolites. Between 2009 and 2012 alone, syntheses of eight 
additional epidithiodioxopiperazine alkaloids have been reported. A casual glance 
through Chapter 1 is enough to impress upon the reader the great degree of structural 
similarity shared among and between families of epidithiodioxopiperazines. We 
anticipate that in the coming decade total syntheses of entire families of this class of 
fungal metabolites will be completed concomitantly with great advances in synthetic 
methods and biosynthetic understanding. In this chapter, we present a comprehensive 
review of total syntheses of epidithiodioxopiperazines. 
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2.2: Early Epidithiodioxopiperazine Syntheses (1973-1981) 
The total synthesis of sporidesmin A was completed by Kishi and coworkers in 
1973. In a series of communications Kishi described a novel strategy for the synthesis of 
epidithiodioxopiperazines using a dithioacetal moiety as a protecting group for the 
disulfide bridge.113-115 Thus protected, the dithioacetal is stable to acidic, basic, and 
reducing conditions, allowing for the introduction of thiol groups at an early stage in a 
total synthesis. Synthesis of the sporidesmins began with the treatment of 
dioxopiperazine 2.1 with the dithiane derivative of p-anisaldehyde in the presence of acid 
to afford dithioacetal-protected dioxopiperazine 2.2 (Scheme 2.1).113 Condensation with 
acid chloride 2.3 and subsequent methoxymethyl deprotection gave compound 2.4. 
Treatment of ketone 2.4 with DIBAL-H at -78 °C resulted in stereoselective reduction to 
the alcohol, which was then converted into acetate 2.5 in 80% yield. Cyclization to the 
diacetate (2.6) proceeded upon addition of iodosobenzene diacetate, and hydrolysis of the 
acetates gave the corresponding diol. Treatment of the diol with m-chloroperbenzoic acid 
(mCPBA) afforded an intermediate sulfoxide, which decomposed to the disulfide upon 
exposure to strong Lewis acid, revealing (±)-sporidesmin A (1.11). 
Intermediate 2.5 was also used by Kishi in a total synthesis of (±)-sporidesmin B 
(Scheme 2.2).116 Reduction of the acetate gave the methylene (2.7), which underwent an 
oxidative cyclization similar to that reported in the sporidesmin A synthesis to benzoate 
2.8. The disulfide was revealed as described above, completing the synthesis of (±)-
sporidesmin B (1.62). 
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 Scheme 2.1. Total synthesis of (±)-sporidesmin A. 
 
 Scheme 2.2. Synthesis of (±)-sporidesmin B. 
Fukuyama and Kishi reported the first synthesis of dehydrogliotoxin (1.18, 
Scheme 2.3) in 1973.114 Benzoic acid derivative 2.10 was coupled to dioxopiperazine 2.9 
and treated with diazomethane to give methyl ester 2.11. Radical bromination with NBS 
and benzoyl peroxide was followed by treatment with potassium thioacetate to give 




































































































































































and boron trifluoride etherate gave a 1:1 diasteromeric mixture of thioacetals 2.13 in 
good yield. This masked disulfide is stable to a variety of conditions that the disulfide 
would not otherwise survive, allowing Kishi to introduce sulfur at an early stage in the 
synthesis. 
 
 Scheme 2.3. Synthesis of (±)-dehydrogliotoxin. 
A three-step conversion to the primary chloride (2.14) was followed by addition 
of phenyllithium to affect cyclization on the desired bridgehead carbon in 79% yield 
(2.15). Addition of phenyllithium with benzyl chloromethyl ether efficiently installed the 
benzyl protected serine side chain (2.16). Cleavage of the benzyl and methyl ethers and 
conversion to the epidithiodioxopiperazine gave (±)-dehydrogliotoxin (1.18). 
The biosynthesis of gliotoxin (1.2) is believed to proceed through the 
intramolecular nucleophilic ring-opening of a phenylalanine-derived arene oxide (1.122) 
and has been the subject of considerable speculation and interest. Kishi and coworkers 
drew inspiration from this biogenetic hypothesis in devising a brilliant total synthesis of 
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disulfide protecting strategy as employed above for the sporidesmins, and was re-
engineered in 1981 by the same route starting from optically pure dithioacetal 2.17 
obtained from resolution (Scheme 2.4).117,118 Coupling of 2.17 with t-butoxy arene oxide 
2.18 in the presence of triton B afforded 2.19 and 2.20 in a 2 :1 ratio. Acetylation, 
deprotection, mixed anhydride formation, and reduction gave alcohol 2.21 in 77% yield 
from 2.19. Primary alcohol 2.21 was converted to the chloride following mesylation, and 
the secondary ester deprotected to reveal alcohol 2.22. The key stereoselective 
cyclization-alkylation reaction was achieved upon addition of phenyllithium to 2.22 and 
benzoxymethyl chloride, affording cycloadduct 2.23 in modest yield (53%). The primary 
alcohol was revealed upon removal of the benzyl group, and the thioacetal oxidatively 
removed to afford either (±)- or (+)-gliotoxin (1.2). 
 
 Scheme 2.4. Synthesis of (+)-gliotoxin. 
 Strunz and Kakushima followed the precedent set by Kishi and completed a total 









































































sequentially with chloromethyl methyl ether and benzyl bromide, then deprotected to 
reveal hyalodendrin (1.3). 
 
 Scheme 2.5. Synthesis of (±)-hyalodendrin.  
 In 1979 and 1980, Williams and Rastetter reported the total synthesis of gliovictin 
(1.32, Scheme 2.6).120,121 Sarcosine anhydride (2.25) was converted in three steps to silyl 
enol ether 2.27. Alkylation with benzyl bromide and concomitant sulfenylation and 
deprotection gave methyl sulfide 2.29. Additional sulfenylation gave a 3:1 mixture of 
diastereomers (2.30), favoring the undesired anti isomer. Reduction of the mixture of 
aldehydes completed the total synthesis of gliovictin (1.32) and epi-gliovictin (2.31). 
 
 Scheme 2.6. Total synthesis of (±)-gliovictin and epi-gliovictin. 
 A synthesis of hyalodendrin (1.3, Scheme 2.7) was achieved from silyl enol ether 






















































































2.30, anti:syn = 3:1
+
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enolate of 2.28 followed by reductive workup provided thiol 2.32. Conversion to the 
enolic methyl disulfide, deprotection of the silyl group, and sulfenylation with 
triphenylmethyl chlorodisulfide gave a mixture of diastereomers, unfortunately favoring 
the undesired anti isomer (2.34). Reduction and oxidation of 2.34 gave hyalodendrin (1.3) 
in 29% yield. 
 
 Scheme 2.7. Rastetter’s total synthesis of (±)-hyalodendrin. 
 
2.3: Recent Epidithiodioxopiperazine Syntheses (2009-2012) 
 Several total syntheses of epidithiodioxopiperazines have been reported in the last 
three years. Movassaghi and coworkers were the first to publish in this modern synthetic 
revival, reporting the synthesis of (+)-11,11’-dideoxyverticillin A (2.43, Scheme 2.8).122 
The authors showed that the amine resulting from cleavage of the N-Boc carbamate of 
2.35 was readily cyclized to dioxopiperazine 2.36 in morpholine. Exposure of 2.36 to 
bromine produced 3-bromopyrroloindoline 2.37, and the amides were subsequently 
methylated upon treatment with iodomethane. Addition of tris(triphenylphosphine)cobalt 
chloride gave the desired dimeric intermediate 2.38. After extensive investigation 
searching for appropriate stereoselective hydroxylation conditions, the dimer was 
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tetraol (2.39). Exposure of 2.39 to Fu’s (R)-(+)-4-pyrrolidinopyridinyl(pentamethyl-
cyclopentadienyl)iron (PPY) catalyst with t-butyldimethylsilyl chloride (TBSCl) gave 
selectively the alanine-derived protected hemiaminals (2.40). Removal of the 
benzenesulfonyl groups with sodium amalgam revealed diaminodiol 2.41. Treatment of 
2.41 with K2CS3 followed by ethanolamine gave diaminotetrathiol 2.42, which readily 
oxidized to (+)-11,11’-dideoxyverticillin A (2.43) when partitioned between aqueous 
hydrochloric acid and dichloromethane and treated with potassium triiodide. 
 

























































































































































 Chaetocin (1.13) is quite similar in structure to 11,11’-dideoxyverticillin A, 
derived from two molecules of serine rather than alanine. Substituted dioxopiperazine 
2.46 was prepared in five steps from N-Me,Cbz-D-Ser (2.44) and D-Trp-OMe 
(2.45).123,124 Bromocyclization gave tetracycle 2.47, converted to the tribromide (2.48) 
under radical conditions and hemiaminal 2.49 following addition of water. Movassaghi’s 
reductive dimerization conditions using a Co(I) complex afforded the desired dimer 
(2.50) in modest yield. Addition of 2.50 to condensed hydrogen sulfide and BF3⋅OEt2 
formed the tetrathiol, oxidized to the bis(disulfide) upon addition of iodine to complete 
the synthesis of (+)-chaetocin (1.13).  
 
 Scheme 2.9. Sodeoka’s total synthesis of (+)-chaetocin. 
 Sodeoka originally planned to form the tetraol from the product resulting from 
dimerization of 2.47. It was noted that this dimer was not stable to the radical conditions 


























































































circumvent this problem. Recall that Movassaghi had similar difficulties in forming 
related tetraol 2.39 and eventually settled on the mild oxidation discussed above. 
 Mere months after Sodeoka reported the first total synthesis of chaetocin, 
Movassaghi published the synthesis of (+)-chaetocin (Scheme 2.10), the hexasulfide (+)-
chaetocin C (1.79), and the octasulfide (+)-12,12’-dideoxychetracin A (1.81, Scheme 
2.11), all from the natural amino acids L-serine and L-tryptophan.125  
 
 Scheme 2.10. Movassaghi’s total synthesis of (+)-chaetocin. 
 Bromocyclization of dioxopiperazine 2.51 gave endo-tetracyclic bromide 2.52. N-
methylation, protecting group exchange, and key reductive radical dimerization afforded 
the dimeric octacycle (2.53). Selective tetrahydroxylation was achieved using 
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interestingly the acetate allows for differentiation of the hemiaminals, resulting in 
regioselective substitution of hydrogen sulfide. Protection of resulting thiohemiaminal as 
the dithioisobutyrate (2.55) served both to prevent opening of the hemiaminal under polar 
protic conditions and to activate the hemiaminal to mild ionization in future steps. Mild 
deprotection of the sulfonyl group was followed by chemoselective hydrazinolysis and 
addition of triphenylmethanesulfenyl chloride to give disulfane 2.56. Ionization of the 
isobutyrates and cyclization to the epidithiodioxopiperazines with concomitant loss of a 
triphenylmethyl cation was followed by removal of the acetates using Otera’s catalyst to 
afford (+)-chaetocin (1.13). 
 Chaetocin C (1.79) and 12,12’-dideoxychetracin A (1.81), the epitri- and 
epitetrathiodioxopiperazine analogues of chaetocin, were similarly synthesized from a 
common intermediate (Scheme 2.11).125  
 














































































(m=3): Otera's cat., 
90 °C (95%)
or



















(+)-chaetocin C (1.79), m=3




 Hydrazinolysis of diaminodithioisobutyrate 2.57 was followed by treatment with 
the corresponding sulfur source to give 2.58 or 2.59. It was necessary to protect the 
indoline nitrogens as the trifluoroacetates before addition of Lewis acid to form the 
polysulfide bridges (2.60 and 2.61), presumably to prevent decomposition pathways 
encountered over longer reactions times necessary to the formation of the larger 
polysulfide bridges. Global deprotection gave either (+)-chaetocin C (1.79) or (+)-12,12’-
dideoxychetracin A (1.81). 
 In 2011, Overman and coworkers reported the total synthesis of (+)-gliocladine C 
(1.99, Scheme 2.12).126 Known 2-indolinone 2.62 (prepared from isatin and indole) was 
reduced and Boc-protected to afford compound 2.63. Conversion to the oxindole ester 
(2.64) proceeded efficiently upon treatment with 2,2,2-trichloro-1,1-dimethylethyl 
chloroformate, triethyl amine, and 10 mol % of Fu’s (S)-(–)-4-pyrrolidinopyrindinyl-
(pentamethylcyclopentadienyl)iron catalyst. The oxindole was elaborated to indoline 2.65 
over four steps in 54% yield. Aldol condensation with the lithium enolate of the 
piperazinedione provided exclusively the Z isomer of 2.66, which readily cyclized to 
hexacycle 2.67 upon treatment with BF3·OEt2. Grignard addition, silyl protection of the 
resultant alcohol, asymmetric dihydroxylation, and acetylation gave advanced 
intermediate 2.68. Addition of the epimeric mixture of silyl ethers to condensed hydrogen 
sulfide and BF3·OEt2 gave the dithiol, oxidized to the disulfide upon exposure to oxygen. 
Removal of the acetate revealed (+)-gliocladine C (1.99). 
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 Scheme 2.12. Synthesis of (+)-gliocladine C. 
 Boyer and Movassaghi recently completed the total synthesis of two compounds 
related to the gliocladines. The most direct route to the first, (+)-gliocladin B (2.73), is 
detailed in Scheme 2.13.127 Bromocyclization proceeded as above, providing tetracycle 
2.70 in good yield with excellent stereoselectivity (97:3 endo:exo). A Friedel–Crafts type 
coupling of N-TIPS-5-bromoindole with 2.70 formed the desired 3-3’ bond. Several 
indole derivatives were screened, and the 5-bromo derivative was found to give the best 
yield and selectivity. The bromine and silyl protecting group were removed and the 
resulting compound oxidized to diol 2.72. Exposure of this diol to sodium thiomethoxide 
and trifluoracetic acid gave the bismethylthio derivative. (+)-Gliocladin B (2.73) was 
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 Scheme 2.13. Total synthesis of (+)-gliocladin B. 
 Although it has not to date been isolated from a natural source, it is worth noting 
that the authors were able to convert diol 2.72 into the disulfide (+)-12-deoxybionectin A 
(2.76) using conditions analogous to those discussed above in the chaetocin syntheses 
(Scheme 2.14).127 Disulfide 2.76 is also easily converted to (+)-gliocladin B (2.73) by 
reduction of the disulfide with sodium borohydride in the presence of iodomethane. 
 
 Scheme 2.14. Synthesis of (+)-12-deoxybionectin A and (+)-gliocladin B. 
 Epiccocin G (2.84) lacks a disulfide bridge and was thus not discussed in Chapter 
1. Nonetheless, the structure is remarkably similar to that of epicorazine A (1.8), and a 
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Hydroxy enone 2.77 (prepared in two steps from N-Boc-tyrosine) was converted in four 
steps to hydroxy methyl ester 2.78 (Scheme 2.15). Separate deprotections to either the 
amine or carboxylic acid gave two derivatives that were coupled to form amide 2.79. 
Deprotection and cyclization to the dioxopiperazine was followed by conversion to the 
bistrifluoroacetate (2.80), which eliminated to bisdiene 2.81 upon exposure to Pd(PPh3)4 
catalyst. Treatment with S8 and NaHMDS gave a mixture of oligosulfenylated 
compounds (2.82) that were readily converted to the bisdimethylthio compound (2.83) 
upon reduction with sodium borohydride and addition of iodomethane. Bisendoperoxide 
2.85 was generated on reaction with singlet oxygen, and addition of DBU induced a 
Kornblum–DeLaMare rearrangement to give a bishydroxy enone. Reduction to the 
ketone completed the total synthesis of epicoccin G (2.84). 
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 The last epidithiodioxopiperazine total synthesis to be discussed was reported 
recently by the Reisman group, who completed an elegant synthesis of (–)-acetylaranotin 
(1.35).129 Pyrrolidine 2.88 was synthesized with >98% ee by (1,3)-dipolar cycloaddition 
of cinnamaldimine 2.87 to t-butyl acrylate (2.86) and subsequent cleavage of the t-butyl 
ester (Scheme 2.16). Protection of the amine and ozonolytic cleavage of the alkene 
provided lactone 2.89 in good yield. Ethynylmagnesium bromide was added to the 
hydroxylactone to form the hydroxy acid, which upon addition of triphenylphosphine and 
DIAD underwent Mitsunobu lactonization to 2.90. Reduction to the diol (2.91) was 
followed by bis-TBS protection of the alcohols and selective deprotection of the primary 
alcohol. The aldehyde obtained following oxidation with Dess–Martin periodinane was 
efficiently converted to chlorohydrin 2.92.  
 
 Scheme 2.16. Key pyrrolidine synthesis. 
 Formation of the dihydrooxepine (2.93) was realized upon treatment of alkyne 
2.92 with catalytic [Rh(cod)-Cl]2 and tris(4-fluorophenyl)phosphine (Scheme 2.17).129 
Elimination of HCl and hydrolysis of the ester gave acid 2.94, while deprotection of the 
Teoc group and HCl elimination of the same compound gave amine 2.95. BOP-Cl–
mediated coupling of 2.94 and 2.95 delivered amide 2.96, which readily cyclized to 
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acetylaranotin (1.35) was completed following formation of tetrasulfide 2.98, 
bisacetylation, mild reduction to the dithiol, and oxidation to the natural disulfide. This 
publication marked the first total synthesis of a dihydrooxepine-containing 
epidithiodioxopiperazine natural product. 
 
 Scheme 2.17. Completion of the total synthesis of (–)-acetylaranotin (1.35). 
 
2.4: Other Relevant Syntheses: Formation of the C3-N1’ Bond 
 Recall that chetomin (1.12) contains a C3-N1’ linkage between two indole–
derived fragments. This unique structural feature was synthetically unprecedented when 
we began our synthetic efforts toward a total synthesis of chetomin. In the last few years, 



























    100 °C
2. Me3SnOH, 
    80 °C
1. TBAF, 0 °C
2. LiCl, Li2CO3,




























































feel it prudent to discuss in the remainder of this chapter methods for the formation of the 
challenging C3-N1’ bond as it relates to the synthesis of chetomin.  
 In 2008, Newhouse and Baran reported the total synthesis of (±)-psychotrimine 
(Scheme 2.18).130,131 The key C3-N1’ bond forming reaction was completed by treating 
tryptamine derivative 2.99 with N-iodosuccinimide and 2-iodoaniline to afford compound 
2.100. Larock indole synthesis with alkyne 2.101 completed the carbon framework for 
the top tryptamine fragment (2.102). A total synthesis of psychotrimine (2.103) was 
completed in two steps from 2.102. 
 
 Scheme 2.18. Synthesis of (±)-psychotrimine via novel C3-N1’ bond formation. 
 Baran used the same method in the synthesis of kapakahine B (2.108, Scheme 
2.19).130,132 In this instance, dipeptide 2.104 was cyclized and coupled to 2-iodoaniline to 
give 2.105. Indole formation by a Larock annulation with TES-alkyne 2.106 gave indole 










































 Scheme 2.19. Total synthesis of kapakahine B. 
 In 2008, Espejo and Rainier reported a new method for the synthesis of C3-N1’ 
heterodimeric indolines from bromopyrroloindoline 2.110 (Scheme 2.20, prepared in one 
step from N,N’-Boc2-L-Trp-OMe).133  
 
 Scheme 2.20. Rainier’s synthetic C3-N1’ bond forming method. 
 Addition of potassium tert-butoxide to a stirring solution of 2.110 and an indole 








































































































3:1 to >95:5 endo:exo



































This method is far more general and cost effective than that reported by Baran, as a 
variety of indole derivatives can be coupled directly without the added Larock annulation 
step. 
 The utility of this method was demonstrated through the total synthesis of 
kapakahine F (2.121, Scheme 2.21).134 Pyrroloindoline dimer 2.118 was synthesized as 
described above and transformed to phenylalanine derivative 2.119 over several steps. 
This substrate was originally intended to serve as a model for the subsequent trimethyl 
aluminum induced rearrangement, but unfortunately the product resulting from the 
coupling of 2.110 to a tryptophan derivative decomposed under the rearrangement 
conditions. Thus, indole 2.120 was ultimately used to complete the synthesis of 
kapakahine F (2.121). 
 
 Scheme 2.21. Total synthesis of kapakahine F. 
 The final total synthesis to be discussed in this chapter featuring a C3-N1’ bond 
forming step is that of (+)-pestalazine B (2.126, Scheme 2.22), a natural product with 
similar carbon framework to chetomin (1.12).135 Pestalazine B is unique in this discussion 























































above examples. Accordingly, D-tryptophan was selected as the starting material, 
converted to bromopyrroloindoline 2.122 using known methods. Rainier’s coupling 
methodology was employed to join 2.122 with dioxopiperazine 2.123 to form key 
intermediate 2.124. Removal of the Boc groups and peptide coupling produced 
tetrapeptide 2.125. Treatment of 2.125 with diethyl amine resulted in concomitant Fmoc 
deprotection and cyclization to the naturally occurring dioxopiperazine, completing the 
total synthesis of pestalazine B (2.126).  
 
 Scheme 2.22. Concise total synthesis of (+)-pestalazine B. 
 
2.5: Concluding Remarks 
 Epidithiodioxopiperazine alkaloids possess an astonishing array of molecular 
architecture and, with that, corresponding synthetic challenges to construct such 
substances. The biosynthesis of many of the natural metabolites touched on in Chapter 1 
has certainly inspired many of the chemists cited in this chapter, as several have sought to 
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context. Our own synthetic efforts toward chetomin and sporidesmin A as described in 
the following chapters were undertaken before all of the recent reports were published, 
although insight and inspiration were drawn from each as new developments in the 




Studies Toward the Total Synthesis of Chetomin 
  
3:1: Introduction 
 Our interest in chetomin stems both from its novel mechanism of action as a 
potential cancer chemotherapeutic agent and the synthetic challenge posed by the unique 
architecture of the molecule. Chetomin (1.12) and related metabolites isolated from 
Chaetomium sp. (Figure 3.1) are the only known epidithiodioxopiperazine alkaloids to 
contain a nearly dimeric structure joined by a C3-N1’ linkage.73,74 The densely 
functionalized structure contains five tetrasubstituted carbons and six stereocenters. The 
synthetic challenge imposed by the epidithiodioxopiperazine rings is also not to be 
overlooked, as the disulfide bridge is sensitive to oxidative, reductive, basic, and strongly 
acidic conditions. 
 
3.2: Goals and Early Studies 
3.2.1: Goals for the Project  
The primary goal of this project was to develop a scalable, divergent synthesis of 
(+)-chetomin (1.12). We hoped to bring in as much functionality as possible when 
forming the C3-N1’ bond to exploit the pseudo-dimeric architecture. Introduction of the 
disulfide bridges would be reserved for a late stage in the synthesis to circumvent the 
troubling sensitivity of the functional group. However, no precedent existed in the
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infancy of this project for the formation of the key C3-N1’ bond. Our initial synthetic 
efforts were focused on this bond. 
 
Figure 3.1. Chetomin and related fungal metabolites. 
 
3.2.2: Iminium Ion Approach 
 A simple model study was designed to gain access to oxindole 3.1 (Scheme 3.1). 
A side chain mimicking the amino acid fragment could be added by nucleophilic addition 
to iminium 3.2, formed from condensation of isatin (3.3) with indoline (3.4). 
 
 Scheme 3.1. Proposed model study for C3-N1’ bond formation. 
Condensation of indoline (3.4) on N-Boc isatin showed promise at forming the 










































































































reagent to the condensation product (Scheme 3.2). However, further structural analysis 
by NMR revealed that water was not eliminated in the condensation, and hemiaminal 3.6 
was instead formed through direct addition of indoline to the C3 carbonyl of isatin. Vinyl 
Grignard reagent was adding to the lactam carbonyl carbon. Numerous conditions were 
attempted to effect elimination of water, but all failed to produce the desired iminium ion 
(3.7).   
 
 Scheme 3.2. Attempted iminium ion formation. 
 Looking back, we did achieve our goal of forming a tetrasubstituted carbon on an 
indole surrogate. However, no reasonable plan existed for the incorporation of the amino 
acid residue, let alone with any stereocontrol.  
 
3.2.3: Pinacol-type Rearrangement 
Inspired by past Williams group chemistry and aryl pinacol-type rearrangements 
recently reported by Movassaghi, we next envisioned forming the C3 tetrasubstituted 
center through a pinacol-type rearrangement of tryptophan dimer 3.9 to oxindole 3.8 
(Scheme 3.3).136-138 The amino acid fragment of indole 3.9 could be installed through 






























of aniline 3.11. The nitro alkene dimer could be accessed via coupling of bromoalkyne 
3.12 with 2,3-dihydrotryptophan (3.13). 
 
 Scheme 3.3. Retrosynthesis of key intermediate 3.8 through a pinacol-type 
rearrangement. 
 Bromoalkyne 3.12 was prepared in two steps by treating 2-nitrobenzaldehyde 
with carbon tetrabromide and triphenylphosphine to afford dibromoalkene 3.15 in 91% 
yield, which under basic conditions eliminated to form 3.12 in quantitative yield (Scheme 
3.4).139  
 
 Scheme 3.4. Synthesis of 2-alkynyl aniline derivative 3.17. 
 Standard copper-mediated coupling of the bromoalkyne with indoline (3.4) failed 
to proceed in appreciable yields.140 Microwave-assisted coupling successfully formed 



































































of the nitro group using zinc and ammonium chloride gave aniline 3.17 in 61% yield, 
although copper iodide mediated indole formation failed to produce the desired indole 
(3.18). 
 Protected 2,3-dihydrotryptophan was synthesized in parallel to this model study to 
be used in place of indoline (3.4) above. N-Cbz tryptophan was treated with iodomethane 
to form the methyl ester (3.20) in quantitative yield (Scheme 3.5). Reduction of 3.20 
using BH3·Me2S in THF and TFA gave 2,3-dihydrotryptophan derivative 3.21 in 79% 
yield. Coupling using the previously optimized conditions afforded alkyne 3.22 in 45% 
yield, although reduction to aniline 3.23 gave only trace amounts of the desired product. 
 
 Scheme 3.5. Synthesis of 2,3-dihydrotryptophan alkyne derivative. 
 
3.3: Evolution of Coupling Strategy 
3.3.1: Witkop’s Pyrroloindole 
 At this point, we took a step back and looked to nature for inspiration. It is 
unlikely that fungi synthesize chetomin by such contrived routes. If chetomin is derived 
naturally from two molecules each of tryptophan and serine, why not start with 




































that the pyrroloindoline core is formed in nature prior to coupling with the second half of 
the molecule, if not concomitantly. Witkop’s pyrroloindole (3.24) was identified as a 
synthetically useful intermediate in the synthesis of chetomin that could be formed 
readily from tryptophan.141 Halogenation of the indole double bond would provide a 
handle that could be substituted with another indole, ideally tryptophan, all with the 
potential for some stereocontrol (Scheme 3.6). 
  
 Scheme 3.6. Witkop’s pyrroloindole inspiration. 
 Retrosynthetically, we could form advanced intermediate 3.26 from the coupling 
of bromopyrroloindoline 3.28 and a suitably protected tryptophan derivative (3.27, 
Scheme 3.7). Both of these coupling partners could be synthesized in a few steps from 
tryptophan. 
 
 Scheme 3.7. Retrosynthetic plan using pyrroloindoline. 
 Tryptophan methyl ester (3.30) was protected as the trifluoroacetate amide (3.31), 
then cyclized to pyrroloindole 3.32 using t-BuOCl in 63 % overall yield (Scheme 3.8). 




































 Scheme 3.8. Attempted synthesis of 3-bromopyrroloindole. 
 
3.3.2: Indole–Aniline Coupling  
 This stepwise procedure to 3.33 was put on hold after a report from the Baran 
group was published, showing an analogous sequence that showed promise at reducing 
our synthesis of 3.26 to one step. Baran showed that treatment of N-Boc-Trp-OMe (3.34) 
and 2-iodoaniline with N-iodosuccinimide in acetonitrile afforded the desired C-N bond 
and C-3 quaternary center in one pot (Scheme 3.9).130-132 
 
 Scheme 3.9. Formation of key C-3 quaternary center. 
 We repeated this chemistry using indoline in place of 2-iodoaniline, but only 
starting material was recovered (Scheme 3.10). Ideally, this reaction would be done with 
tryptophan or 2,3-dihydrotryptophan, eliminating the need for a Larock indole synthesis 
with the iodoaniline. To our disappointment, the reaction only worked as originally 
reported with 2-iodoaniline, despite numerous attempts at the reaction with indoline (3.4), 













































 Scheme 3.10. Attempted formation of functionalized C3-N bond. 
 A suitable TMS-acetylene derivative was synthesized from L-serine methyl ester 
(3.39) and TMS-acetylene (Scheme 3.11). Serine methyl ester (3.39) was N-Boc 
protected (3.40) and the alcohol converted to the iodide (3.41) upon treatment with 
triphenylphosphine, imidazole, and iodine. TMS-acetylene bromide (prepared in one 
step, 72% yield) was coupled to serine-derived halide 3.41 to afford the desired alkyne 
(3.42) in 40% yield.132  
 
 Scheme 3.11. Key alkyne synthesis. 
 Alkyne 3.42 was subjected to Larock annulation with iodoaniline 3.12 to form 
indole 3.43. Saponification to the diacid (3.44) proceeded in good yield. While this route 
afforded access to advanced intermediate 3.44 in decent yields, it suffered from high step 
count due to the necessary Larock annulation and provided access to a diastereomer of 












































previously envisioned (Scheme 3.7) and attempted the desired sequence in a stepwise 
manner. 
 
 Scheme 3.12. Larock indole synthesis of tryptophan dimer. 
 
3.3.3: Coupling to exo-3-bromopyrroloindoline 
 N-Cbz-Trp-OMe (3.20) was synthesized in >99% yield from tryptophan and the 
indole nitrogen protected as the Boc carbamate (3.46). Per a report published by Espejo 
and Rainier in 2008, addition of NBS and PPTS to 3.46 afforded exo-3-
bromopyrroloindoline 3.47 in 89% yield (Scheme 3.13).133,144 Deprotonation by KOtBu 
in the presence of indole formed the C3-N bond in 28% yield and resulted in 
epimerization of the methyl ester to the thermodynamically more favorable endo position 
(3.48).133 
 
















































































 This result evolved into our current strategy for the formation of the C3-N1’ bond. 
The stereochemistry of 3.48 matches the enantiomer of what would be needed for a 
synthesis of chetomin (i.e. 3.51, Scheme 3.14). We could either form the 
bromopyrroloindoline from L-tryptophan and to it couple D-tryptophan and D-serine to 
synthesize the enantiomer of chetomin, or we could synthesize the D-tryptophan-derived 
pyrroloindoline (3.52) and use the natural amino acid isomers for the remaining three 
couplings in a synthesis of (+)-chetomin (1.12). Initially, however, only the cheaper L-
isomers were used for all four fragments as conditions were worked out for the remaining 
steps.  
 
 Scheme 3.14. Retrosynthetic analysis of (+)-chetomin. 
 
3.3.4: Attempted Coupling to Tetracyclic Bromide 
 The next goal was to test a more divergent approach. Ideally, the dioxopiperazine 

























































































 Scheme 3.15. Coupling with more advanced bromopyrroloindoline. 
 Unfortunately, synthesis of 3.55 was more challenging than expected. Peptide 
coupling of tryptophan derivative (3.56) with N-Me-L-Ser-OMe initially suffered from 
poor yield. Eventually, the coupling was optimized using EDCI as the coupling reagent to 
afford dipeptide 3.57a in good, reproducible yield (Scheme 3.16). Cyclization to the 
dioxopiperazine (3.58a) failed under methods traditionally used in the Williams group 
(i.e. refluxing toluene with catalytic 2-hydroxy pyridine following Boc deprotection). 
However, microwave heating of neat N-Boc dipeptide 3.57a at 180 °C effected 
deprotection and cyclization to the dioxopiperazine (3.58a) in two minutes. The 
recovered product did not require any purification before proceeding to the next step. 
 
 Scheme 3.16. Optimized peptide coupling and dioxopiperazine formation. 
 Gratifyingly, this procedure was generally applicable to a variety of related 
dipeptides. Dioxopiperazines 3.58a-e were all synthesized with consistently good yield 
on scales up to 500 mg (Scheme 3.17). 
 Several of the dioxopiperazines were cyclized to the corresponding 
bromopyrroloindolines (3.55, Scheme 3.18). Despite numerous attempts, coupling of 












































 Scheme 3.17. Microwave assisted dioxopiperazine synthesis.  
 
 Scheme 3.18. Attempted coupling with indole. 
 
3.4: Epidithiodioxopiperazine Formation 
 While unsuccessfully attempting to couple indole or tryptophan to 3.55, we also 
began to explore methods for the introduction of sulfur to the same dioxopiperazine. 
Epidithiodioxopiperazine 3.63, essentially a monomer of chetomin, was synthesized by a 
general method recently described by the Sodeoka group in Japan (Scheme 3.19).123,124 
Benzenesulfonamide protection of L-tryptophan (3.59) gave compound 3.56, to which L-
Ser-OMe was coupled to afford dipeptide 3.57d. The primary alcohol was protected as 
the silyl ether (3.57e) and suffered microwave-induced deprotection and cyclization to 
dioxopiperazine 3.58e. Treatment with bromine affected the bromocyclization to endo-
pyrroloindoline 3.55e. Addition of iodomethane successfully methylated the secondary 
amide, but also resulted in the loss of the silyl ether to primary alcohol 3.60. After 


















3.57a (R1=SO2Ph, R2=Me, R3=H)
3.57b (R1=H, R2=Me, R3=H)
3.57c (R1=H, R2=H, R3=H)
3.57d (R1=SO2Ph, R2=H, R3=H)

































substitution of 3.61. Addition of the diol to condensed hydrogen sulfide and BF3·OEt2 
and oxidation of the resultant disulfide with iodine gave epidithiodioxopiperazine 3.63. 
 
 Scheme 3.19. Formation of the disulfide bridge. 
 
3.5: Attempted Core Construction 
3.5.1: Problematic Peptide Couplings 
 With a method for the formation of an epidithiodioxopiperazine in hand, we went 
back to the method described in Scheme 3.13 for construction of the key C3-N1’ bond. 
N-Boc-tryptophan methyl ester (3.34) was prepared and further protected as the 
benzenesulfonamide (3.64, Scheme 3.20). Cyclization to the bromopyrroloindoline 
(3.65) proceeded readily upon treatment with NBS and PPTS, and coupling of 3.65 with 
N-Boc-Trp-OMe (3.34) gave 3.66 in poor yield (34%). Saponification to diacid 3.67 was 




























































































protection of the primary alcohols proceeded in good yield, although cyclization to the 
dioxopiperazines (3.70) using the previously described microwave conditions failed, as 
did the reaction with traditional thermal conditions. 
 
 Scheme 3.20. Coupling to 3-bromopyrroloindoline and attempted 
dioxopiperazine formation. 
 Deprotection of the Boc groups of intermediate 3.66 and peptide couplings on the 
resultant amines gave tripeptide 3.71 (Scheme 3.21). Intriguingly, formation of the 
tetrapeptide of 3.66 was never achieved, despite numerous attempts with varying 


































































































 Scheme 3.21. Attempted synthesis of alternate dioxopiperazine precursor. 
 
3.6: Synthesis of Heptacyclic Core 
3.6.1: Synthesis of Dioxopiperazines 
 We reasoned that the failed cyclization attempts in Scheme 3.20 and peptide 
coupling problems in Scheme 3.21 could be due to steric congestion caused by the 
indoline protecting group. Thus, N,N’-Boc2-D-Trp-OMe was prepared from D-tryptophan 
(3.73, Scheme 3.22). Bromocyclization proceeded stereoselectively to exo-
bromopyrroloindoline 3.74. Coupling with N-Boc-L-Trp-OMe gave endo-intermediate 
3.75 in decent yield, while deprotection of the carbamate gave the key intermediate for 
peptide coupling. In the absence of an aniline protecting group, peptide coupling 
proceeded in 44% yield to tetrapeptide 3.76. With the Fmoc amines, deprotection and 
cyclization to dioxopiperazine 3.77 proceeded in one pot upon treatment with morpholine 
in THF with gentle heating. At this point, all of the amides needed to be methylated prior 
to the introduction of sulfur, which first required protection of the aniline nitrogen. 
Selective Boc protection at this position was never achieved, nor was protection of 

























 Scheme 3.22. Synthesis of dioxopiperazine 3.77. 
 
3.6.2: Initial N-Methyl Amino Acid Incorporation 
 It was clear that N-methyl tryptophan and serine derivatives needed to be prepared 
to avoid late stage N-methylation. Months of laborious chemistry went in to preparing 
these seemingly simple derivatives, and ultimately bromopyrroloindoline 3.74 was 
coupled to N-Me,Boc-L-Trp-OMe (Scheme 3.23). Deprotection of the two Boc groups 
gave 3.80, a key intermediate used extensively in the remainder of this chapter. Peptide 















































































































dioxopiperazine 3.82 in excellent yield after Boc deprotection and addition of 
morpholine. 
 
 Scheme 3.23. Synthesis of (N-Me)3 dioxopiperazine. 
 Initially we attempted to again protect the aniline nitrogen before subjecting the 
material to radical bromination conditions. All attempts to Boc or TBS protect 3.82 failed 
(Scheme 3.24). We decided to move forward to try the bromination anyway on diol 3.84, 
but the benzyl ether resisted all deprotection attempts.  
A serine derivative lacking the benzyl group was added to diamine 3.80, but this 
coupling failed to give the desired tetrapeptide (Scheme 3.25). The benzyl group seemed 































































 Scheme 3.24. Attempted protection and deprotection of 3.82. 
 
 Scheme 3.25. Attempted peptide coupling with N-Me,Boc-Ser(OH). 
 
3.6.3: Bypassing the Serine Side Chain with Sarcosine 
 While working out the synthesis of an appropriate N-Me serine derivative, the 
entire serine side chain was eliminated from the synthesis. N-Fmoc sarcosine (3.87) was 
prepared and coupled to diamine 3.80 (Scheme 3.26). Cyclization to dioxopiperazine 
3.88 proceeded smoothly. However, the radical bromination and hydroxylation did not 













































































































 Scheme 3.26. Synthesis of sarcosine-derived dioxopiperazine. 
 
3.6.4: Completion of the Carbon Skeleton of Chetomin 
 Meanwhile, N-Me,Fmoc-Ser(OTBS) was successfully prepared and coupled to 
3.80 (Scheme 3.27). Dioxopiperazine 3.90 was easily formed as described above. 
 
 Scheme 3.27. Synthesis of (N-Me)3 dioxopiperazine. 
 
3.6.5: Attempted Epidithiodioxopiperazine Formation 
 Numerous attempts have been made to convert both the serine- and sarcosine-
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(1.12 and 3.91, Scheme 3.28). Much to our disappointment, both have refused to yield to 
our continued efforts. 
 
 Scheme 3.28. Attempted epidithiodioxopiperazine formations. 
 
3.7: Proposed Future Studies 
3.7.1: Proposed Synthesis of Tetraol 
 We have successfully synthesized the carbon framework of chetomin. The final 
key to a total synthesis is the oxidation of this core (3.90 or 3.88) to tetraols 3.92 or 3.89 
(Scheme 3.29). Numerous examples (see Chapter 2) suggest that this compound should 
readily form intermediate iminium ions such as 3.93 and 3.94. Addition of sulfur should 







































































 Scheme 3.29. Key tetraols and iminium intermediates. 
 Synthesis of the tetraols should be possible either by the method previously 
attempted (radical bromination and substitution) or by mild oxidation with 
bis(pyridine)silver(I) permanganate (Scheme 3.30). In the synthesis of gliocladin B, n-
Bu4NMnO4 was also used as an oxidant for this reaction.127 Repeated trials will be 
necessary to produce optimal conditions, requiring sufficient time, material, and 
persistence. Three potential problems may complicate this route: (1) The free indoline 
nitrogen may require protection if it proves to be reactive under the proposed radical or 
oxidation conditions. This has previously been a difficult protection, and while a Boc or 
silyl group would be ideal, a trifluoroacetate group would also be appropriate (although it 
would introduce an additional deprotection step). (2) The desired hemiaminal may very 
well be unstable and require additional functionalization after it is formed before sulfur 
can be introduced. (3) The serine-derived bis(dioxopiperazine) (3.90) is susceptible to 






































































 Scheme 3.30. Possible oxidations. 
 
3.7.2: Bypassing the Tetraol 
 It would also be worth attempting the addition of sulfur directly to 
dioxopiperazines 3.90 and 3.88. Both Nicolaou and Reisman took this approach in their 
respective epidithiodioxopiperazine syntheses, using S8 and NaHMDS (Scheme 
3.31).128,129 
 
 Scheme 3.31. Alternative sulfenylation. 
 
3.7.3: Late-Stage Alkylation of Sarcosine Analogue 
 Lastly, if access to sarcosine-derived epidithiodioxopiperazine 3.91 proves to be 
the most efficient route, conversion to chetomin can occur using inspiration from Kishi’s 




















































































disulfide bridges and protection as the thioacetals would give 3.95. Alklation with 
BOMCl would install the protected serine side chain (3.96), which could be deprotected 
and the disulfide revealed to give chetomin (1.12). 
 
 Scheme 3.32. Proposed conversion of 3.91 to chetomin. 
 
3.8: Concluding Remarks 
 It will be difficult to leave this project behind with the total synthesis of chetomin 
so near to completion. However, short of a completed synthesis, we did achieve the 
remaining goals for this project in the synthesis of dioxopiperazines 3.88 and 3.90. The 
key C3-N1’ bond formation works for a variety of substrates and is a convergent 
approach to the core structure. A variety of peptide couplings were optimized for this 
system, producing di- and tetrapeptides in respectable yields. Cyclization of the 
dioxopiperazine rings is now performed consistently and in high yields. Moreover, the 





















































































Synthetic Approach to Sporidesmin A 
  
4:1: Introduction 
 In 2010, we had the opportunity to write a book chapter on biomimetic syntheses 
of tryptophan-derived dioxopiperazines, in which Kishi’s elegant synthesis of (±)-
sporidesmin A (1.11) was featured (Figure 4.1).145 We were drawn to the densely 
functionalized structure of sporidesmin A, including the polysubstituted aromatic ring, 
pyrroloindoline core, hydroxyl groups at C3 and C12, and the epidiothiodioxopiperazine 
ring. We hoped that chemistry developed for the synthesis of chetomin (see Chapter 3) 
could be applied to an improved, stereoselective synthesis of sporidesmin A. 
 As detailed in Chapter 1, sporidesmin A was isolated from Pithomyces chartarum 
in 1959 as part of a forty-year nationwide search for the cause of facial eczema, a disease 
that was plaguing sheep herds of New Zealand.63-65 Facial eczema causes extensive liver 
damage in sheep and has been responsible for massive economic losses in New Zealand 
since the late 1890s. A dental nurse allegedly discovered that the addition of zinc sulfate 
to drinking water could prevent the disease, a measure still endorsed by veterinarians.146 
Epidithiodioxopiperazines are known to form a 2:1 complex with zinc ions, inhibiting the 
generation of the superoxide anion radical and likely providing the observed protective 
effects of zinc against sporidesmin.69,70 The toxicity of sporidesmin toward sheep was 
responsible for many of the early advances made in the study of 
 76 
epidithiodioxopiperazines, including the isolation and characterization of sporidesmin 
and related metabolites (Figure 4.1). 
 
 Figure 4.1. Sporidesmin A and related fungal metabolites. 
No reasonable argument can be made advocating that a new synthesis of 
sporidesmin A will have any direct impact on mankind, medicine, or even sheep herds in 
New Zealand. Our interest is purely academic. Sporidesmin A is a synthetically 
challenging molecule, and pursuit of a total synthesis will allow us both to explore the 
scope of similar reactions employed toward the total synthesis of chetomin and to expand 
our general understanding of the reactivity of epidithiodioxopiperazine alkaloids. 
 
4.2: Retrosynthetic Analysis 
 The primary goal of this project was to develop a scalable total synthesis of (–)-
sporidesmin A (1.11). Compared to chetomin (1.12), sporidesmin A presents several 






















































































































sporidesmin J (1.69)sporidesmin H (1.68)
sporidesmin F (1.66)sporidesmin D (1.64)
sporidesmin C (1.63)sporidesmin B (1.62)sporidesmin A (1.11)
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ring. We hoped to develop an efficient synthesis of the requisite substituted L-tryptophan 
derivative and to apply the previously used bromocyclization reaction (Scheme 3.13) to 
form the pyrroloindoline core.  
 As with chetomin, we planned to introduce the disulfide bridge of (–)-sporidesmin 
A (1.11) at a late stage in the synthesis from hemiaminal 4.1 (Scheme 4.1). The 
hemiaminal could be formed by oxidation of tetracycle 4.2 after forming the 
pyrroloindoline core through oxidative cyclization and N-methylation of dioxopiperazine 
4.3. This intermediate is similar to many of the dioxopiperazines prepared in the previous 
chapter and was envisioned to arise via coupling of 4.4 with alanine, followed by 
cyclization.  
 
 Scheme 4.1. Retrosynthetic analysis of (–)-sporidesmin A. 
 One key to an asymmetric synthesis is the preparation of β-hydroxytryptophan 
derivative 4.4. We hoped to introduce both stereocenters and the amino acid portion of 
this intermediate through Sharpless asymmetric aminohydroxylation of unsaturated ester 































































































4.6 4.7 vanillin (4.8)
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Vilsmeier–Haack reaction of indole 4.6. Modified dinitrostyrene Batcho–Leimgruber 
conditions were planned for the formation of the indole from styrene 4.7, prepared in 
several precedented steps from vanillin (4.8). 
 
4.3: Synthetic Approach to Sporidesmin A 
4.3.1: Preparation of Dinitrostyrene Derivative 
 Nitration of O-acetyl vanillin (4.9) afforded 4.10 when fuming nitric acid (>90%) 
was used as the nitronium source (Scheme 4.2). Fuming nitric acid was originally 
prepared fresh by distillation from a slurry of potassium nitrate and concentrated sulfuric 
acid, but this procedure seemed quite dangerous on scales producing more than 50 mL of 
nitric acid, prompting us to obtain the reagent from a commercial source. 
 
 Scheme 4.2. Nitration of vanillin. 
 Following nitration, 4.10 was heated to reflux in aqueous KOH to afford phenol 
4.11, then O-methylation with dimethyl sulfate gave 4.12 in 99% yield (Scheme 4.3). 
The Henry reaction was used to prepare dinitrostyrene derivative 4.13 through addition of 
nitromethane to the aldehyde and subsequent elimination of water. Indole 4.14 was then 
prepared in low yield using modified Batcho–Leimgruber conditions.147 
 Originally, we had envisioned preparing chloroindole 4.6 from indole 4.14. 
However, it seemed more prudent to chlorinate vanillin, as we would be less concerned 

























vanillin (4.15) was prepared by bubbling chlorine gas through a solution of vanillin in 
acetic acid (Scheme 4.4).148 Nitration, deacetylation, and methylation proceeded in good 
yield to provide aldehyde 4.18. The Henry reaction gave dinitrostyrene 4.7 in low 
yield.149 
 
 Scheme 4.3. Dimethoxyindole synthesis. 
 
 Scheme 4.4. Synthesis of 5-chloro-dinitrostyrene derivative. 
 We determined that the small amount of ethyl acetal 4.19 formed during the 
methylation reaction was detrimental to the yield of the Henry reaction (Scheme 4.5). To 
circumvent this problem, the crude mixture of 4.18 and 4.19 was treated with TFA in 
chloroform to cleave the acetal, affording pure 4.18. Use of clean material greatly 






































































 Scheme 4.5. Undesired acetal formation. 
 
4.3.2: Indole Synthesis and Sharpless Asymmetric Aminohydroxylation 
 Synthesis of indole 4.6 proceeded in good yield using modified Batcho–
Leimgruber conditions (Scheme 4.6). Following N-methylation, an aryl aldehyde was 
installed at C3 via the Vilsmeier–Haack reaction.150 This aldehyde (4.20) was 
immediately converted to the unsaturated ester (4.5) upon Wittig reaction with the 
requisite phosphonium ylide. Sharpless asymmetric aminohydroxylation gave β-
hydroxytryptophan derivative 4.4, albeit in modest yield.151 
 
 Scheme 4.6. Asymmetric aminohydroxylation. 
 While it is commercially available, we opted to prepare the ligand for the 












































































2. POCl3, DMF; 







difluorobenzene gave dione 4.23, which was alkylated to form the dihydroquinidinyl 
anthraquinone ligand (4.24) in good yield. 
 
 Scheme 4.7. Preparation of (DHQD)2AQN. 
 
4.3.3: Dioxopiperazine Formation 
 β-hydroxytryptophan derivative 4.4 was protected as the silyl ether (4.25) and the 
Cbz group cleaved to reveal the free amine (4.26, Scheme 4.8). EDCI-mediated coupling 
of N-Boc-Ala-OH provided dipeptide 4.27 in 59% yield.  
 
 Scheme 4.8. Formation of the dioxopiperazine and an undesired elimination. 
 Attempts to form the desired dioxopiperazine directly from 4.27 using the 
microwave conditions described in the previous chapter resulted in decomposition. 
O
O
O 1. AlCl3, reflux,

























































































Following more traditional methods, we first removed the Boc group, then heated the 
crude product (4.28) in toluene in the presence of 2-hydroxypyridine. The 
dioxopiperazine was formed, but unfortunately the conditions also caused elimination of 
the silyl ether to afford 4.29. 
 An alternative cyclization precursor was synthesized from 4.25 by saponification 
of the methyl ester and coupling of L-Ala-OMe (Scheme 4.9). The low yielding coupling 
step forced a quick screen of coupling reagents, through which T3P was identified as the 
most efficient of those tested, providing dipeptide 4.31 in a mere 34% yield. 
 
 Scheme 4.9. Preparation of dipeptide. 
 The unoptimized reaction allowed us access to enough material to attempt the 
cyclization reaction. Dipeptide 4.31 was converted to the free amine and heated gently in 
toluene with catalytic 2-hydroxypyridine (Scheme 4.10). A mixture of the elimination 
product (4.29) and the desired dioxopiperazine (4.3) was obtained in poor yield. 
 


















































































 We returned to amine 4.26 and to it coupled N-Fmoc-L-Ala (Scheme 4.11). 
Again, our standard EDCI-mediated coupling produced dipeptide 4.32 in very poor yield. 
Use of T3P nearly doubled the yield and greatly simplified purification of 4.32. Gentle 
heating of the dipeptide in THF and morpholine resulted in concomitant Fmoc 
deprotection and cyclization to the desired dioxopiperazine (4.3). 
 
 Scheme 4.11. Improved synthesis of dioxopiperazine 4.3. 
 
4.3.4: Oxidative Cyclization Attempts 
 Elated to finally have access to dioxopiperazine 4.3, we pressed forward and 
attempted the oxidative cyclization to the pyrroloindoline. Treatment of 4.3 with NBS or 
bromine resulted in products containing two bromine atoms. We turned to the conditions 
reported in Kishi’s synthesis, but only isolated starting material from the reaction mixture 
(Scheme 4.12).113 Alcohol 4.34 was expected to result from aqueous conditions, but only 
a small amount of 4.35, formed by oxidative fission of the indole double bond and 









































 Scheme 4.12. First attempts at oxidative cyclization. 
 Dioxopiperazine 4.3 was precious material at this point in the synthesis, and we 
certainly did not have large enough quantities to attempt a variety of conditions. 
Therefore, simple dioxopiperazine 4.36 was prepared and subjected numerous times to 
variations of the above conditions (Scheme 4.13). Unfortunately, model compound 4.36 
also failed to react. Dioxopiperazine 4.36 is nearly insoluble in most solvents, so we were 
never able to determine if this was the true cause of the failure. The unique electronics of 
dioxopiperazine 4.3 and the poor solubility of any readily accessible surrogate forced us 
to study the cyclization using advanced material. 
 
 Scheme 4.13. Model cyclization study. 
 We next attempted the oxidative cyclization using DMDO in acetone and 



































































































reaction of either dioxopiperazine 4.3 or amine 4.26. However, trace amounts of 3-
hydroxypyrroloindoline 4.40 were detected from the reaction with Cbz protected 
derivative 4.25. 
 
 Scheme 4.14. More oxidative cyclization attempts. 
 Interestingly, only the TBS-protected derivative (4.25) would cyclize. The 
unprotected analogue (4.4) also failed to react when treated with DMDO to form the 
desired tricycle (4.41, Scheme 4.15). Unfortunately, even the successful cyclization (4.25 
to 4.40) had limited potential, as the best yield obtained for this sequence was 9%, 
obtained from the crude reaction mixture by a difficult separation. The recovered alcohol 
needed to be protected before moving forward, but only trace amounts of the bis-TBS 
product were obtained. Steric congestion of the two neighboring silyl groups likely 








































































 Scheme 4.15. Progression of cyclization. 
 We also attempted the cyclization using other oxidants, including Davis’s 
oxaziridine and benzoyl peroxide (Scheme 4.16).116,156 Only starting material was 
recovered, with no trace of the desired products (4.34 and 4.43). 
 
 Scheme 4.16. Attempted cyclizations. 
 
4.3.5: Toward a Formal Synthesis of Sporidesmin A 
 These repeated attempts at forming the requisite 3-hydroxypyrroloindoline were 















































































































similar substrate. That said, it should be noted that in the original sporidesmin synthesis, 
the authors only recovered diacetate 2.6 in 30% yield and completed the synthesis using 
authentic diacetate prepared from the degradation of sporidesmin A (Scheme 4.17).113 
One can only conclude that they also were unable to access appreciable quantities of the 
pyrroloindoline. Moreover, in Kishi’s later synthesis of sporidesmin B, benzoyl peroxide 
was used as the oxidant instead of iodosobenzene diacetate, yielding only 20% of the 
desired oxidative cyclization product.116 We recognized that intermediate 2.5 reported in 
the Kishi sporidesmin A synthesis could be intercepted from alcohol 4.4. 
 
 Scheme 4.17. Kishi’s final steps in the sporidesmin A synthesis. 
 A suitable N-Me alanine derivative needed to be prepared for the formal synthesis 
of sporidesmin A. N-Fmoc-Ala-OH (4.44) was converted to the oxazolidinone (4.45), 
then reduced to afford N-Me,Fmoc-Ala-OH (4.46, Scheme 4.18).157 
 
 Scheme 4.18. Preparation of N-Me,Fmoc-Ala-OH. 
 Alcohol 4.4 was acetylated by standard procedures to give 4.47. Amine 4.48 was 




























































4.44 4.45 4.4655% (2 steps)
 88 
derivative 4.46 to afford dipeptide 4.49. This substrate, however, did not cyclize to the 
dioxopiperazine when heated in morpholine and THF. Only 4.50, the product resulting 
from Fmoc-deprotection and elimination of acetic acid, was recovered. 
 
 Scheme 4.19. Incorporation of N-Me-Ala. 
  
4.4: Future Direction 
 Given more time, I would like to prepare bis(N,N’-Cbz) tryptophan derivatives 
4.51 and 4.53 from indole 4.6 (Scheme 4.20). The bromocyclizations that were carried 
out for the synthesis of chetomin were all performed on tryptophan derivatives bearing an 
electron-withdrawing group on the indole nitrogen. Cyclization to the pyrroloindoline 
should be more favorable with these substrates than for the N-Me derivatives. Experience 
thus far with the oxidative cyclization reaction shows that a complex mixture of products 
will likely be recovered from each reaction, so sufficient starting material will be required 





















































 Scheme 4.20. Full panel of oxidation conditions to screen. 
 The proposed installation of the epidithiodioxopiperazine ring may also be 
problematic, especially considering the attempts made in the chetomin synthesis. Still, we 
propose forming (–)-sporidesmin A (1.11) through oxidation of the disulfide prepared by 
reaction of hemiaminal 4.1 with hydrogen sulfide (Scheme 4.21). The hemiaminal could 
be prepared from dioxopiperazine 4.2 or a related derivative.  
 
 Scheme 4.21. Proposed epidithiodioxopiperazine formation. 
 
4.5: Concluding Remarks 
 In summary, we have developed an asymmetric approach toward the synthesis of 
(–)-sporidesmin A. Advanced dioxopiperazine 4.3 can be prepared in decent overall yield 


















































f.  N-PSP; mCPBA
g. Br2; AgCN, H2O
h. O2, methylene blue,     



























































many of the synthetic advances made over the course of this synthesis were applied in 
our approach to chetomin. Particularly, use of N-Fmoc amino acids as precursors to 
dioxopiperazine rings eliminated a deptrotection step from each synthesis while 
improving the cyclization yields. While it is difficult to leave this project behind 
unfinished, I have no doubt that capable hands will pick it up in the future to achieve the 
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Unless otherwise noted, all reagents were obtained from commercial suppliers 
and were used without further purification. All air or moisture sensitive reactions were 
performed under a positive pressured of argon in flame-dried glassware. Tetrahydrofuran 
(THF), toluene, diethyl ether (Et2O), dichloromethane, benzene (PhH), acetonitrile 
(MeCN), triethylamine (Et3N), pyridine, diisopropyl amine, methanol (MeOH), 
dimethylsulfoxide (DMSO), and N,N-dimethylformamide (DMF) were obtained from a 
dry solvent system (Ar degassed solvents delivered through activated alumina columns, 
positive pressure of argon). Column chromatography was performed on Merck silica gel 
Kieselgel 60 (230-400 mesh). Melting points were determined in open-end capillary 
tubes and are uncorrected. 1HNMR and 13CNMR spectra were recorded on Varian 300, or 
400 MHz spectrometers. Chemical shifts are reported in ppm relative to CHCl3 at δ 7.27 
(1HNMR) and δ 77.23 (13CNMR). Mass spectra were obtained on Fisons VG Autospec. 
IR spectra were obtained from thin films on a NaCl plate using a Bruker Tensor 27 FT-IR 
spectrometer. Optical rotations were collected at 589 nm on a Rudolph Research 
automatic polarimeter Autopol III. 
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Tert-butyl 2,3-dioxoindoline-1-carboxylate (3.5). To a solution of isatin (4.0 g, 27.2 
mmol) in THF (100 mL) at 0°C was added Boc2O (7.1 g, 32.6 mmol) and DMAP (195 
mg, 1.6 mmol). The resulting mixture was stirred overnight at r.t. under Ar, then 
concentrated under reduced pressure. The product was recrystallized in EtOAc/hexanes 
to afford 3.5 (4.7 g, 70% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  7.92 (d, J = 8.2 Hz, 1H), 7.76-7.65 (m, 2H), 7.29 (t, J 
= 7.5 Hz, 1H), 1.56 (s, 9H). 


















































Boc-Hemiaminal (3.6). To a flame-dried RBF was added 3.5 (500 mg, 2.02 mmol) and 
toluene (20 mL). Indoline (134 µL, 1.2 mmol), K2CO3 (372 mg, 2.7 mmol), and 4 Å M.S. 
(5 g) were subsequently added, and the resulting suspension heated to reflux for 12 h 
under Ar. The reaction mixture was filtered through celite and the fitrate concentrated 
under reduced pressure to afford 419 mg of 3.6 as a tan solid (100% yield) that was taken 
on without further purification.  
1H-NMR (400 MHz; CDCl3): δ  10.59 (s, 1H), 8.55 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 8.1 
Hz, 1H), 7.74 (dd, J = 8.1, 1.4 Hz, 1H), 7.57 (dd, J = 8.6, 7.2 Hz, 1H), 7.24-7.20 (m, 1H), 
7.13-7.11 (m, 1H), 7.03-6.99 (m, 1H), 3.97 (t, J = 8.4 Hz, 2H), 3.15 (t, J = 8.3 Hz, 2H), 
1.54 (s, 9H); 13C-NMR (101 MHz; CDCl3): δ 193.7, 163.4, 152.9, 144.1, 141.7, 137.0, 
133.9, 132.0, 129.2, 128.0, 125.5, 121.7, 119.3, 117.7, 81.4, 48.1, 28.49, 28.42. 









Figure 5.2a. 1H NMR spectrum of compound 3.6. 
 






















































































































































1-(2,2-dibromovinyl)-2-nitrobenzene (3.15). 2-nitrobenzaldehyde (3.14, 2.0 g, 13.2 
mmol) and CBr4 (6.57 g, 19.8 mmol) were dissolved in CH2Cl2 (100 mL). The resulting 
solution was cooled to 0 °C and a solution of PPh3 (10.38 g, 39.6 mmol) in CH2Cl2 (80 
mL) slowly added. The reaction was stirred an additional 30 minutes at 0 °C, then 
concentrated under reduced pressure. The residue was taken up in chloroform (30 mL), 
filtered, and the solid washed with chloroform (2 x 30 mL). The filtrate was concentrated, 
then purified by SiO2 chromatography (8:1 hexanes:EtOAc) to afford 3.15 (3.69 g, 91% 
yield). 
1H-NMR (300 MHz; CDCl3): δ  8.12 (dd, J = 8.2, 1.3 Hz, 1H), 7.78 (s, 1H), 7.71-7.65 
(m, 1H), 7.60-7.51 (m, 2H). 

































































1-(bromoethynyl)-2-nitrobenzene (3.12). To a solution of dibromoalkene 3.15 (3.60 g, 
11.7 mmol) and BnEt3NCl (1.33 g, 5.85 mmol) in CH2Cl2 (46 mL) at 0 °C was added a 
solution of KOH (30 g) in 23 mL of H2O. The resulting solution was stirred for 1 h at 0 
°C, then extracted with CH2Cl2. The organic extracts were dried over Na2SO4, filtered, 
concentrated under reduced pressure, and purified by SiO2 chromatography (10-20% 
EtOAc in hexanes) to afford 3.12 in quantitative yield. 
1H-NMR (300 MHz; CDCl3): δ  8.06 (dd, J = 8.2, 1.4 Hz, 1H), 7.66 (dd, J = 7.7, 1.7 Hz, 
1H), 7.58 (td, J = 7.5, 1.4 Hz, 1H), 7.49 (td, J = 7.8, 1.6 Hz, 1H). 


























































1-((2-nitrophenyl)ethynyl)indoline (3.16). Bromoalkyne 3.12 (185 mg, 0.82 mmol) was 
dissolved in toluene (2.75 mL). Indoline (110 µL, 0.98 mmol), K3PO4 (418 mg, 1.97 
mmol), CuSO4⋅5H2O (40 mg, 0.16 mmol), and 1,10-phenanthroline (60 mg, 0.33 mmol) 
were added successively. The resulting suspension was heated to 120 °C for 4 h in a 
microwave. Upon completion of the reaction, the solution was cooled and diluted with 
ether, then filtered through celite. The filtrate was concentrated under reduced pressure 
and purified by SiO2 chromatography (10-20% EtOAc in hexanes) to afford 3.16 (80 mg, 
37% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.38 (d, J = 7.9 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.68 
(d, J = 9.1 Hz, 1H), 7.40 (t, J = 7.7 Hz, 1H), 7.30-7.26 (m, 2H), 7.19 (td, J = 10.2, 6.6 Hz, 
2H), 4.72 (t, J = 8.3 Hz, 2H), 3.32 (t, J = 8.3 Hz, 2H). 









































































2-(indolin-1-ylethynyl)aniline (3.17). Nitroalkyne 3.16 was dissolved in a 4 to 1 
acetone/water mixture (4.3 mL). Zinc dust (141 mg, 2.15 mmol) and NH4Cl (228 mg, 
4.30 mmol) were added successively, and the resulting suspension stirred briskly for 10 
minutes at r.t. The mixture was concentrated under reduced pressure, diluted with EtOAc, 
washed with water, washed with brine, dried over Na2SO4 and concentrated. Purification 
by SiO2 chromatography (3:1 hexanes:EtOAc, 1:1 hexanes:EtOAc, then 100% EtOAc) 
afforded pure aniline derivative 3.17 (61 mg, 61% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.33 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 15.6 Hz, 2H), 7.20-
7.04 (m, 4H), 6.72 (dd, J = 7.4, 2.3 Hz, 2H), 4.39-4.14 (m, 2H), 3.96 (td, J = 10.4, 6.1 
Hz, 1H), 3.54 (td, J = 10.4, 7.0 Hz, 1H), 3.21-2.99 (m, 2H); 13C-NMR (75 MHz; CDCl3): 
δ 131.5, 130.1, 129.1, 127.9, 124.98, 124.95, 122.2, 118.8, 117.6, 117.3, 112.5, 71.6, 
47.5, 28.4. 







Figure 5.6a. 1H NMR spectrum of compound 3.17. 
 




























































































































































































Methyl 3-(benzyloxycarbonylamino)-4-(indolin-3-yl)butanoate (3.21). N-Cbz-L-Trp-
OMe (3.52 g, 10.0 mmol) was dissolved in THF/TFA (16.5 mL/16.5 mL) and cooled to 0 
°C. BH3⋅Me2S was added dropwise and the resulting solution stirred 15 min. at 0 °C. 
Water (33 mL) was added and the mixture stirred 15 min. at r.t. The solvent was removed 
in vacuo and TFA azeotroped off with toluene (3x). The residue was taken up in EtOAc, 
washed with 1M NaOH (3x), water (1x), and brine (1x) successively. The organic layer 
was dried over Na2SO4, filtered, concentrated under reduced pressure, and purified by 
SiO2 chromatography (2:1 – 1:1 hexanes:EtOAc) to afford indoline 3.21 (2.81 g, 79% 
yield). 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 5H), 7.03 (t, J = 7.1 Hz, 2H), 6.74-6.71 (m, 1H), 
6.64 (dd, J = 9.5, 1.8 Hz, 1H), 5.37 (dd, J = 26.1, 8.8 Hz, 1H), 5.12 (s, 2H), 4.53-4.44 (m, 




















































































































(S)-methyl 3-(1H-indol-3-yl)-2-(2,2,2-trifluoroacetamido)propanoate (3.31). To a 
solution of L-Trp-OMe·HCl (1.0 g, 3.92 mmol) in MeOH was added trifluoromethyl 
propionate (0.94 mL, 7.84 mmol) and Et3N (1.1 mL, 7.84 mmol). After stirring 1 h at r.t., 
the reaction mixture was concentrated and the resulting residue dissolved in CH2Cl2. The 
organic phase was washed with ammonium hydroxide (5%, 1x) and brine (1x), then dried 
over Na2SO4 and concentrated to afford 1.23 g of the title compound, carried forward as 
crude (>99% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.25-8.23 (bs, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 
8.1 Hz, 1H), 7.21 (td, J = 7.5, 1.1 Hz, 1H), 7.13 (td, J = 7.4, 1.0 Hz, 1H), 6.98 (d, J = 2.4 
Hz, 1H), 6.87-6.85 (bs, 1H), 4.94 (dt, J = 7.8, 5.0 Hz, 1H), 3.73 (s, 3H), 3.42 (d, J = 5.1 
Hz, 2H). 











































































































carboxylate (3.32). To a solution of 3.31 (1.07 g, 3.4 mmol) in CH2Cl2 (34 mL) and Et3N 
(1.9 mL, 13.6 mmol) at 0 °C was added t-BuOCl (0.41 mL, 3.4 mmol) dropwise. The 
resulting solution was allowed to warm to r.t. O/N with stirring. Water was added and the 
product extracted in to Et2O. The combined organic layers were washed with brine, dried 
over Na2SO4, and concentrated. Recrystallization from EtOAc/hexanes provided the pure 
title compound (670 mg, 63% yield). 
1H-NMR (300 MHz; CDCl3): δ  9.17-9.16 (bs, 1H), 7.39 (td, J = 6.7, 2.6 Hz, 2H), 7.17 
(ddd, J = 7.0, 4.3, 2.2 Hz, 2H), 5.55 (dt, J = 9.7, 1.8 Hz, 1H), 3.82 (s, 3H), 3.74 (dd, J = 
14.8, 9.7 Hz, 1H), 3.36 (dd, J = 14.8, 2.3 Hz, 1H). 





















































































tetrahydropyrrolo[2,3-b]indole-1,2(2H)-dicarboxylate (3.35). N-Boc-Trp-OMe (100 
mg, 0.31 mmol) was dissolved in acetonitrile (6 mL), then 2-iodoaniline (81 mg, 0.37 
mmol) added and the resulting solution cooled to -45 °C. Freshly recrystallized NIS (113 
mg, 0.50 mmol) was added dropwise over 1 h as a solution in acetonitrile (1.5 mL). The 
reaction was allowed to warm to -35 °C as it stirred an additional hour. The entire 
reaction mixture was poured into a separatory funnel containing sat’d Na2S2O4 and 
EtOAc. The product was extracted in EtOAc (3x) and the combined organic layers 
washed with brine, dried over Na2SO4, and concentrated. Crude 3.35 was purified by 
SiO2 chromatography (5-10% EtOAc in hexanes) to afford pure 3.35 in 78% yield (130 
mg). 
1H-NMR (300 MHz; CDCl3): δ  7.64 (t, J = 7.8 Hz, 1H), 7.12 (dt, J = 13.7, 7.3 Hz, 2H), 
6.99 (t, J = 7.7 Hz, 1H), 6.75-6.65 (m, 2H), 6.40 (t, J = 7.6 Hz, 1H), 6.30 (dd, J = 16.2, 
8.2 Hz, 1H), 5.89 (d, J = 34.7 Hz, 1H), 4.63 (d, J = 25.6 Hz, 1H), 4.39 (ddd, J = 25.8, 8.3, 
4.3 Hz, 1H), 3.82 (s, 3H), 2.72 (qd, J = 15.3, 6.6 Hz, 2H), 1.46 (d, J = 30.4 Hz, 9H). 
























































































































L-serine-OMe (3.39). To a solution of L-serine (50.0 g, 0.48 mol) in MeOH (450 mL) at 
0 °C was added SOCl2 (35 mL, 0.48 mol). The reaction was allowed to warm to r.t. as it 
stirred O/N. The resulting solution was concentrated, taken up in ether, filtered, and the 
solid washed with ether. The crude solid material was recrystallized in MeOH/ether to 
afford pure crystalline methyl ester 3.39 as the HCl salt. 
REF: TRW-I-462, TRW-II-118. 
 
 
N-Boc-Ser-OMe (3.40). Boc anhydride (12.2 g, 56 mmol) was dissolved in acetonitrile 
(190 mL), then Et3N (24 mL, 168 mmol) and L-Ser-OMe·HCl (8.74 g, 56 mmol) added. 
The reaction was allowed to stir for 6 h at r.t., then CH2Cl2 (950 mL) and 1M HCl (665 
mL) added. The organic layer was separated and washed with sat’d NaHCO3, then dried 
over Na2SO4 and concentrated to afford the title material, used as crude (10.01 g, 82% 
yield). 
1H-NMR (300 MHz; CDCl3): δ  5.43 (m, J = 1.6, 0.8 Hz, 1H), 4.40-4.38 (m, 1H), 3.97-
3.91 (m, 2H), 3.79 (s, 3H), 2.20-2.19 (m, 1H), 1.46 (s, 9H). 




































































































Methyl 2-(tert-butoxycarbonylamino)-3-iodopropanoate (3.41). To a solution of Ph3P 
(2.13 g, 8.13 mmol) and imidazole (553 mg, 8.13 mmol) in CH2Cl2 (30 mL) at 0 °C was 
added I2 (2.07 g, 8.13 mmol) in 3 portions. The reaction mixture was warmed to r.t. for 
10 minutes, then cooled to 0 °C before adding dropwise a solution of Boc-Ser-OMe (1.42 
g, 6.5 mmol) in 10 mL CH2Cl2. The resulting solution was stirred 1 h at 0 °C, then 
allowed to warm to r.t. as it stirred an additional 1.5 h. The crude reaction mixture was 
filtered through a plug of silica with 1:1 EtOAC/hexanes. The filtrate was concentrated 
under reduced pressure and purified by SiO2 chromatography (5-20% EtOAc in hexanes) 
to afford iodide 3.41 (1.17 g, 55% yield). 
1H-NMR (300 MHz; CDCl3): δ  5.36-5.33 (m, 1H), 4.55-4.50 (m, 1H), 3.80 (s, 3H), 3.56 
(dq, J = 9.8, 5.0 Hz, 2H), 1.46 (s, 9H). 















































































(S)-methyl 2-((tert-butoxycarbonyl)amino)-5-(trimethylsilyl)pent-4-ynoate (3.42). A 
flask (Flask A) containing CuCN (123 mg, 1.37 mmol) and LiCl (115 mg, 2.74 mmol) 
was heated to 150 °C under vacuum for 2 h, then cooled to r.t. DMF (4 mL) was added 
and the suspension sonicated until full dissolution was observed. This solution was then 
cooled to -20 °C. A second flask (Flask B) containing Zn dust (358 mg, 5.47 mmol) was 
heated under vaccum, cooled to r.t., filled with Ar, then DMF (1.75 mL) and 
dibromoethane (26 µL, 0.30 mmol) added. The suspension was heated to 80 °C for 30 
min, then cooled to r.t. before addition of TMSCl (19 µL, 0.15 mmol). Following an 
additional 30 min of stirring, N-Boc-Ser(I)-OMe (3.41, 500 mg, 1.52 mmol) was added 
slowly as a solution in a minimal amount of DMF. After complete addition, this 
suspension was transferred to Flask A. The combined reaction mixture was allowed to 
stir for 15 min at -20 °C, then TMS-acetylene bromide (269 mg, 1.52 mmol) added 
dropwise. The reaction mixture was allowed to warm to r.t. O/N. Water was added (15 
mL) and the product extracted in EtOAc. The combined organic layers were washed with 
brine, dried over Na2SO4, and concentrated. SiO2 chromatography (3:1 hexanes/EtOAc) 
afforded the pure title compound (180 mg, 40% yield, stains with vanillin). 
1H-NMR (300 MHz; CDCl3): δ  5.28 (d, J = 8.4 Hz, 1H), 4.43-4.37 (m, 1H), 3.70 (s, 3H), 
2.75-2.59 (m, 2H), 1.39 (s, 9H), 0.07 (s, 8H). 
























































(Bromoethynyl)trimethylsilane. To a solution of TMS-acetylene (5 mL, 35.5 mmol) in 
acetone (120 mL) was added AgNO3 (604 mg, 3.55 mmol) and NBS (6.94 g, 39 mmol). 
After stirring 3 h, the reaction was quenched by addition of ice water. The product was 
extracted in pentane and the combined organic layers washed with brine, dried over 
Na2SO4, and concentrated (bath at 0 °C) to afford pure (bromoethynyl)trimethylsilane 
(4.51 g, 72% yield). 
1H-NMR (300 MHz; CDCl3): δ  0.18 (s, 9H). 
REF: TRW-I-442, TRW-I-457. 
 











1,2(2H)-dicarboxylate (3.43). A flask containing 3.35 (300 mg, 0.56 mmol), 3.42 (370 
mg, 1.24 mmol), NaOAc (321 mg, 3.92 mmol), LiCl (24 mg, 0.56 mmol), and Pd(OAc)2 
(25 mg, 0.11 mmol) was vacated and backfilled with Ar. DMF (3 mL) was added and the 
suspension sonicated for 15 minutes while bubbling Ar through reaction. Three freeze-
pump-thaw cycles were performed to complete the degassing procedure. The reaction 
mixture was heated to 100 °C for 24 h, then diluted with toluene and concentrated. The 
crude residue was taken up in EtOAc, filtered through celite, and washed with 3M HCl. 
The organic fraction was further washed with brine, dried over Na2SO4, and concentrated 
to afford the title compound (3.43, 250 mg, 70% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.62 (d, J = 8.1 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.35-
7.25 (m, 3H), 7.14 (d, J = 7.4 Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), 
6.64 (s, 1H), 6.05-5.91 (m, 1H), 5.02 (d, J = 7.9 Hz, 1H), 4.55-4.53 (m, 1H), 4.28-4.20 
(m, 1H), 3.80 (d, J = 3.1 Hz, 3H), 3.58-3.47 (m, 3H), 3.36 (dd, J = 13.1, 9.3 Hz, 1H), 
3.15-3.14 (m, 1H), 2.98 (dd, J = 13.2, 7.8 Hz, 1H), 1.42 (complex, J = 28.4 Hz, 18H). 














































































































































carboxylic acid (3.44). To a solution of 3.43 (100 mg, 0.136 mmol) in THF and MeOH 
(2:1, 0.40 mL:0.20 mL) was added LiOH (20 mg, 0.80 mmol). After stirring under Ar 
O/N, 10% KHSO4 was added until the solution was acidic, then the product extracted in 
EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, and 
concentrated. Crude 3.44 recovered as such was carried forward to the next reaction (90.4 
mg, 93% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.55-7.53 (m, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.06-7.00 
(m, 1H), 6.90-6.86 (m, 1H), 6.79-6.62 (m, 3H), 6.48-6.32 (m, 1H), 6.24-6.13 (m, 1H), 
4.63-4.34 (m, 2H), 3.56-3.47 (m, 1H), 3.20-3.18 (m, 1H), 3.04-2.82 (m, 2H), 1.50-1.38 
(m, 18H). 









































































































































































































(2S,3aR,8aR)-1-benzyl 8-tert-butyl 2-methyl 3a-bromo-3,3a-dihydropyrrolo[2,3-
b]indole-1,2,8(2H,8aH)-tricarboxylate (3.47). To a solution of N-Cbz,N’-Boc-Trp-OMe 
(1.0 g, 2.2 mmol) in CH2Cl2 (100 mL) was added PPTS (552 mg, 2.2 mmol) and NBS 
(392 mg, 2.2 mmol). The resulting solution was stirred O/N at r.t, then diluted with 
CH2Cl2, washed with brine, dried over Na2SO4, and concentrated. Crude 3.47 was 
purified by SiO2 chromatography (25% EtOAc in hexanes) to afford pure material in 
88% yield (1.03 g). 
1H-NMR (300 MHz; CDCl3): δ  7.37-7.28 (m, 8H), 7.12 (td, J = 7.5, 0.7 Hz, 1H), 6.43 (s, 
1H), 5.19-5.16 (m, 2H), 3.97 (dd, J = 10.3, 6.5 Hz, 1H), 3.69-3.41 (m, 3H), 3.26 (dd, J = 

































































































































(2R,3aR,8aR)-1-benzyl 8-tert-butyl 2-methyl 3a-(1H-indol-1-yl)-3,3a-
dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (3.48). 
Bromopyrroloindoline 3.47 (500 mg, 0.94 mmol) was dissolved in acetonitrile (20 mL), 
and to it added indole (74 mg, 0.63 mmol). The suspension was cooled to 0 °C, then 
KOtBu (141 mg, 1.26 mmol) added slowly. Once the reaction was deemed complete by 
TLC, the mixture was quenched by addition of sat’d NaHCO3 and the product extracted 
in CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4, 
concentrated, and purified by SiO2 chromatography (3:1 hexanes:EtOAc) to afford pure 
3.48 (100 mg, 28% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.79-7.75 (bs, 1H), 7.65-7.62 (m, 1H), 7.44-7.27 (m, 
8H), 7.19-7.15 (m, 3H), 6.96 (d, J = 3.0 Hz, 1H), 6.44 (d, J = 3.4 Hz, 1H), 5.30-5.20 (m, 
2H), 4.97 (d, J = 8.9 Hz, 1H), 3.57 (dd, J = 13.0, 9.3 Hz, 1H), 3.22 (s, 3H), 3.07 (d, J = 
13.1 Hz, 1H), 1.47 (bs, 9H). 











































































































































N-Boc-L-tryptophan-N-SO2Ph (3.56). N-Boc-Trp (14.8 g, 48.7 mmol) was dissolved in 
THF (100 mL) and the resulting solution cooled to -78 °C. LHMDS (146 mL, 146.1 
mmol) was added slowly over 5 minutes. The reaction was stirred at -78 °C for 1 h, then 
PhSO2Cl (7.5 mL, 58.4 mmol) added in one portion. After stirring an additional 2 h at -78 
°C, the reaction was quenched by addition of 1:1 AcOH:EtOAc then allowed to warm to 
r.t. The suspension was diluted with 1M HCl and the product extracted in EtOAc. The 
combined organic layers were dried and concentrated to afford crude 3.56, purified by 
SiO2 chromatography (5% AcOH, 45% hexanes, 50% CH2Cl2) to afford pure 3.56 (17.12 
g, 79% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  12.64-12.63 (m, 1H), 7.90-7.87 (m, 2H), 7.61 (t, J = 
7.8 Hz, 2H), 7.56-7.50 (m, 2H), 7.25-7.20 (m, 2H), 7.16-7.13 (m, 2H), 4.20-4.17 (m, 1H), 
3.11 (dd, J = 14.8, 4.2 Hz, 1H), 2.95 (dd, J = 14.8, 10.0 Hz, 1H), 1.31 (s, 9H). 















































































































Dipeptide (3.57a). To a solution of N-Me-L-serine-OMe (2.0 g, 15 mmol) in CH2Cl2 (75 
mL) was added iPr2NEt (2.61 mL, 15 mmol). After stirring 15 minutes, the suspension 
was added to a stirring solution of 3.56 (6.66 g, 15 mmol) and EDCI (2.88 g, 15 mmol) in 
CH2Cl2. The reaction was stirred O/N at r.t., then concentrated and purified through a 
plug of SiO2 (100% EtOAc) to afford 3.57a (86% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.40 (d, J = 7.4 Hz, 1H), 7.87 (t, J = 8.8 Hz, 2H), 
7.67 (dt, J = 21.1, 6.5 Hz, 2H), 7.54 (t, J = 7.7 Hz, 2H), 7.29 (complex, 2H), 6.95 (d, J = 
8.9 Hz, 1H), 5.14 (dt, J = 11.2, 5.6 Hz, 1H), 4.47 (d, J = 5.7 Hz, 1H), 4.38-4.34 (m, 1H), 
3.77-3.70 (m, 1H), 3.60 (s, 3H), 3.07-3.01 (m, 1H), 2.88-2.80 (m, 1H), 2.48 (s, 3H), 1.25 



































































































































































Dioxopiperazine (3.58a). Dipeptide 3.57a (500 mg) was transferred to a microwave 
tube, then heated neat in the microwave at maximum power to a safe temperature of 180 
°C (microwave set to ‘open-vessel’). After cooling, the residue was suspended in CH2Cl2, 
transferred to a vial, and concentrated to afford dioxopiperazine 3.58a (94% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.15 (d, J = 2.4 Hz, 1H), 8.03 (d, J = 2.0 Hz, 1H), 
7.89 (dd, J = 24.0, 7.8 Hz, 3H), 7.64 (t, J = 3.6 Hz, 2H), 7.56 (d, J = 4.0 Hz, 1H), 7.33-
7.27 (m, 2H), 5.14 (t, J = 5.7 Hz, 1H), 4.47 (d, J = 5.6 Hz, 1H), 4.05-4.00 (m, 1H), 3.74 
















































































































































hydroxypropanoate (3.57c). To a solution of L-Ser-OMe·HCl (2.56 g, 16.4 mmol) in 
CH2Cl2 (80 mL) was added iPr2NEt (2.85 mL, 16.4 mmol). After stirring 15 minutes, N-
Boc-L-Trp (5.0 g, 16.4 mmol) and EDCI (3.15 g, 16.4 mmol) were added. The reaction 
was stirred O/N at r.t., then concentrated and purified through a plug of SiO2 (100% 
EtOAc) to afford 3.57c (5.71 g, 86% yield). 
1H-NMR (400 MHz; CDCl3): δ  8.69 (bs, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 8.0 
Hz, 1H), 7.06 (t, J = 7.4 Hz, 1H), 7.01-6.97 (m, 2H), 5.34 (d, J = 7.4 Hz, 1H), 4.42 (bs, 
2H), 3.70 (bs, 2H), 3.54 (s, 3H), 3.16 (bs, 2H), 1.30 (s, 9H); 13C-NMR (101 MHz; 
CDCl3): δ 172.4, 170.6, 155.8, 136.2, 127.5, 123.5, 122.0, 119.4, 118.5, 111.4, 109.8, 














Figure 5.22a. 1H NMR spectrum of compound 3.57c. 
 

















































































































Dipeptide (3.57d). To a solution of L-Ser-OMe·HCl (6.0 g, 38.5 mmol) in CH2Cl2 (200 
mL) was added iPr2NEt (6.7 mL, 38.5 mmol). After stirring 15 minutes, the suspension 
was added to a stirring solution of 3.56 (17.12 g, 38.5 mmol) and EDCI (7.39 g, 38.5 
mmol) in CH2Cl2. The reaction was stirred O/N at r.t., then concentrated and purified 
through a plug of SiO2 (100% EtOAc) to afford 3.57d (13.78 g, 66% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.96 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 7.1 Hz, 2H), 7.52 
(t, J = 7.0 Hz, 2H), 7.44 (dd, J = 13.3, 5.5 Hz, 3H), 7.31 (t, J = 7.1 Hz, 1H), 6.96 (d, J = 
6.7 Hz, 1H), 5.24-5.21 (m, 1H), 4.59-4.56 (m, 1H), 4.44 (q, J = 7.2 Hz, 1H), 3.89 (dt, J = 
1.3, 0.7 Hz, 2H), 3.72 (s, 3H), 3.18 (d, J = 6.0 Hz, 2H), 1.40 (s, 9H); 13C-NMR (101 
MHz; CDCl3): δ 171.9, 170.7, 155.9, 138.0, 135.0, 133.7, 130.8, 129.2, 126.6, 124.72, 
124.70, 123.2, 119.6, 117.9, 113.5, 80.3, 62.4, 54.7, 52.6, 28.16, 28.00. 













Figure 5.23a. 1H NMR spectrum of compound 3.57d. 
 

































































































































































2,5-dione (3.58d). The general cyclization procedure given for compound 3.58a was 
repeated. 
1H-NMR (300 MHz; DMSO-d6): δ  8.14-7.86 (m, 4H), 7.64-7.56 (m, 4H), 7.30-7.28 (m, 
J = 5.5, 0.8 Hz, 2H), 5.13-5.13 (m, 1H), 4.38-4.03 (m, 1H), 3.74-3.60 (m, 2H), 3.43-3.33 
(m, 2H), 3.15-2.85 (m, 2H); 13C-NMR (101 MHz; DMSO): δ 167.5, 167.3, 137.6, 137.2, 
134.8, 131.4, 130.2, 126.9, 125.9, 123.6, 120.4, 118.5, 113.40, 113.31, 63.0, 57.3, 54.7, 
50.9. 












Figure 5.24a. 1H NMR spectrum of compound 3.58d. 
 


































































































































































Dipeptide (3.57e). Alcohol 3.57d (2.9 g, 5.3 mmol) was dissolved in DMF (13 mL), and 
to it added imidazole (864 mg, 12.7 mmol) and TBSCl (2.08 g, 13.8 mmol). The reaction 
stirred O/N at r.t., then was concentrated, dissolved in EtOAc, washed with H2O (3x), 
washed with brine, dried, and concentrated to afford silylether 3.57e (3.14 g, 90% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.14 (d, J = 7.8 Hz, 1H), 7.85 (t, J = 7.9 Hz, 3H), 
7.65 (t, J = 7.2 Hz, 2H), 7.58-7.50 (m, 3H), 7.33-7.20 (m, 2H), 7.00 (d, J = 8.8 Hz, 1H), 
4.46-4.40 (m, 1H), 4.34-4.30 (m, 1H), 3.86 (dd, J = 10.3, 4.7 Hz, 1H), 3.74 (dd, J = 10.3, 
4.9 Hz, 1H), 3.60 (s, 3H), 3.05-2.99 (m, 1H), 2.89-2.80 (m, 1H), 1.25 (s, 9H), 0.82 (s, 
9H), 0.00 (d, J = 3.2 Hz, 6H); 13C-NMR (101 MHz; CDCl3): δ 170.6, 170.2, 138.2, 
135.1, 133.7, 130.8, 129.2, 126.7, 124.9, 124.6, 123.3, 119.6, 117.6, 113.6, 63.3, 54.2, 
52.4, 28.20, 28.10, 25.70, 25.61, 18.1, -5.63, -5.77. 













Figure 5.25a. 1H NMR spectrum of compound 3.57e. 
 















































































































































































































































Dioxopiperazine (3.58e). Dipeptide 3.57e (500 mg) was transferred to a microwave tube, 
then heated neat in the microwave at maximum power to a safe temperature of 180 °C 
(microwave set to ‘open-vessel’). After cooling, the residue was suspended in CH2Cl2, 
transferred to a vial, and concentrated to afford dioxopiperazine 3.57e (2.47 g over 6 
batches, 98%). 
1H-NMR (300 MHz; DMSO-d6): δ  7.92-7.83 (m, 4H), 7.64 (t, J = 3.7 Hz, 2H), 7.58-7.52 
(m, 4H), 7.33-7.28 (m, 1H), 7.25-7.20 (m, 1H), 4.15-4.05 (m, 1H), 3.84-3.77 (m, 1H), 
3.61-3.43 (m, 2H), 3.16-2.94 (m, 2H), 0.79 (s, 9H), -0.02 (s, 3H), -0.06 (s, 3H). 

















































































































































































Dipeptide (5.1). Alcohol 3.57c (2.0 g, 4.9 mmol) was dissolved in DMF (12 mL), and to 
it added imidazole (802 mg, 11.8 mmol) and TBSCl (1.92 g, 12.7 mmol). The reaction 
stirred O/N at r.t., then was concentrated, dissolved in EtOAc, washed with H2O (3x), 
washed with brine, dried, and concentrated to afford silylether 5.1 (2.38 g, 93% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.18 (bs, J = 0.4 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.34 
(d, J = 8.0 Hz, 1H), 7.20-7.18 (m, 1H), 7.16-7.11 (m, 2H), 6.55-6.52 (m, 1H), 5.19-5.16 
(m, 1H), 4.54 (broad, J = 7.0, 4.1 Hz, 2H), 3.95 (dd, J = 10.1, 2.7 Hz, 1H), 3.66 (s, 3H), 
3.62-3.58 (m, 1H), 3.31-3.30 (m, 1H), 3.21 (dd, J = 14.6, 6.9 Hz, 1H), 1.42 (s, 9H), 0.77 















































































































































































butyldimethylsilyl)oxy)methyl)piperazine-2,5-dione (5.2). The general cyclization 
procedure given for compound 3.58a was repeated. 
1H-NMR (300 MHz; DMSO-d6): δ  10.88 (m, 1H), 7.95 (s, 1H), 7.60-7.48 (m, 1H), 7.29 
(t, J = 7.8 Hz, 1H), 7.05-6.93 (m, 2H), 4.09-3.97 (m, 1H), 3.82-3.70 (m, 1H), 3.52-3.43 
(m, 1H), 3.27-3.14 (m, 2H), 2.79 (d, J = 47.6 Hz, 1H), 0.81 (s, 9H), -0.02--0.05 (m, 6H); 
13C-NMR (101 MHz; DMSO): δ 167.6, 165.5, 136.5, 127.9, 124.4, 121.3, 118.96, 













Figure 5.28a. 1H NMR spectrum of compound 5.2. 
 











































































































































































































yl)methyl)-1H-indole-1-carboxylate. The general cyclization procedure given for 
compound 3.58a was repeated. 
1H-NMR (300 MHz; CDCl3): δ  8.01 (d, J = 8.2 Hz, 1H), 7.47 (dd, J = 7.7, 0.4 Hz, 1H), 
7.35 (s, 1H), 7.23-7.10 (m, 2H), 4.16-4.12 (m, 1H), 3.87-3.84 (m, 3H), 3.63 (dd, J = 10.1, 
3.1 Hz, 1H), 3.31 (dd, J = 10.1, 5.8 Hz, 2H), 3.05 (dd, J = 14.4, 8.8 Hz, 1H), 1.54 (s, 9H), 
0.75 (s, 9H), -0.09 (s, 6H); 13C-NMR (101 MHz; CDCl3): δ 173.3, 171.6, 135.4, 130.61, 
130.58, 130.50, 128.6, 124.8, 121.0, 120.2, 89.7, 70.5, 62.7, 60.5, 54.7, 54.5, 36.5, 33.7, 













Figure 5.29a. 1H NMR spectrum of compound 5.3. 
 










































































































































































N-Boc-L-tryptophan-N’-SO2Ph (3.56). Compound 3.59 (14.8 g, 48.7 mmol) was 
dissolved in THF (100 mL) and the resulting solution cooled to -78 °C. LHMDS (146 
mL, 146.1 mmol) was added slowly over 5 minutes. The reaction was stirred at -78 °C 
for 1 h, then PhSO2Cl (7.5 mL, 58.4 mmol) added in one portion. After stirring an 
additional 2 h at -78 °C, the reaction was quenched by addition of 1:1 AcOH:EtOAc then 
allowed to warm to r.t. The suspension was diluted with 1M HCl and the product 
extracted in EtOAc. The combined organic layers were dried and concentrated to afford 
crude 3.56, purified by SiO2 chromatography (5% AcOH, 45% hexanes, 50% CH2Cl2) to 
afford pure 3.56 (17.12 g, 79% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  12.64-12.63 (m, 1H), 7.90-7.87 (m, 2H), 7.61 (t, J = 
7.8 Hz, 2H), 7.56-7.50 (m, 2H), 7.25-7.20 (m, 2H), 7.16-7.13 (m, 2H), 4.20-4.17 (m, 1H), 
3.11 (dd, J = 14.8, 4.2 Hz, 1H), 2.95 (dd, J = 14.8, 10.0 Hz, 1H), 1.31 (s, 9H). 















































































































Bromopyrroloindoline (3.55e). A solution of dioxopiperazine 3.58e (2.47 g, 4.68 mmol) 
in MeCN (50 mL) was cooled to 0 °C and to it added bromine (0.962 mL, 18.7 mmol) 
dropwise. After stirring 5 minutes, 1:1 Na2S2O3:NaHCO3 was added and the product 
extracted in EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated. Purification by SiO2 chromatgraphy (10/40/50 iPrOH/hexanes/ 
CH2Cl2) afforded pure pyrroloindoline 3.55e in 38% yield (1.09 g). 
1H-NMR (300 MHz; DMSO-d6): δ  8.06 (s, 1H), 7.87-7.84 (m, 2H), 7.66-7.53 (m, 4H), 
7.42 (d, J = 2.3 Hz, 2H), 7.27-7.22 (m, 1H), 6.46 (s, 1H), 4.05 (d, J = 1.0 Hz, 1H), 3.77-
3.75 (m, 2H), 3.73-3.68 (m, 2H), 3.60-3.56 (m, 2H), 1.01 (d, J = 6.1 Hz, 9H), -0.02 (s, 
6H). 

















































































































N-Me-bromopyrroloindoline (3.60). Dioxopiperazine 3.55e (2.09 g, 3.4 mmol) was 
dissolved in acetone (50 mL). Potassium carbonate (11.73 g, 85 mmol) and MeI (27.5 
mL, 442 mmol) were added, the flask covered with foil, and the reaction allowed to stir at 
r.t. under Ar for 5 d. The crude reaction mixture was concentrated, partitioned between 
EtOAc and H2O (200 mL each), and the product extracted in EtOAc. The combined 
organic layers were dried and concentrated. SiO2 chromatography (10/40/50 
iPrOH/hexanes/CH2Cl2) gave the pure title compound (1.69 g, 98% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.89-7.71 (m, J = 1.6 Hz, 2H), 7.69 (d, J = 8.2 Hz, 1H), 
7.58-7.52 (m, 1H), 7.44 (ddd, J = 8.4, 6.8, 1.4 Hz, 2H), 7.38-7.32 (m, 2H), 7.21 (d, J = 
7.0 Hz, 1H), 6.54 (d, J = 28.9 Hz, 1H), 4.08-3.78 (m, 4H), 3.17 (ddd, J = 28.8, 12.6, 5.2 
Hz, 1H), 2.98 (s, 3H), 2.89-2.76 (m, 1H). 





































































































































































































OTBS-N-Me-bromopyrroloindoline (3.61). The same general procedure for TBS 
protection was followed as for 3.57e. Instead of carrying the crude product forward as 
before, it was necessary for the subsequent radical bromination to purify the product by 
SiO2 chromatography (20-60% EtOAc in hexanes) to afford 3.61 (47% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.89 (dd, J = 8.1, 1.0 Hz, 2H), 7.70 (dd, J = 7.9, 0.6 Hz, 
1H), 7.56-7.53 (m, 1H), 7.48-7.43 (m, 2H), 7.35-7.32 (m, 2H), 7.21-7.16 (m, 1H), 6.63 
(s, 1H), 4.28 (dd, J = 10.2, 1.3 Hz, 1H), 4.06 (s, 1H), 3.94 (dd, J = 10.1, 2.7 Hz, 1H), 3.78 
(dd, J = 12.4, 4.5 Hz, 1H), 3.09 (dd, J = 12.0, 4.5 Hz, 1H), 2.91 (s, 3H), 2.73 (t, J = 12.2 
Hz, 1H), 0.89 (s, 9H), 0.10 (s, 6H). 




















































































































































Diol (3.62). To a solution of Br-dioxopiperazine 3.61 (710 mg, 1.14 mmol) in CCl4 (40 
mL) was added NBS (406 mg, 2.28 mmol) and V-70 (89 mg, 0.29 mmol). The resulting 
suspension was stirred 8 h. at r.t., then filtered through a cotton plug, the solid washed 
with CCl4, and the combined filtrate concentrated. The resulting residue was dissolved in 
1:1 MeCN:pH 7 phosphate buffer (58 mL) and stirred 3 h. at r.t. The product was 
extracted in EtOAc (3x), washed with brine, dried, and concentrated to afford the diol in 
97% yield (720 mg), carried forward to the next step as the crude material. 















Epidithiodioxopiperazine (3.63). Hydrogen sulfide (ca. 8 mL) gas was condensed in a 
sealed tube capped with a rubber septum at -78 °C. Diol 3.62 (125 mg, 0.19 mmol) and 
BF3·OEt2 (0.119 mL, 0.95 mmol) were added as a solution in CH2Cl2 (7.6 mL). The 
rubber septum was removed and the sealed tube capped with a teflon cap and placed 
behind a blast shield. The reaction mixture stirred at r.t. for 90 min., recooled to -78 °C, 
uncapped and sealed with a rubber septum, then allowed to warm to r.t. with 3 NaOH and 
1 bleach trap in place as the gas vented. The resulting solution was diluted with EtOAc, 
washed with sat’d NH4Cl, and the product extracted in EtOAc. Iodine (100 mg, 2 eq) was 
added to the EtOAc extracts and the mixture allowed to stir 1 min. 10% Na2S2O3 was 
added and the product extracted in EtOAc, dried, and concentrated. Purification by SiO2 
chromatography (1:1 hexanes:EtOAc) afforded pure epidithiodioxopiperazine 3.63 in 
42% yield (44.9 mg). 
1H-NMR (300 MHz; CDCl3): δ  7.78 (dd, J = 8.4, 1.1 Hz, 2H), 7.64 (d, J = 8.2 Hz, 1H), 
7.52-7.49 (m, 1H), 7.41-7.36 (m, 4H), 7.28-7.26 (m, 1H), 6.49 (s, 1H), 4.33 (d, J = 12.8 
Hz, 1H), 4.18 (d, J = 12.7 Hz, 1H), 3.85 (d, J = 15.3 Hz, 1H), 3.21 (d, J = 15.3 Hz, 1H), 
3.13 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 176.9, 163.7, 134.83, 134.82, 134.3, 133.8, 
132.8, 131.23, 131.22, 131.0, 123.9, 114.6, 72.4, 66.2, 37.6, 31.3, 26.9, 23.7, 20.0; 
HRMS (ESI-APCI): [M+H]+ 567.9670 calcd for C21H19BrN3O5S3, found: 567.9641. REF: 














Figure 5.34a. 1H NMR spectrum of compound 3.63. 
 



















































































































































   
N-Boc-L-tryptophan (3.59). To a solution of L-tryptophan (50 g, 245 mmol) in 1:1 
THF:H2O (700 mL) was added NaOH (10.8 g, 270 mmol) and Boc2O (58.9 g, 270 
mmol). The resulting solution was stirred O/N at r.t. The volume was reduced and the 
product extracted in CH2Cl2. The aqueous layer was acidified with 1M HCl to pH 4, and 
the product extracted in CH2Cl2. The combined organic layers were dried over Na2SO4 
and concentrated to afford 3.59 (70.23 g, 94% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.50 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.09-














































































N-Boc-L-tryptophan-OMe (3.34). To a solution of N-Boc-L-tryptophan (30 g, 98.7 
mmol) in DMF (200 mL) at 0 °C was added MeI (9.2 mL, 148 mmol) and KHCO3 (19.7 
g, 197 mmol). After stirring O/N at r.t., the mixture was diluted with ether, washed with 
H2O (2x), 1M KHSO4 (1x), and brine (1x). The combined organic layers were dried and 
concentrated to afford the title compound (29.86 g, 95% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.10-8.08 (m, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 
8.0 Hz, 1H), 7.22-7.09 (m, 2H), 7.01 (d, J = 2.4 Hz, 1H), 5.09-5.06 (m, 1H), 4.68-4.62 
(m, 1H), 3.68 (s, 3H), 3.29 (d, J = 5.2 Hz, 2H), 1.43 (s, 9H). 








































































































































N-Boc-L-tryptophan-OMe-N’-SO2Ph (3.64). N-Boc-L-tryptophan-OMe (10.0 g, 31.4 
mmol), NaOH (3.77 g, 94.2 mmol), and Bu4NHSO4 (544 mg, 1.6 mmol) were suspended 
in CH2Cl2 (150 mL), then PhSO2Cl (4.8 mL, 37.7 mmol) added dropwise. After stirring 6 
h. at r.t., aqueous NH4Cl (300 mL) and EtOAc (300 mL) were added and the product 
extracted in EtOAc (3x). The combined organic extracts were dried and concentrated to 
afford the title compound (14.4 g, >99% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.97 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 7.5 Hz, 2H), 7.56-
7.50 (m, 1H), 7.47-7.44 (m, 2H), 7.42 (d, J = 7.2 Hz, 1H), 7.36 (s, 1H), 7.31-7.20 (m, 
2H), 5.05 (dt, J = 7.9, 0.6 Hz, 1H), 4.66-4.59 (m, 1H), 3.61 (s, 3H), 3.27-3.11 (m, 2H), 
1.44 (s, 9H). 
























































































































































































































Bromopyrroloindoline (3.65). To a solution of N-Boc-L-tryptophan-OMe-N’-SO2Ph (42 
g, 91.5 mmol) in CH2Cl2 (1000 mL) was added NBS (16.29 g, 91.5 mmol) and PPTS 
(22.97 g, 91.5 mmol). The reaction was stirred O/N at r.t., then washed with 10% 
NaHCO3 and 10% Na2S2O4 (1:1), and the organic extract concentrated to afford 3.65 in 
quantitative yield. 
1H-NMR (300 MHz; CDCl3): δ  7.83-7.79 (bs, 2H), 7.57 (d, J = 8.0 Hz, 1H), 7.46 (ddd, J 
= 8.4, 6.4, 1.6 Hz, 1H), 7.34 (td, J = 7.7, 1.4 Hz, 3H), 7.27-7.25 (m, 1H), 7.17 (td, J = 7.5, 
1.0 Hz, 1H), 6.33-6.31 (bs, 1H), 3.85-3.80 (m, 1H), 3.73 (s, 3H), 3.06 (dd, J = 12.6, 5.9 
Hz, 1H), 2.81-2.73 (m, 1H), 1.54-1.53 (bs, 9H); 13C-NMR (101 MHz; CDCl3): δ 171.9, 
138.0, 133.8, 133.4, 130.9, 129.2, 128.6, 128.3, 127.3, 126.6, 124.9, 124.3, 123.9, 123.3, 
113.6, 86.7, 80.0, 59.4, 52.4, 28.26, 28.17, 27.8, 21.0, 14.2. 










Figure 5.38a. 1H NMR spectrum of compound 3.65. 
 












































































































































































































































Indole (3.66). Bromopyrroloindoline 3.65 (16.41 g, 30.6 mmol) was dissolved in 
CH3CN, and to the resulting solution added N-Boc-L-tryptophan-OMe (6.49 g, 20.4 
mmol). The solution was cooled to 0 °C, then KOtBu (4.57 g, 40.8 mmol) added. After 
stirring 1 h at 0 °C, the reaction was quenched with NaHCO3, extracted in CH2Cl2, 
washed with brine, dried, and concentrated. Purification by SiO2 chromatography (40% 
EtOAc in hexanes) afforded 3.66 in 34% yield (5.36 g). 
1H-NMR (300 MHz; CDCl3): δ  7.85-7.79 (m, 1H), 7.85-7.79 (m, 1H), 7.60-7.43 (m, 
2H), 7.60-7.43 (m, 2H), 7.34 (t, J = 7.7 Hz, 3H), 7.34 (t, J = 7.7 Hz, 3H), 7.22-7.01 (m, 
7H), 7.22-7.01 (m, 7H), 6.85 (s, 1H), 6.85 (s, 1H), 6.31 (bs, 1H), 6.31 (s, 1H), 5.06 (bs, 
1H), 5.06 (s, 1H), 4.64-4.61 (m, 1H), 4.64-4.61 (m, 1H), 3.73 (s, 3H), 3.73 (s, 3H), 3.68 
(s, 3H), 3.68 (s, 3H), 3.28-3.21 (m, 2H), 3.28-3.21 (m, 2H), 3.07 (dd, J = 12.6, 5.9 Hz, 
1H), 3.07 (dd, J = 12.6, 5.9 Hz, 1H), 2.77 (t, J = 11.6 Hz, 1H), 2.77 (t, J = 11.6 Hz, 1H), 
1.58-1.55 (bs, 9H), 1.58-1.55 (m, 9H), 1.43 (s, 9H), 1.43 (s, 9H); 13C-NMR (101 MHz; 
CDCl3): δ 172.4, 161.2, 154.9, 143.2, 133.7, 132.9, 132.2, 131.61, 131.58, 131.52, 130.5, 
128.9, 128.5, 128.1, 127.0, 126.46, 126.35, 125.2, 124.1, 122.4, 121.82, 121.76, 120.24, 
120.17, 119.57, 119.43, 114.8, 82.2, 59.44, 59.36, 54.4, 53.3, 52.1, 51.6, 37.9, 37.7, 
28.18, 28.14, 28.08, 28.01, 27.99, 27.97, 27.94, 27.93, 27.91, 27.79; HRMS (ESI-
APCI+): [M+Na]+ 797.2832 calcd for C40H46N4NaO10S, found: 797.2829. 











Figure 5.39a. 1H NMR spectrum of compound 3.66. 
 



















































































































































































































































































































Diacid (3.67). To a solution of 3.66 (5.35 g, 6.9 mmol) in 2:1 THF:H2O (24 mL) was 
added LiOH (828 mg, 34.5 mmol). The reaction stirred O/N before acidifying with 10% 
KHSO4. The product was extracted in EtOAc, and the combined organic extracts washed 
with brine, dried, and concentrated. SiO2 chromatography (1:1 hexanes:EtOAc) gave the 
pure diacid (5.01 g, 97% yield). 
1H-NMR (300 MHz; CDCl3): δ  9.51 (bs, 2H), 7.70-7.67 (m, 1H), 7.55 (dt, J = 7.0, 0.8 
Hz, 1H), 7.42-7.38 (m, 1H), 7.19-7.13 (m, 8H), 6.95-6.88 (m, 2H), 6.70 (d, J = 5.8 Hz, 
1H), 6.06-5.93 (m, 1H), 4.99-4.92 (m, 1H), 4.54-4.40 (m, 1H), 3.43-3.34 (m, 1H), 3.19-
3.05 (m, 1H), 2.81-2.72 (m, 2H), 1.56 (s, 8H), 1.42 (d, J = 11.7 Hz, 9H); 13C-NMR (101 
MHz; CDCl3): δ 178.03, 177.95, 159.41, 159.30, 146.7, 141.6, 137.56, 137.44, 136.8, 
136.3, 135.3, 134.47, 134.33, 132.8, 132.4, 131.7, 130.8, 130.4, 129.5, 128.35, 128.18, 
126.2, 123.97, 123.91, 123.64, 123.63, 123.58, 123.54, 123.52, 123.50, 123.47, 113.45, 
113.42, 98.4, 86.33, 86.25, 83.81, 83.68, 64.5, 63.3, 32.0, 31.8. 












Figure 5.40a. 1H NMR spectrum of compound 3.67. 
 































































































































































































































































































































































































































































Tetrapeptide (3.68). To a solution of L-serine-OMe·HCl (2.09 g, 13.4 mmol) in CH2Cl2 
(70 mL) was added iPr2NEt (2.3 mL, 13.4 mmol). After stirring 15 minutes, the 
suspension was added to a stirring solution of 3.67 (5.01 g, 6.69 mmol) and EDCI (2.57 
g, 13.4 mmol) in CH2Cl2. The reaction was stirred O/N at r.t., then concentrated and 
purified through a plug of SiO2 (100% EtOAc) to afford 3.68 (2.11 g, 33% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.10-8.08 (broad, 1H), 7.73-7.58 (m, 5H), 7.44-7.31 
(m, 3H), 7.10-7.07 (m, 3H), 6.83-6.74 (m, 1H), 6.44-6.42 (m, 1H), 5.04-4.86 (m, 3H), 
4.34-4.22 (m, 3H), 3.61-3.43 (m, 9H), 3.02-2.83 (m, 1H), 2.76-2.51 (m, 2H), 1.34-1.27 
(m, 18H). 












































































































































































































































































































































TBS2-Tetrapeptide (3.69). To a solution of diol 3.68 (2.11 g, 2.22 mmol) in DMF (12 
mL) was added imidazole (728 mg, 10.7 mmol) and TBSCl (1.74 g, 11.5 mmol). The 
reaction mixture stirred O/N at r.t., then was concentrated. The crude residue was taken 
up in EtOAc and washed with water (3x), brine (1x), dried over Na2SO4, and 
concentrated to afford the title compound (2.27 g, 87% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.02-7.99 (m, 1H), 7.72-7.42 (m, 6H), 7.37-7.21 (m, 
2H), 7.13-6.86 (m, 4H), 6.48-6.39 (m, 1H), 4.92-4.89 (m, 1H), 4.43-4.39 (m, 1H), 4.21-
4.06 (m, 2H), 3.82-3.69 (m, 3H), 3.63-3.58 (m, 6H), 3.00-2.89 (m, 1H), 2.86-2.80 (m, 





























































































































































































































































































































































Diamine (5.4). To a solution of 3.66 (2 g, 2.58 mmol) in CH2Cl2 (50 mL) at 0 °C was 
added TFA (4.8 mL). The resulting solution was warmed to r.t. and stirred for 2 h under 
Ar. The reaction was quenched with sat’d NaHCO3, and the product extracted in CH2Cl2. 
The combined organic layers were dried and concentrated to afford 5.4 in quantitative 
yield (1.48 g). 
1H-NMR (300 MHz; DMSO-d6): δ  7.69 (d, J = 7.4 Hz, 2H), 7.63-7.58 (m, 2H), 7.50-
7.36 (m, 6H), 7.20-7.15 (m, 1H), 7.09-7.04 (m, 1H), 6.99-6.98 (m, 1H), 6.82-6.75 (m, 
2H), 5.89 (d, J = 4.1 Hz, 1H), 4.51 (t, J = 4.2 Hz, 1H), 4.33-4.29 (m, 1H), 3.78 (s, 1H), 
3.52 (d, J = 6.2 Hz, 3H), 3.39-3.32 (m, 3H), 2.95-2.78 (m, 2H), 2.71-2.65 (m, 2H), 
HRMS (ESI-APCI-): [M-H]- 574.1886 calcd for C30H30N4O6S, found: 574.1867. 
























































































































































































Tripeptide (3.71). N-Cbz-L-serine(OTBS) (2.52 g, 7.14 mmol), iPr2NEt (1.3 mL, 7.14 
mmol), and EDCI (1.37 g, 7.14 mmol) were added to a solution of 5.4 (2.05 g, 3.57 
mmol) in CH2Cl2 (20 mL). The reaction stirred O/N, then was concentrated and purified 
through an SiO2 plug to afford pure 3.71 (2.37 g, 73% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  8.48-8.37 (m, 1H), 7.70-7.58 (m, 5H), 7.48-7.42 (m, 
3H), 7.37-7.29 (m, 8H), 7.09-6.99 (m, 3H), 6.79-6.71 (m, 2H), 5.90-5.87 (m, 1H), 5.03-
4.96 (m, 2H), 4.49-4.40 (m, 2H), 4.31-4.29 (m, 1H), 4.23-4.19 (m, 1H), 3.78 (s, 1H), 
3.64-3.61 (m, 1H), 3.53 (d, J = 4.4 Hz, 3H), 3.41-3.34 (m, 1H), 3.19 (d, J = 9.1 Hz, 3H), 
3.01-2.93 (m, 1H), 2.68-2.64 (m, 1H), 0.78 (d, J = 10.3 Hz, 9H), -0.02 (s, 6H); HRMS 
(ESI-APCI): [M+H]+ 910.3517 calcd for C47H56N5O10SSi, found: 910.3543. 


































































































































































































































































1-carboxylate (5.5). Powdered NaOH (19.0 g, 475 mmol) was added to a stirring 
suspension of D-Trp-OMe·HCl (24.14 g, 95 mmol) and Bu4NHSO4 (3.23 g, 9.5 mmol) in 
CH2Cl2 (950 mL). After stirring 2.5 h, Boc2O (62.1 g, 285 mmol) was added, and the 
resulting suspension stirred O/N at r.t. The mixture was filtered through celite, 
concentrated, and purified by SiO2 chromatography (9:1 hexanes:EtOAc) to afford N,N’-
Boc2-D-Trp-OMe (18.53 g, 47% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.11 (d, J = 7.4 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.39 
(s, 1H), 7.27 (td, J = 16.1, 8.4 Hz, 2H), 5.11 (d, J = 7.2 Hz, 1H), 4.65 (q, J = 6.4 Hz, 1H), 
3.69 (s, 3H), 3.22 (qd, J = 13.5, 5.5 Hz, 2H), 1.66 (s, 9H), 1.43 (s, 9H). 
















































































Bromopyrroloindoline (3.74). To a solution of N,N’-Boc2-D-Trp-OMe (18.53 g, 44.3 
mmol) in CH2Cl2 (1000 mL) was added NBS (7.89 g, 44.3 mmol) and PPTS (11.12 g, 
44.3 mmol). The resulting solution was allowed to stir at r.t. O/N. The reaction mixture 
was washed with brine, the organic layer dried (Na2SO4) and concentrated. Purification 
by SiO2 chromatography (30% EtOAc in hexanes) gave the desired product in 96% yield 
(21.20 g). 
[α]D = +150.0 (CH2Cl2); 1H-NMR (400 MHz; CDCl3): δ  7.53-7.52 (bs, 1H), 7.34-7.24 
(m, 2H), 7.09 (t, J = 7.6 Hz, 1H), 6.37 (s, 1H), 3.86 (dd, J = 10.3, 6.3 Hz, 1H), 3.71 (s, 
3H), 3.18 (dd, J = 12.6, 6.3 Hz, 1H), 2.79 (dd, J = 12.6, 10.3 Hz, 1H), 1.56 (s, 9H), 1.37 
(bs, 9H); 13C-NMR (101 MHz; CDCl3): δ 171.46, 171.41, 171.0, 152.1, 141.5, 130.6, 
124.37, 124.35, 123.2, 83.8, 82.2, 59.4, 52.3, 36.4, 28.6, 28.2, 24.1, 21.0, 14.2; IR (NaCl, 
film) 2980, 1719, 1395, 1334, 1163, 753 cm-1; HRMS (ESI-APCI): [M+Na]+ 519.1107 
calcd for C22H29BrN2NaO6, found: 519.1102. 











Figure 5.46a. 1H NMR spectrum of compound 3.74. 
 











































































































































1,2,8(2H,8aH)-tricarboxylate (3.75). KOtBu (3.02 g, 27 mmol) was added to a solution 
of bromopyrroloindoline 3.74 (10.0 g, 20.2 mmol) and N-Boc-Trp-OMe (4.29 g, 13.5 
mmol) in CH3CN (1000 mL) at 0 °C at stirred 1h under Ar. NaHCO3 was added and the 
product extracted in CH2Cl2, washed with brine, dried (Na2SO4), and concentrated. 
Purification by SiO2 chromatography (40% EtOAc in hexanes) afforded pure dipeptide 
(5.47 g, 55% yield). 
[α]D = -7.2 (CH2Cl2); 1H-NMR (400 MHz; CDCl3): δ  7.70-7.64 (bs, 1H), 7.51 (t, J = 7.5 
Hz, 1H), 7.37-7.32 (m, 1H), 7.26 (s, 1H), 7.20-7.05 (m, J = 7.8 Hz, 4H), 6.74 (s, 1H), 
6.67 (s, 1H), 4.97 (t, J = 6.4 Hz, 1H), 4.88 (d, J = 7.2 Hz, 1H), 4.53 (s, 1H), 3.58 (s, 2H), 
3.53-3.46 (m, 2H), 3.20 (s, 3H), 3.13 (s, 3H), 1.51-1.48 (m, 18H), 1.39 (d, J = 7.7 Hz, 
9H); 13C-NMR (101 MHz; CDCl3): δ 172.7, 171.0, 155.0, 151.9, 143.6, 134.7, 131.00, 
130.89, 124.80, 124.78, 122.9, 122.31, 122.30, 122.0, 120.0, 119.55, 119.37, 111.5, 
109.7, 82.1, 79.7, 72.57, 72.54, 60.3, 54.2, 52.1, 28.29, 28.17; IR (NaCl, film) 2979, 
1716, 1457, 1207, 739 cm-1; HRMS (ESI-APCI): [M+Na]+ 757.3425 calcd for 
C39H50N4NaO10, found: 757.3427. 













Figure 5.47a. 1H NMR spectrum of compound 3.75. 
 

























































































































































































































1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (5.6). TFA (15 mL) was 
slowly added to a solution of the Boc-protected compound 3.75 (5.47 g, 7.5 mmol) in 
CH2Cl2 (150 mL) at 0 °C. The reaction mixture was allowed to warm to r.t. as it stirred 
O/N. NaHCO3 was added and the product extracted into CH2Cl2. The combined organic 
extracts were dried (Na2SO4) and concentrated to afford the deprotected product (3.02 g, 
93% yield), used without further purification. 
[α]D = +80.0 (CH2Cl2); 1H-NMR (400 MHz; CDCl3): δ  7.52 (dt, J = 6.6, 3.0 Hz, 1H), 
7.40-7.37 (m, 1H), 7.11-6.99 (m, 5H), 6.70 (t, J = 7.4 Hz, 1H), 6.62 (dd, J = 7.9, 3.4 Hz, 
1H), 5.44 (s, 1H), 4.14 (dd, J = 7.8, 2.6 Hz, 1H), 3.72 (t, J = 6.0 Hz, 1H), 3.60 (d, J = 
17.0 Hz, 3H), 3.40 (ddd, J = 13.0, 7.9, 2.3 Hz, 1H), 3.29 (s, 3H), 3.15 (dt, J = 14.4, 4.3 
Hz, 1H), 2.95-2.86 (m, 2H), 1.99-1.90 (bs, 3H); 13C-NMR (101 MHz; CDCl3): δ 175.6, 
173.8, 149.7, 135.2, 130.5, 129.80, 129.76, 127.5, 125.4, 125.0, 121.8, 119.5, 119.2, 
112.1, 110.9, 109.7, 81.8, 75.7, 60.3, 55.0, 52.1, 40.6, 30.5, 28.4; IR (NaCl, film) 3373, 
2950, 1735, 1459, 1207, 744 cm-1; HRMS (ESI-APCI): [M+H]+ 435.2032 calcd for 
C24H27N4O4, found: 435.2036. 












Figure 5.48a. 1H NMR spectrum of compound 5.6. 
 














































































































































































































































b]indole-2-carboxylate (3.76). Diamine 5.6 (1.03 g, 2.4 mmol), N-Fmoc-L-Ser(OTBS)-
OH (2.12 g, 4.8 mmol), T3P (50% by weight in DMF, 3.51 g, 5.5 mmol), iPr2NEt (2.1 
mL, 12 mmol), and CH2Cl2 (24 mL) were combined and stirred under Ar O/N at 35 °C. 
Water was added, the product extracted in EtOAc, the combined extracts washed with 
brine, dried (Na2SO4), concentrated, and purified by SiO2 chromatography (10-25% 
EtOAc in hexanes) to afford the tetrapeptide (2.15 g, 70% yield). 
[α]D = +61.9 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.77 (d, J = 7.4 Hz, 4H), 7.60 (d, 
J = 8.0 Hz, 5H), 7.41 (t, J = 7.3 Hz, 5H), 7.35-7.30 (m, 4H), 7.26-7.15 (m, 4H), 6.82-6.67 
(m, 2H), 5.68 (d, J = 7.7 Hz, 1H), 5.42 (s, 1H), 4.90 (s, 1H), 4.40-4.33 (m, 4H), 4.24-4.10 
(m, 3H), 4.05-3.88 (m, 2H), 3.74 (s, 1H), 3.63 (d, J = 13.3 Hz, 3H), 3.20 (s, 4H), 2.95 (s, 
1H), 0.94-0.82 (m, 18H), 0.08 (dd, J = 35.4, 2.8 Hz, 12H); 13C-NMR (101 MHz; CDCl3): 
δ 177.5, 177.3, 175.7, 175.35, 175.20, 160.8, 156.0, 150.0, 149.48, 149.34, 149.30, 147.1, 
146.9, 140.3, 137.11, 137.00, 135.96, 135.82, 133.25, 133.17, 132.6, 131.5, 130.75, 
130.70, 130.64, 130.60, 130.57, 130.4, 130.1, 127.8, 125.65, 125.58, 125.48, 125.1, 

















72.62, 70.8, 68.7, 65.3, 59.06, 58.90, 58.4, 57.7, 56.0, 52.75, 52.72, 52.69, 35.3, 33.9, 
33.4, 31.8, 31.52, 31.43, 24.1, 23.75, 23.71, 0.23, 0.11, 0.08, 0.03, -0.01; IR (NaCl, film) 
2953, 1724, 1673, 1450, 1253, 1107, 740 cm-1; HRMS (ESI-APCI): [M+H]+ 1281.5764 
calcd for C72H85N6O12Si2, found: 1281.5759. 




Figure 5.49a. 1H NMR spectrum of compound 3.76. 
 






























































































































































































































































































































































Dioxopiperazine2 (3.77). Tetrapeptide 3.76 (2.18 g, 1.7 mmol) and morpholine (17 mL) 
were dissolved in THF (70 mL) and heated to 35 °C. After stirring O/N, the reaction 
mixture was concentrated and purified by SiO2 chromatography (5% MeOH in CH2Cl2) 
to afford pure dioxopiperazine 3.77 (1.11 g, 85% yield). 
1H-NMR (400 MHz; CDCl3): δ  7.68 (d, J = 8.0 Hz, 1H), 7.56 (s, 1H), 7.29 (d, J = 7.4 
Hz, 1H), 7.16 (t, J = 7.4 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 7.7 Hz, 1H), 6.81-
6.79 (m, 2H), 6.63 (d, J = 17.9 Hz, 1H), 6.42 (s, 1H), 6.13 (d, J = 3.5 Hz, 1H), 5.53 (d, J 
= 3.5 Hz, 1H), 4.83 (dd, J = 11.1, 6.1 Hz, 1H), 4.37-4.35 (m, 1H), 4.25 (q, J = 5.4 Hz, 
2H), 4.11 (t, J = 3.8 Hz, 1H), 4.03 (dd, J = 10.0, 3.5 Hz, 1H), 3.85 (dd, J = 19.1, 8.2 Hz, 
2H), 3.72 (d, J = 14.7 Hz, 2H), 3.59 (dd, J = 9.9, 8.0 Hz, 1H), 3.54 (s, 1H), 3.34-3.29 (m, 
1H), 3.19 (dd, J = 14.6, 9.8 Hz, 1H), 2.83 (dd, J = 14.7, 11.4 Hz, 1H), 0.96 (s, 18H), 0.16 
(s, 12H); HRMS (ESI-APCI): [M+Na]+ 795.3698 calcd for C40H56N6NaO6Si2, found: 
795.3696. 























































































































































































(2S,3aS,8aS)-1,8-di-tert-butyl 2-methyl 3a-(3-((S)-2-((tert-butoxycarbonyl) 
(methyl)amino)-3-methoxy-3-oxopropyl)-1H-indol-1-yl)-3,3a-dihydro-pyrrolo[2,3-
b]indole-1,2,8(2H,8aH)-tricarboxylate (5.7). KOtBu (3.04 g, 27.2 mmol) was added to 
a solution of bromopyrroloindoline 3.74 (10.08 g, 20.3 mmol) and N-Me,Boc-Trp-OMe 
(4.50 g, 13.6 mmol) in CH3CN (1000 mL) at 0 °C and stirred 1h under Ar. NaHCO3 was 
added and the product extracted in CH2Cl2, washed with brine, dried (Na2SO4), and 
concentrated. Purification by SiO2 chromatography (10-20% EtOAc in hexanes) afforded 
pure dipeptide (5.41 g, 53% yield). 
[α]D = -3.1 (CH2Cl2); 1H-NMR (400 MHz; CDCl3): δ  7.68-7.67 (bs, 1H), 7.56 (d, J = 7.5 
Hz, 1H), 7.35-7.32 (m, 2H), 7.23 (s, 1H), 7.16-7.08 (m, 3H), 6.84 (d, J = 15.2 Hz, 1H), 
6.74 (d, J = 3.3 Hz, 1H), 4.87-4.86 (bs, 1H), 4.73-4.56 (broad, 2H), 3.69 (broad, J = 7.1 
Hz, 3H), 3.49-3.43 (m, 1H), 3.29 (dd, J = 15.0, 4.9 Hz, 1H), 3.20 (s, 3H), 3.02-2.91 (m, 
2H), 2.67-2.59 (m, 3H), 1.57-1.11 (m, 27H); 13C-NMR (101 MHz; CDCl3): δ 171.7, 
170.9, 151.9, 134.7, 130.97, 130.82, 129.9, 125.0, 123.3, 122.2, 119.88, 119.86, 119.2, 
111.6, 110.6, 82.0, 79.9, 72.59, 72.57, 59.9, 59.32, 59.30, 52.12, 52.09, 52.05, 52.00, 
51.97, 34.6, 31.5, 28.19, 28.17, 25.2, 22.6, 20.7, 14.1; IR (NaCl, film) 2978, 1703, 1482, 
1394, 1157, 738 cm-1; HRMS (ESI-APCI): [M+Na]+ 771.3581 calcd for C40H52N4NaO10, 
found: 771.3600. 












Figure 5.51a. 1H NMR spectrum of compound 5.7. 
 






















































































































































































































































































1-yl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (3.80). TFA (11 mL) 
was slowly added to a solution of Boc-protected material 5.7 (4.11 g, 5.49 mmol) in 
CH2Cl2 (110 mL) at 0 °C. The reaction mixture was allowed to warm to r.t. as it stirred 
O/N. NaHCO3 was added and the product extracted into CH2Cl2. The combined organic 
extracts were dried (Na2SO4) and concentrated to afford the deprotected product (2.35 g, 
96% yield), used without further purification. 
[α]D = +73.3 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.61-7.58 (m, 1H), 7.46-7.43 (m, 
1H), 7.18-7.05 (m, 6H), 6.77 (t, J = 7.4 Hz, 1H), 6.68 (dd, J = 7.9, 0.9 Hz, 1H), 5.51 (s, 
1H), 4.55 (bs, 1H), 4.21 (d, J = 7.6 Hz, 1H), 3.61 (d, J = 9.5 Hz, 3H), 3.53-3.46 (m, 2H), 
3.36 (d, J = 1.1 Hz, 3H), 3.10-2.93 (m, 4H), 2.35 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 
174.7, 173.8, 149.69, 149.66, 135.26, 135.23, 130.4, 129.7, 127.58, 127.54, 125.3, 
125.00, 124.89, 121.8, 119.5, 119.30, 119.13, 112.1, 110.74, 110.71, 109.55, 109.49, 
82.0, 75.72, 75.69, 63.71, 63.69, 60.2, 52.1, 51.7, 40.76, 40.70, 34.68, 34.62, 28.91, 
28.81; IR (NaCl, film) 2950, 1734, 1459, 1206, 742 cm-1; HRMS (ESI-APCI): [M+H]+ 
449.2189 calcd for C25H29N4O4, found: 449.2179. 












Figure 5.52a. 1H NMR spectrum of compound 3.80. 
 






































































































































































































































b]indole-2-carboxylate (3.81). The diamine (3.80, 430 mg, 0.96 mmol), N-Me,Boc-L-
Ser(OBn)-OH (591 mg, 1.91 mmol), T3P (50% by weight in DMF, 1.41 g, 2.21 mmol), 
iPr2NEt (0.835 mL, 4.8 mmol), and CH2Cl2 (10 mL) were combined and stirred under Ar 
O/N at 35 °C. Water was added, the product extracted in EtOAc, the combined extracts 
washed with brine, dried (Na2SO4), concentrated, and purified by SiO2 chromatography 
(60% EtOAc in hexanes) to afford the tetrapeptide (420 mg, 42% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.58-7.55 (m, 1H), 7.41-7.15 (m, 16H), 6.99 (s, 1H), 
6.76-6.69 (m, 1H), 6.26-6.02 (m, 1H), 5.42-5.12 (m, 3H), 4.96-4.86 (m, 1H), 4.61-4.41 
(m, 5H), 3.71-3.54 (m, 7H), 3.40-3.35 (m, 2H), 3.18 (d, J = 16.2 Hz, 5H), 2.93-2.67 (m, 
8H), 1.42 (t, J = 8.2 Hz, 18H); HRMS (ESI-APCI): [M+H]+ 1031.5130 calcd for 
C57H71N6O12, found: 1031.5126. 
















































































































































































carboxylate (5.8). TFA (0.2 mL) was slowly added to a solution of Boc-protected 
material 3.81 (103 mg, 0.1 mmol) in CH2Cl2 (2 mL) at 0 °C. The reaction mixture was 
allowed to warm to r.t. as it stirred O/N. NaHCO3 was added and the product extracted 
into CH2Cl2. The combined organic extracts were dried (Na2SO4) and concentrated to 
afford the deprotected product (81 mg, 98% yield), used without further purification. 



















Dioxopiperazine2 (3.82). Tetrapeptide 5.8 (81 mg, 0.098 mmol) and morpholine (1 mL) 
were dissolved in THF (4 mL) and heated to 35 °C. After stirring O/N, the reaction 
mixture was concentrated and purified by SiO2 chromatography (5% MeOH in CH2Cl2) 
to afford pure dioxopiperazine (75 mg, >99% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.53-7.05 (m, 23H), 6.91 (t, J = 7.1 Hz, 2H), 6.76-6.71 
(m, 2H), 6.46-6.34 (m, 2H), 5.72 (d, J = 4.1 Hz, 1H), 4.99-4.92 (m, 1H), 4.63-4.52 (m, 
3H), 4.29-4.23 (m, 2H), 3.96 (dd, J = 9.7, 4.1 Hz, 2H), 3.69-3.54 (m, 5H), 3.26-3.21 (m, 
2H), 3.08 (s, 3H), 2.87 (d, J = 3.9 Hz, 2H), 2.71 (dd, J = 12.2, 2.8 Hz, 1H), 2.21 (s, 3H); 
HRMS (ESI-APCI): [M+Na]+ 789.3377 calcd for C45H46N6NaO6, found: 789.3379. 


























































































































































































1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (5.9). The diamine (3.80, 
896 mg, 2.0 mmol), N-Fmoc-sarcosine-OH (1.24 g, 4.0 mmol), T3P (50% by weight in 
DMF, 2.93 g, 4.6 mmol), iPr2NEt (1.7 mL, 10.0 mmol), and CH2Cl2 (20 mL) were 
combined and stirred under Ar O/N at 35 °C. Water was added, the product extracted in 
EtOAc, the combined extracts washed with brine, dried (Na2SO4), concentrated, and 
purified by SiO2 chromatography (50-100% EtOAc in hexanes) to afford tetrapeptide 5.9 
(1.17 g, 57% yield). 
[α]D = +92.1 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.78-7.74 (m, 4H), 7.63-7.59 (m, 
6H), 7.35 (dd, J = 19.2, 7.0 Hz, 8H), 7.16-7.04 (m, 5H), 6.78-6.65 (m, 2H), 6.10-6.00 (m, 
1H), 4.54-4.20 (m, 7H), 3.99-3.86 (m, 2H), 3.72-3.61 (m, 5H), 3.37-3.33 (m, 3H), 3.23-
3.08 (m, 6H), 2.99-2.90 (m, 4H), 2.80-2.56 (m, 4H); IR (NaCl, film) 2951, 1703, 1451, 











































































































































































































b]indole-1,4(10bH)-dione (3.88). Tetrapeptide 5.9 (1.0 g, 0.97 mmol) and morpholine 
(10 mL) were dissolved in THF (40 mL) and heated to 35 °C. After stirring O/N, the 
reaction mixture was concentrated and purified by SiO2 chromatography (2-6% MeOH in 
CH2Cl2) to afford pure dioxopiperazine 3.88 (470 mg, 92% yield). 
[α]D = +145.5 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.49 (t, J = 7.3 Hz, 1H), 7.26-
7.15 (m, 2H), 7.09-6.91 (m, 3H), 6.79-6.73 (m, 2H), 6.01 (dd, J = 51.3, 3.1 Hz, 1H), 5.45 
(dd, J = 53.9, 3.8 Hz, 1H), 4.57-4.49 (m, 1H), 4.18 (t, J = 3.2 Hz, 1H), 3.84-3.46 (m, 4H), 
3.23-3.12 (m, 2H), 3.06-2.98 (m, 6H), 2.68 (ddd, J = 15.3, 11.5, 4.2 Hz, 1H), 2.33 (d, J = 
32.5 Hz, 3H), 2.06-1.94 (m, 1H); 13C-NMR (101 MHz; CDCl3): δ 166.3, 166.0, 164.6, 
164.2, 146.7, 135.4, 130.1, 129.1, 128.1, 127.8, 124.7, 124.4, 122.8, 122.5, 120.2, 119.7, 
112.4, 110.2, 108.3, 82.6, 82.0, 74.1, 62.7, 57.2, 53.5, 40.1, 39.7, 33.5, 32.9, 32.0; IR 
(NaCl, film) 2931, 1664, 1459, 1324, 1259 cm-1; HRMS (ESI-APCI): [M+H]+ 527.2407 



















Figure 5.56a. 1H NMR spectrum of compound 3.88. 
 


















































































































































































































































































Tetrapeptide (5.10). The diamine (3.80, 327 mg, 0.73 mmol), N-Me,Fmoc-L-
Ser(OTBS)-OH (663 g, 1.46 mmol), T3P (50% by weight in DMF, 1.07 g, 1.68 mmol), 
iPr2NEt (0.635 mL, 5.0 mmol), and CH2Cl2 (7.3 mL) were combined and stirred under Ar 
O/N at 35 °C. Water was added, the product extracted in EtOAc, the combined extracts 
washed with brine, dried (Na2SO4), concentrated, and purified by SiO2 chromatography 
(35% EtOAc in hexanes) to afford tetrapeptide 5.10 (351 mg, 36% yield). 
[α]D = -1.5 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.78-7.71 (m, 4H), 7.61-7.53 (m, 
5H), 7.41-7.15 (m, 14H), 6.93-6.66 (m, 3H), 5.13-5.07 (m, 2H), 4.41 (d, J = 6.8 Hz, 2H), 
4.16-4.01 (m, 5H), 3.93-3.89 (m, 1H), 3.75-3.66 (m, 5H), 3.40-3.35 (m, 2H), 3.25 (d, J = 
10.7 Hz, 2H), 3.09-2.94 (m, 5H), 2.82-2.81 (m, 4H), 2.72-2.66 (m, 2H), 2.34 (dd, J = 6.3, 
3.2 Hz, 1H), 2.10-1.95 (m, 2H), 0.87-0.81 (m, 18H), 0.09--0.02 (m, 12H); IR (NaCl, 
film) 2953, 1696, 1651, 1451, 1317, 1154, 740 cm-1; HRMS (ESI-APCI): [M+H]+ 
1323.6234 calcd for C75H91N6O12Si2, found:1323.6253. 































































































































































































































































pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-1,4(10bH)-dione (3.90). Tetrapeptide 5.10 (300 
mg, 0.227 mmol) and morpholine (2.3 mL) were dissolved in THF (9 mL) and heated to 
35 °C. After stirring O/N, the reaction mixture was concentrated and purified by SiO2 
chromatography (4% MeOH in CH2Cl2) to afford pure dioxopiperazine 3.90 (153 mg, 
83% yield). 
3.90A: [α]D = +56.6 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.51 (d, J = 7.9 Hz, 1H), 
7.18 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 11.2 Hz, 2H), 6.90 (t, J = 6.1 Hz, 2H), 6.69 (t, J = 
7.5 Hz, 2H), 6.50 (d, J = 8.4 Hz, 1H), 5.70 (s, 1H), 4.80 (dd, J = 11.9, 5.9 Hz, 1H), 4.33-
4.09 (m, 4H), 3.76 (d, J = 10.4 Hz, 1H), 3.66 (dt, J = 9.9, 4.9 Hz, 2H), 3.50-3.43 (m, 2H), 
3.37 (t, J = 4.8 Hz, 1H), 3.19 (dd, J = 14.8, 4.6 Hz, 1H), 3.10 (s, 3H), 3.02 (s, 3H), 2.31 
(s, 3H), 0.82 (s, 9H), 0.74 (s, 9H), 0.04 (d, J = 4.6 Hz, 6H), -0.11 (d, J = 4.3 Hz, 6H); 13C-
NMR (101 MHz; CDCl3): δ 167.9, 166.5, 165.73, 165.62, 146.6, 135.6, 130.2, 129.5, 
124.4, 123.1, 122.5, 120.2, 112.3, 110.0, 108.6, 82.9, 62.6, 62.2, 62.0, 60.5, 59.9, 56.9, 
40.7, 32.5, 30.4, 30.0, 27.2, 25.64, 25.52, 18.1, 17.9, -5.60, -5.66, -5.69; IR (NaCl, film) 
2930, 2857, 1662, 1461, 1256, 1116 cm-1; HRMS (ESI-APCI): [M+H]+ 815.4348 calcd 


















3.90B: [α]D = +80.0 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.60 (d, J = 7.9 Hz, 1H), 
7.30 (s, 1H), 7.15 (td, J = 7.7, 1.0 Hz, 1H), 7.07 (t, J = 7.4 Hz, 1H), 6.99-6.94 (m, 1H), 
6.88 (d, J = 7.4 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.69-6.63 (m, 2H), 5.91 (d, J = 2.6 Hz, 
1H), 5.59 (d, J = 2.6 Hz, 1H), 4.57-4.52 (m, 1H), 4.26-4.19 (m, 2H), 4.03 (dd, J = 10.8, 
2.7 Hz, 1H), 3.87-3.77 (m, 2H), 3.68-3.61 (m, 2H), 3.40 (dd, J = 9.4, 5.6 Hz, 2H), 3.26-
3.21 (m, 1H), 2.99 (d, J = 9.6 Hz, 6H), 2.71 (s, 3H), 2.60-2.55 (m, 1H), 0.84 (s, 9H), 0.74 
(s, 9H), -0.01--0.08 (m, 12H); 13C-NMR (101 MHz; CDCl3): δ 166.0, 164.56, 164.55, 
164.35, 146.7, 135.6, 130.1, 129.5, 123.1, 122.6, 120.4, 119.5, 112.1, 111.2, 109.7, 82.7, 
65.1, 64.2, 63.7, 63.3, 60.6, 56.8, 41.5, 33.8, 33.1, 31.1, 30.7, 25.9, 25.5, 18.4, 18.0, -
5.38, -5.40, -5.71, -5.74; IR (NaCl, film) 2930, 2857, 1654, 1462, 1255, 1112 cm-1; 
HRMS (ESI-APCI): [M+H]+ 815.4348 calcd for C43H63N6O6Si2, found:815.4349. 




Figure 5.58a. 1H NMR spectrum of compound 3.90A. 
 































































































































































































































































Figure 5.59a. 1H NMR spectrum of compound 3.90B. 
 








































































































































































































































































































5-chlorovanillin (5.11). Vanillin (25 g, 164 mmol) was dissolved in AcOH (150 mL), 
then chlorine gas bubbled through the solution. After a significant amount of white solid 
had precipitated, the solution was filtered and the solid washed with hexanes. To the 
AcOH filtrate was added an additional batch of vanillin (25 g), and chlorine gas again 
bubbled through the solution. The resulting precipitate was filtered, washed with hexanes, 
combined with the first yield, and dried to afford 5-chlorovanillin (39.30 g, 64% yield). 
1H-NMR (400 MHz; acetone-d6): δ  9.83 (s, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.43 (d, J = 
1.7 Hz, 1H), 3.98 (s, 3H); 13C-NMR (101 MHz; acetone): δ 189.5, 148.7, 129.2, 125.6, 
120.0, 108.7, 56.0. 








Figure 5.60a. 1H NMR spectrum of compound 5.11. 
 





























































5-chlorovanillin-OAc (4.15). To a solution of 5-chlorovanillin (58.5 g, 313 mmol) in 
THF (1000 mL) was added Ac2O (35.5 mL, 376 mmol), Et3N (65.5 mL, 470 mmol), and 
DMAP (200 mg). The resulting solution was stirred O/N, then concentrated. The product 
was extracted in CH2Cl2 from 1M HCl, the combined organic extracts washed with brine, 
dried over Na2SO4, and concentrated to give 4.15 (71.45 g, >99% yield). 
1H-NMR (400 MHz; acetone-d6): δ  9.98 (s, 1H), 7.67 (d, J = 1.7 Hz, 1H), 7.59 (d, J = 
1.7 Hz, 1H), 3.97 (s, 3H), 2.36 (s, 3H); 13C-NMR (101 MHz; acetone): δ 190.0, 166.8, 
153.6, 141.3, 135.4, 128.5, 123.2, 110.4, 56.2, 19.2; HRMS (ESI-APCI): [M-H]- 
229.0268 calcd for C10H9ClO4, found: 229.9854. 









Figure 5.61a. 1H NMR spectrum of compound 4.15. 
 










































































5-chloro-2-nitrovanillin (4.17). Nitric acid (fuming, 125) was chilled in an ethylene 
glycol/dry ice bath, then 4.15 (28 g) added in small batches such that the internal 
temperature did not rise above 5 °C. Following the addition, the reaction was stirred for 2 
additional hours at -15 °C. The reaction mixture was carefully poured into ice water, and 
the resulting bright orange precipitate filtered and rinsed with cold water until the 
washings were pH neutral. This solid (combined from 2x28 g batches) was dissolved in 
2M KOH (500 mL) and the solution heated to a boil for 10 min. After cooling to r.t., the 
solution was poured into ice-cold concentrated HCl, and the resulting precipitate filtered, 
washed with cold water, and dried to afford 4.17 (43.21 g, 76% yield). 
1H-NMR (400 MHz; acetone-d6): δ  9.82 (s, 1H), 7.94 (s, 1H), 3.95 (s, 3H); 13C-NMR 
(101 MHz; acetone): δ 186.0, 153.0, 140.9, 129.6, 123.2, 119.6, 98.5, 62.4; HRMS (-
APCI): [M-H]- 229.9856 calcd for C8H6ClNO5, found: 229.9860. 
REF: TRW-II-417,419; TRW-II-424,425; TRW-II-484, TRW-III-080. 
Nitric acid (fuming). Potassium nitrate (500 g) was added to concentrated sulfuric acid 
(500 mL) in a flask equipped with a distillation column, and the resulting suspension 
heated in an oil bath at 170 °C. Fuming nitric acid (75 mL) was collected over a 4 hour 










Figure 5.62a. 1H NMR spectrum of compound 4.17. 
 







































5-chloro-3,4-dimethoxy-2-nitrobenzaldehyde (4.18). Phenol 4.17 (15.0 g, 64.7 mmol) 
was dissolved in absolute EtOH (26.3 mL), then Me2SO4 (26.3 mL, 278 mmol) added. 
The resulting solution was immersed in an ice/brine bath before adding a solution of 
NaOH (11.1 g, 278 mmol) in water (13.2 mL) dropwise. The reaction was heated to 50 
°C for 3 hours, then cooled to r.t. and diluted with water. The product was extracted into 
ether, and the organic extracts dried and concentrated to afford the title compound (15.9 
g, >99% yield). 
1H-NMR (400 MHz; CDCl3): δ  9.80 (d, J = 17.5 Hz, 1H), 7.73 (s, 1H), 4.05 (s, 3H), 4.01 
(s, 3H); 13C-NMR (101 MHz; CDCl3): δ 184.7, 155.3, 151.4, 131.6, 126.7, 123.1, 120.3, 
62.7, 61.4; HRMS (-APCI): [M-H]- 245.0091 calcd for C10H9ClN2O6, found: 245.0080. 
4.19: 1H-NMR (300 MHz; CDCl3): δ  7.45 (s, 1H), 5.58 (s, 1H), 3.97 (s, 3H), 3.93 (s, 
3H), 3.65-3.50 (m, 4H), 1.22 (t, J = 7.1 Hz, 6H). 










Figure 5.63a. 1H NMR spectrum of compound 4.18. 
 









































































































Dinitrostyrene (4.7). Aldehyde 4.18 (13.64 g, 55.4 mmol) was suspended in EtOH (180 
mL), and to it added nitromethane (4.4 mL, 77.6 mmol). The mixture was cooled to -15 
°C, then a solution of KOH (13.3 g, 238 mmol) in water (18 mL) and EtOH (180 mL) 
added dropwise over 2 hours. Upon complete addition of the KOH solution, the reaction 
was acidified with concentrated HCl (34 mL), diluted with H2O (200 mL), and the 
product extracted into chloroform. The organic extracts were dried and concentrated. To 
the resulting oil was added 55 mL acetic anhydride and sodium acetate (5.5 g). The 
solution was heated to reflux for 30 min., then poured into water and stirred. Water was 
decanted from the brown paste then EtOH added and heated to dissolve the crude 
product. Pure nitrostyrene crystals were recovered (10.3 g, 64% yield). 
1H-NMR (400 MHz; DMSO-d6): δ  8.33 (d, J = 13.3 Hz, 1H), 8.15 (s, 1H), 7.63 (d, J = 
13.4 Hz, 1H), 3.98 (s, 3H), 3.97 (s, 3H); 13C-NMR (101 MHz; DMSO): δ 152.3, 146.3, 
145.0, 142.2, 131.5, 129.8, 124.9, 119.3, 63.1, 61.9; IR (NaCl, film) 1639, 1519 cm-1; 
HRMS (-APCI): [M-H]- 288.0149 calcd for C10H9ClN2O6, found: 288.0141. 










Figure 5.65a. 1H NMR spectrum of compound 4.7. 
 




















































5-chloro-6,7-dimethoxy-1H-indole (4.6). A suspension of 4.7 (380 mg, 1.3 mmol), SiO2 
(3.8 g, 1000 wt%), Fe powder (1.37 g, 24.4 mmol), AcOH (7.6 mL), and PhCH3 (13 mL) 
was heated to reflux for 3 h, then cooled to r.t. and diluted with CH2Cl2. The mixture was 
filtered and the solid washed with CH2Cl2. The filtrate was washed with NaHSO3 (5% 
aq), NaHCO3 (sat’d aq), and brine, then dried and concentrated. The resulting oil was 
dissolved in CH2Cl2 (13 mL) and SiO2 added until the suspension was just fluid. After 
stirring under Ar for 30 min, the suspension was filtered and the solid washed with 
MeOH. The filtrate was concentrated and the product deemed sufficiently pure as crude 
(250 mg, 91% yield). 
1H-NMR (400 MHz; CDCl3): δ  8.40 (bs, 1H), 7.27 (s, 1H), 7.03 (t, J = 2.8 Hz, 1H), 6.32 
(t, J = 2.6 Hz, 1H), 3.94 (s, 3H), 3.82 (s, 3H).; 13C-NMR (101 MHz; CDCl3): δ 191.9, 
142.7, 139.1, 130.6, 128.8, 121.1, 115.8, 102.5, 61.4, 61.0; IR (NaCl, film) 3357, 2939, 
2831, 1655 cm-1; HRMS (ESI-APCI+): [M+H]+ 212.0478 calcd for C10H11ClNO2, found: 
212.0472. 










Figure 5.66a. 1H NMR spectrum of compound 4.6. 
 



























































5-chloro-6,7-dimethoxy-1-methyl-1H-indole (5.12). To a solution of indole 4.6 (126 
mg, 0.59 mmol) in DMF (1.5 mL) at 0 °C was slowly added NaH (47 mg). After stirring 
30 minutes, iodomethane (0.044 mL, 0.71 mmol) was added dropwise, and the reaction 
stirred an additional 30 minutes at 0 °C. The reaction was warmed to r.t. and stirred 5 h 
before adding water. The product was extracted in EtOAc, washed with water (2x) and 
brine, then dried and concentrated to afford the title compound, deemed sufficiently pure 
as crude (133 mg, >99% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.35 (s, 1H), 6.93 (d, J = 3.1 Hz, 1H), 6.34 (d, J = 3.1 
Hz, 1H), 4.02 (s, 3H), 3.98 (s, 3H), 3.93 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 143.7, 
140.6, 131.0, 126.9, 120.6, 116.0, 115.7, 100.6, 61.8, 61.2, 35.4; IR (NaCl, film) 2928, 
1048 cm-1; HRMS (ESI-APCI+): [M+H]+ 226.0635 calcd for C11H13ClNO2, found: 
226.0618. 










Figure 5.67a. 1H NMR spectrum of compound 5.12. 
 





























































5-chloro-6,7-dimethoxy-1-methyl-1H-indole-3-carbaldehyde (4.20). DMF (6.5 mL) 
was cooled to 0 °C, then POCl3 (0.586 mL, 6.42 mmol) added dropwise. Indole 5.12 
(1.32 g, 5.84 mmol) was added dropwise as a solution in DMF. After warming the 
mixture to 35 °C and stirring an additional 1.5 h, ice water was added followed by 2M 
NaOH (15 mL). The resulting solution was boiled for 10 min, then cooled and diluted 
with EtOAc. The organic layer was washed with water and brine, then dried and 
concentrated to give the aldehyde (1.38 g, 93% yield), used as crude in the next reaction. 
1H-NMR (400 MHz; CDCl3): δ  9.76 (s, 1H), 7.96 (s, 1H), 7.44 (s, 1H), 3.95 (s, 3H), 3.94 
(s, 3H), 3.82 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 183.9, 145.4, 140.92, 140.89, 
129.6, 124.5, 123.1, 117.26, 117.20, 61.9, 61.1, 36.7; IR (NaCl, film) 2930, 2853, 1656, 
1044 cm-1; HRMS (ESI-APCI+): [M+H]+ 254.0584 calcd for C12H13ClNO3, found: 
254.0581. 











Figure 5.68a. 1H NMR spectrum of compound 4.20. 
 




























































(E)-methyl 3-(5-chloro-6,7-dimethoxy-1-methyl-1H-indol-3-yl)acrylate (4.5). To a 
solution of aldehyde 4.20 (133 mg, 0.52 mmol) in toluene (1.8 mL) was added 
methyl(triphenyl-phosphoranylidene)acetate (347 mg, 1.04 mmol). The resulting solution 
was heated to reflux O/N, then concentrated and purified by SiO2 chromatography (9:1 – 
4:1 – 2:1 hexanes:EtOAc) to afford olefin 4.5 (128 mg, 80% yield). 
1H-NMR (400 MHz; CDCl3): δ  7.67 (d, J = 16.0 Hz, 1H), 7.51 (s, 1H), 7.11 (s, 1H), 6.20 
(d, J = 16.0 Hz, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.83 (s, 3H), 3.71 (s, 3H); 13C-NMR (101 
MHz; CDCl3): δ 168.4, 144.7, 141.0, 137.2, 134.8, 129.9, 124.3, 122.8, 115.7, 112.5, 
111.4, 61.8, 61.2, 51.4, 36.1; IR (NaCl, film) 2940, 1736, 1626, 1043 cm-1; HRMS (ESI-
APCI+): [M+H]+ 310.0846 calcd for C15H17ClNO4, found: 310.0840. 











Figure 5.69a. 1H NMR spectrum of compound 4.5. 
 
















































































methyl-1H-indol-3-yl)-3-hydroxypropanoate (4.4). To a solution of benzyl carbamate 
(178 mg, 1.18 mmol) in 0.4 M NaOH (2.5 mL) and n-propanol (2 mL) in a flask covered 
with foil was added fresh t-butyl hypochlorite (0.135 mL, 1.20 mmol). After stirring 5 
min, (DHQD)2AQN (14 mg, 0.016 mmol) in n-propanol (0.5 mL), olefin 4.5 (100 mg, 
0.32 mmol) in n-propanol (1 mL), and K2OsO2(OH)4 (5 mg, 0.013 mmol) in 0.4 M 
NaOH (0.5 mL) were added successively, and the resulting solution stirred O/N. Sodium 
bisulfite (0.2 g) was added and the product extracted into EtOAc. The organic layer was 
washed with water, then brine, dried over Na2SO4, and concentrated. SiO2 
chromatography (10:1 – 1:1 hexanes:EtOAc) gave pure tryptophan derivative 4.4 (54 mg, 
35% yield). 
[α]D = -20.9 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.40 (s, 1H), 7.32 (s, 5H), 6.92 
(s, 1H), 5.77 (d, J = 9.2 Hz, 1H), 5.46-5.45 (bs, 1H), 5.06 (s, 2H), 4.69-4.65 (m, 1H), 3.98 
(s, 3H), 3.89 (s, 3H), 3.88 (d, J = 9.3 Hz, 3H), 3.78 (s, 3H), 2.69 (bs, 1H); 13C-NMR (101 
MHz; CDCl3): δ 166.1, 144.6, 140.9, 133.75, 133.73, 128.66, 128.60, 128.46, 128.43, 
128.28, 128.18, 128.07, 126.3, 122.6, 114.2, 108.6, 72.9, 67.3, 66.9, 61.9, 61.2, 52.3, 
36.2; IR (NaCl, film) 3346, 2952, 1723, 1465, 1218, 1040 cm-1; HRMS (ESI-APCI+): 
[M+Na]+ 499.1248 calcd for C23H25ClN2NaO7, found: 499.1249. 











Figure 5.70a. 1H NMR spectrum of compound 4.4. 
 





























































































































1,4-difluoroanthracene-9,10-dione (4.23). To a solution of phthalic anhydride (10 g, 
67.6 mmol) in 1,4-difluorobenzene (68 mL) was added AlCl3 (36 g, 270 mmol). The 
resulting solution was stirred at reflux for 48h before removing the solvent by distillation. 
HCl (1M, 400 mL) was added and the product extracted into CH2Cl2 (3x). The combined 
organic extracts were filtered through a cotton plug and concentrated. The crude residue 
was taken up in chloroform (40 mL) and to it added hexanes (100 mL). The solution was 
cooled to -20 °C then filtered to collect the resultant precipitate. After drying the 
precipitate under vacuum, polyphosphoric acid (50 mL) was added and the mixture 
heated to 140 °C for 2h. The mixture was poured over approximately 400 g ice and 
allowed to warm to r.t. while stirring. Solid K2CO3 was added to neutralize the solution, 
then the product was extracted into CH2Cl2. The combined organic extracts were dried 
(Na2SO4) and concentrated. The residue was dissolved in CH2Cl2, filtered through basic 
alumina using CH2Cl2 as the eluent, and concentrated to afford the title compound (920 
mg). 
1H-NMR (400 MHz; CDCl3): δ  8.21-8.16 (m, 2H), 7.76-7.72 (m, 2H), 7.43-7.39 (m, 
2H); 13C-NMR (101 MHz; CDCl3): δ 134.3, 133.2, 127.0, 124.7, 124.48, 124.34. 








Figure 5.71a. 1H NMR spectrum of compound 4.23. 
 












































































(DHQD)2AQN (4.24). To a solution of DHQD (3.1 g, 9.5 mmol) in THF (19 mL) at -50 
°C was added nBuLi (1.6M in hexanes, 6.0 mL, 9.5 mmol) dropwise over 10 min. After 
stirring 15 min at -50 °C, the reaction mixture was warmed to 0 °C and the difluoro 
compound added (920 mg, 3.8 mmol). The reaction was allowed to warm to r.t. as it 
stirred O/N under Ar, then warmed to 40 °C and stirred an additional 2h. EtOAc was 
added and the reaction quenched by addition of sat’d NaHCO3. The product was 
extracted in EtOAc, dried (Na2SO4), concentrated, and purified by SiO2 chromatography 
(5% MeOH, 0.5% NH4OH, in CHCl3) to afford (DHQD)2AQN (2.55 g, 78% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.63 (d, J = 4.5 Hz, 2H), 8.22 (dd, J = 5.8, 3.3 Hz, 2H), 
8.01 (d, J = 9.2 Hz, 2H), 7.79 (dd, J = 5.8, 3.3 Hz, 2H), 7.49 (d, J = 4.5 Hz, 3H), 7.37 
(dd, J = 9.2, 2.5 Hz, 3H), 6.80 (bs, 2H), 5.28 (s, 2H), 3.95 (s, 6H), 3.28-3.26 (bs, 2H), 
3.00-2.53 (broad, 10H), 1.83 (bs, 2H), 1.61-1.45 (broad, 12H), 0.84 (t, J = 7.3 Hz, 6H). 






























































































































































(5-chloro-6,7-dimethoxy-1-methyl-1H-indol-3-yl)propanoate (4.25). Alcohol 4.4 (296 
mg, 0.62 mmol) was dissolved in DMF (1.6 mL), and to it added imidazole (102 mg, 1.5 
mmol) and TBSCl (242 mg, 1.6 mmol). After stirring O/N, the solution was diluted with 
EtOAc, washed with water (3x), brine (1x), dried over Na2SO4, and concentrated to give 
the title compound (366 mg, >99% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 1H), 7.32 (s, 5H), 6.83 (s, 1H), 5.49 (dd, J = 
12.6, 2.3 Hz, 1H), 5.07 (s, 2H), 4.98 (s, 1H), 4.47 (dd, J = 9.6, 2.1 Hz, 1H), 4.00 (s, 3H), 
3.91 (s, 3H), 3.89 (s, 3H), 3.79 (s, 3H), 0.86 (s, 9H), 0.09 (s, 6H); HRMS (ESI-APCI+): 
[M+Na]+ 613.2113 calcd for C29H39ClN2NaO7Si, found: 613.2109. 





































































1-methyl-1H-indol-3-yl)propanoate (4.26). To a suspension of 4.25 (366 mg, 0.61 
mmol) and Pd/C (37 mg) in MeOH (3 mL) was added hydrogen gas. After stirring O/N, 
the reaction was flushed with argon and filtered through celite to afford the free amine 
(262 mg, 94% yield). 
[α]D = +6.4 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.32 (s, 1H), 6.90 (s, 1H), 5.40 (d, 
J = 1.8 Hz, 1H), 4.85-4.63 (m, 1H), 4.00 (s, 3H), 3.94 (s, 3H), 3.90 (s, 3H), 3.75 (s, 3H), 
2.24-2.14 (bs, 2H), 0.88 (s, 9H), -0.01 (s, 3H), -0.15 (s, 3H); 13C-NMR (101 MHz; 
CDCl3): δ 173.3, 143.8, 140.7, 129.3, 129.0, 123.9, 120.6, 114.8, 114.3, 70.4, 61.8, 61.1, 
60.8, 52.0, 35.5, 25.66, 25.61, 25.52, 18.0, -4.6, -5.6; IR (NaCl, film) 3332, 2953, 2858, 
1750, 1464, 1038 cm-1; HRMS (ESI-APCI+): [M+Na]+ 479.1745 calcd for 
C21H33ClN2NaO5Si, found: 479.1746. 












Figure 5.74a. 1H NMR spectrum of compound 4.26. 
 































































































































































(4.27). To a solution of amine 4.26 (262 mg, 0.57 mmol) in CH2Cl2 (3 mL) was added N-
Boc-ala-OH (108 mg, 0.57 mmol), iPr2NEt (0.1 mL, 0.57 mmol), and EDCI (110 mg, 
0.57 mmol). The reaction was stirred at r.t. O/N, the concentrated and purified by SiO2 
chromatography (10% - 25% - 50% EtOAc in hexanes) to afford 4.27 (210 mg, 59% 
yield). 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 1H), 6.86 (s, 1H), 6.73-6.70 (bs, 1H), 5.53 (d, J 
= 2.0 Hz, 1H), 4.97-4.96 (bs, 1H), 4.67 (dd, J = 9.1, 1.7 Hz, 1H), 4.19-4.15 (bs, 1H), 3.99 
(s, 3H), 3.92 (s, 3H), 3.90 (s, 3H), 3.78 (s, 3H), 1.45 (s, 9H), 1.24 (dd, J = 7.1, 0.8 Hz, 
3H), 0.89 (s, 9H), 0.01 (s, 3H), -0.15 (s, 3H). 

































































































































chloro-6,7-dimethoxy-1-methyl-1H-indol-3-yl)propanoate (4.28). Compound 4.27 
(105 mg, 0.167 mmol) was dissolved in CH2Cl2 (1.7 mL), then 2,6-lutadine (0.039 mL, 
0.334 mmol) added. The solution was cooled to 0 °C, then TMSOTf (0.045 mL, 0.251 
mmol) added. After warming to r.t., the reaction was monitored by TLC and once 
complete, quenched with sat’d NH4Cl. The product was extracted into CH2Cl2, the 
organic extracts dried and concentrated, and the product purified by SiO2 
chromatography to afford the title compound (52 mg, 59% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 1H), 6.92 (s, 1H), 5.53 (s, 1H), 4.79-4.77 (bs, 
2H), 4.59 (d, J = 8.8 Hz, 1H), 3.97 (s, 3H), 3.90 (s, 3H), 3.88 (s, 3H), 3.82 (d, J = 7.4 Hz, 
1H), 3.74 (s, 3H), 1.29 (d, J = 8.4 Hz, 3H), 0.87 (s, 9H), -0.01 (s, 3H), -0.16 (s, 3H). 




















































































methylpiperazine-2,5-dione (4.29). To a solution of amine 4.28 (69 mg, 0.167 mmol) in 
toluene (5 mL) was added a small amount of 2-OH-pyridine. The solution was heated to 
reflux O/N, then cooled to r.t. The solvent was decanted off and the remaining solid 
washed with toluene and dried to afford pure 4.29 (37 mg, 61% yield). 
1H-NMR (300 MHz; DMSO-d6): δ  9.43 (s, 1H), 8.32 (s, 1H), 7.87 (s, 1H), 7.43 (s, 1H), 
6.81 (s, 1H), 4.11 (q, J = 6.9 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.81 (s, 3H), 1.32 (d, J = 
6.8 Hz, 3H); 13C-NMR (101 MHz; DMSO): δ 167.9, 160.77, 160.73, 144.2, 141.0, 133.1, 
128.4, 126.3, 123.8, 120.9, 114.2, 107.2, 106.2, 62.4, 61.4, 50.7, 36.0, 19.9; HRMS (ESI-
APCI+): [M+H]+ 364.1064 calcd for C17H19ClN3O4, found: 364.1075. 















Figure 5.77a. 1H NMR spectrum of compound 4.29. 
 



































































































6,7-dimethoxy-1-methyl-1H-indol-3-yl)propanoic acid (4.30). To a solution of methyl 
ester 4.25 (682 mg, 1.2 mmol) in THF/H2O (2:1, 2.6:1.3 mL) was added LiOH (144 mg, 
6.0 mmol) and the resulting suspension stirred O/N. The reaction mixture was acidified 
with 10% KHSO4, then the product extracted in EtOAc. The combined organic extracts 
were washed with brine, dried over Na2SO4, and concentrated to afford 4.30 (545 mg, 
82% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.37-7.28 (m, 6H), 6.87 (bs, 1H), 5.62-5.58 (broad, 1H), 
5.10-5.00 (m, 2H), 4.70 (s, 1H), 4.51-4.49 (bs, 1H), 3.99-3.89 (broad, 9H), 0.91-0.86 (m, 





























































































































yl)propanamido)propanoate (4.31). To a solution of acid 4.30 (100 mg, 0.173 mmol), 
L-Ala-OMe·HCl (24 mg, 0.173 mmol), and iPr2NEt (0.075 mL, 0.433 mmol) in CH2Cl2 
(2 mL) was added T3P (50 wt % in DMF, 127 mg of solution). The resulting solution 
was stirred O/N under Ar at r.t., then quenched by addition of water. The product was 
extracted in EtOAc and the combined organic layers dried over Na2SO4 and concentrated 
to afford the crude material. Purification by SiO2 chromatography (10-40% EtOAc in 
hexanes) gave 4.31 (39 mg, 34% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.58 (d, J = 7.4 Hz, 1H), 7.35 (d, J = 3.1 Hz, 5H), 7.04 
(s, 1H), 5.56 (dd, J = 29.0, 5.4 Hz, 2H), 5.13-5.10 (broad, 3H), 4.76-4.74 (bs, 1H), 4.57-
4.50 (m, 1H), 3.98 (s, 3H), 3.89 (d, J = 3.7 Hz, 6H), 3.78 (s, 3H), 1.42 (d, J = 7.2 Hz, 











































































































indol-3-yl)propanoate (4.32). To a solution of amine 4.26 (100 mg, 0.22 mmol) in 
CH2Cl2 (2.2 mL) was added N-Fmoc-Ala (68 mg, 0.22 mmol), iPr2NEt (0.1 mL, 0.55 
mmol), and T3P (160 mg 50 wt% solution in DMF, 0.25 mmol). The resulting solution 
was allowed to stir O/N at r.t. under Ar, then quenched with water and the product 
extracted in EtOAc. The combined organic layers were dried over Na2SO4, filtered, and 
concentrated. Purification by SiO2 chromatography (1:1 hexanes:EtOAc) afforded 4.32 in 
59% yield (97 mg). 
[α]D = -3.9 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.76 (d, J = 7.5 Hz, 2H), 7.58 (d, J 
= 7.4 Hz, 2H), 7.40 (d, J = 7.5 Hz, 2H), 7.36 (s, 1H), 7.31 (d, J = 7.4 Hz, 2H), 6.85 (s, 
1H), 6.65 (s, 1H), 5.54 (d, J = 1.4 Hz, 1H), 5.41-5.38 (m, 1H), 4.68 (dd, J = 9.0, 1.7 Hz, 
1H), 4.33-4.27 (m, 2H), 3.97 (s, 3H), 3.89 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 1.36 (d, J = 
6.8 Hz, 3H), 0.89 (s, 9H), 0.02 (s, 3H), -0.13 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 
171.4, 165.8, 156.4, 144.4, 143.7, 143.3, 141.27, 141.15, 140.9, 135.1, 128.3, 127.78, 
127.70, 127.5, 127.10, 127.06, 126.5, 124.87, 124.82, 122.4, 119.98, 119.92, 117.9, 
113.9, 108.1, 67.0, 61.8, 61.2, 52.3, 51.5, 47.1, 36.0, 25.61, 25.48, 25.3, 17.94, 17.91, -
3.6; IR (NaCl, film) 3302, 2953, 2857, 1714, 1462, 1254, 1040 cm-1; HRMS (ESI-
APCI+): [M+Na]+ 772.2797 calcd for C39H48ClN3NaO8Si, found: 772.2799. 















Figure 5.80a. 1H NMR spectrum of compound 4.32. 
 

























































































































































































































indol-3-yl)methyl)-6-methylpiperazine-2,5-dione (4.3). Dipeptide 4.32 (350 mg, 0.47 
mmol) was dissolved in THF (20 mL), then morpholine (4.7 mL) added. The resulting 
solution was stirred O/N at r.t., then concentrated. The crude residue was purified by SiO2 
chromatography (10% methanol in CH2Cl2) to afford 181 mg of the title dioxopiperazine 
(78% yield). 
[α]D = -5.8 (CH2Cl2); 1H-NMR (300 MHz; CDCl3): δ  7.31 (s, 1H), 6.98 (s, 1H), 5.67 (s, 
2H), 4.13 (q, J = 6.7 Hz, 1H), 4.05 (d, J = 1.5 Hz, 1H), 4.02 (s, 3H), 3.97 (s, 3H), 3.91 (s, 
3H), 3.76 (s, 1H), 1.61 (d, J = 7.0 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 3H), -0.03 (s, 3H); 13C-
NMR (101 MHz; CDCl3): δ 166.5, 160.4, 140.9, 136.1, 129.7, 127.4, 125.7, 122.7, 114.6, 
108.6, 61.9, 61.2, 51.6, 51.3, 36.02, 36.00, 25.8, 25.6, 25.3, 20.4, 17.9, -1.6, -3.6; IR 
(NaCl, film) 3225, 2932, 1681, 1449, 1259, 1042 cm-1; HRMS (ESI-APCI+): [M+Na]+ 
518.1854 calcd for C23H34ClN3NaO5Si, found: 518.1852. 
















Figure 5.81a. 1H NMR spectrum of compound 4.3. 
 































































































































dicarboxylate (4.40). Indole 4.25 (70 mg, 0.118 mmol) was dissolved in CH2Cl2 (6 mL) 
and the resulting solution cooled to -78 °C. Freshly prepared DMDO (0.056 M in 
acetone, 3 mL, 0.165 mmol) was added and the reaction mixture allowed to warm to r.t. 
O/N. Sodium thiosulfate (sat’d aq) was added and the product extracted in CH2Cl2. The 
combined organic extracts were washed with brine, dried over Na2SO4, and concentrated. 
Purification by pTLC (40% EtOAc in hexanes) afforded pure 4.25 (6.2 mg, 9% yield). 
1H-NMR (400 MHz; CDCl3): δ  7.46-7.40 (m, 5H), 7.05 (t, J = 9.1 Hz, 1H), 5.59 (s, 1H), 
5.42-5.37 (m, 2H), 5.11-5.08 (m, 1H), 4.67-4.61 (m, 1H), 3.97-3.87 (m, 6H), 3.55 (s, 
3H), 3.39 (s, 3H), 0.96 (s, 9H), 0.04 (d, J = 36.9 Hz, 6H); HRMS (ESI-APCI+): [M+H]+ 
607.2242 calcd for C29H40ClN2O8Si, found: 607.2240. 
















































































































dimethoxy-1-methyl-1H-indol-3-yl)propanoate (4.47). To a solution of alcohol 4.4 
(250 mg, 0.52 mmol) in THF (2.5 mL) was added Ac2O (0.059 mL, 0.62 mmol), Et3N 
(0.109 mL, 0.78 mmol), and DMAP (small amt). The resulting solution was stirred at r.t. 
O/N, then concentrated and 1M HCl added. The product was extracted in CH2Cl2, 
washed with brine, dried over Na2SO4, and concentrated. The crude material was purified 
by SiO2 chromatography (1:1 hexanes:EtOAc) to afford 4.47 (150 mg, 56% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.38-7.35 (broad, 6H), 6.92 (d, J = 38.1 Hz, 1H), 5.61-
5.54 (m, 1H), 5.18 (s, 1H), 5.09-5.06 (m, 2H), 4.82 (dd, J = 9.7, 3.7 Hz, 1H), 4.00-3.98 



























































































yl)propanoate (4.48). Compound 4.47 (150 mg, 0.29 mmol) was dissolved in MeOH 
(1.5 mL) and to it added Pd/C (15 mg). The suspension was treated with H2 (atm) O/N, 







dimethoxy-1-methyl-1H-indol-3-yl)propanoate (4.49). Crude 4.48 (78 mg, 0.203 
mmol) was dissolved in CH2Cl2 (2  mL) and to it added N-Me,Fmoc-Ala (66 mg, 0.203 
mmol), iPr2NEt (0.088 mL, 0.233 mmol), and T3P (150 mg 50 wt% solution in DMF, 
0.233 mmol). The resulting solution was allowed to stir O/N at r.t. under Ar, then 
quenched with water and the product extracted in EtOAc. The combined organic layers 
were dried over Na2SO4, filtered, and concentrated. Purification by SiO2 chromatography 

























(methylamino)propanamido)acrylate (4.50). Dipeptide 4.49 (25 mg, 0.037 mmol) was 
dissolved in THF (1.5 mL), then morpholine (0.37 mL) added. The resulting solution was 
stirred O/N at r.t., then concentrated. The crude residue was purified by SiO2 
chromatography (10% methanol in CH2Cl2) to afford the title product as a 1:1 mixture of 
diasteromers (trace yield). 
1H-NMR (400 MHz; CDCl3): δ  7.44 (d, J = 17.9 Hz, 2H), 6.86 (d, J = 4.3 Hz, 2H), 5.07 
(dt, J = 15.5, 4.8 Hz, 2H), 4.84-4.77 (m, 2H), 3.98 (s, 3H), 3.96 (s, 3H), 3.90 (s, 3H), 3.89 
(s, 3H), 3.77 (s, 3H), 3.71 (s, 2H), 3.66 (s, 3H), 3.32 (s, 3H), 3.27 (s, 3H), 2.40 (s, 3H), 
2.29 (s, 3H), 1.18 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 7.0 Hz, 3H); HRMS (ESI-APCI+): 



































































































(S)-(9H-fluoren-9-yl)methyl 4-methyl-5-oxooxazolidine-3-carboxylate (4.45). To a 
solution of N-Fmoc-Ala (5.0 g, 16.1 mmol) in PhMe (50 mL) was added 
paraformaldehyde (3.15 g, 105 mmol) and p-TsOH (247 mg, 1.3 mmol). The resulting 
suspension was heated to reflux for 1 h with a Dean-Stark trap in place. Upon cooling, 
EtOAc was added and the organic phase washed with sat’d NaHCO3, dried over Na2SO4, 
and concentrated to afford 4.45, carried forward as crude. 
1H-NMR (300 MHz; CDCl3): δ  7.78 (d, J = 7.3 Hz, 2H), 7.54 (d, J = 7.4 Hz, 2H), 7.38 
(dt, J = 26.6, 7.4 Hz, 4H), 5.38-5.14 (broad, 3H), 4.61-4.60 (broad, 2H), 4.25 (t, J = 5.6 



































































































































N-Me,Fmoc-L-Ala-OH (4.46). Compound 4.45 (crude, directly from previous reaction) 
was dissolved in CHCl3 (4.1 mL) and to the resulting solution added TFA (4.1 mL) and 
Et3SiH (1.0 mL). After stirring 10 h, additional Et3SiH (3.0 mL) was added. The reaction 
stirred another 24 h, then was concentrated and TFA removed by repeated azeotropic 
distillations with toluene. The crude product was recrystallized from ether/EtOAc to 
afford pure 4.46 (2.87 g, 55% yield over 2 steps). 
1H-NMR (300 MHz; CDCl3): δ  7.77 (d, J = 7.2 Hz, 2H), 7.61-7.53 (m, 2H), 7.43-7.29 
(m, 4H), 4.76 (dq, J = 84.6, 7.2 Hz, 1H), 4.44 (qd, J = 11.3, 9.0 Hz, 2H), 4.28 (t, J = 6.9 

































































































N-Bn-L-Ser-OH (5.13). To a solution of serine (14.7 g, 140 mmol) in 2M NaOH (70 
mL) was added freshly distilled benzaldehyde (14.0 mL, 138 mmol). After stirring for 1 h 
at r.t., the reaction mixture was cooled to 0 °C and NaBH4 (1.5 g, 40 mmol) added 
portionwise such that the internal temperature did not exceed 10 °C. The resulting 
solution was stirred 30 min at 5 °C, 1 h at r.t., then recooled to 0 °C. Additional NaBH4 
(1.5 g, 40 mmol) was added portionwise as before. The reaction was allowed to warm to 
r.t. as it stirred O/N. The crude reaction mixture was washed with ether (3x), then the 
aqueous phase acidified to pH 5 with HCl. The resulting precipitate was filtered and 








N-Me,Bn-L-Ser-OH (5.14). N-Bn-Ser (5.13, 2.49 g, 12.8 mmol) was dissolved in formic 
acid (1.6 mL, 38.4 mmol) and formaldehyde (37% in H2O, 1.1 mL, 15.4 mmol) and 
heated to 90 °C for 2 h. The reaction mixture was concentrated, then acetone added and a 
solid triturated out of the solution. The suspension was concentrated, acetone added, and 
the trituration process repeated 3x. Following the final concentration, acetone was again 
added and the suspension allowed to stir 1 h at r.t, then 3 h at -20 °C. The solid was 
filtered, washed with cold acetone, and dried to afford 5.14 (1.47 g, 55% yield). 
1H-NMR (300 MHz; CD3OD): δ  7.58-7.45 (m, 5H), 4.52 (d, J = 12.6 Hz, 1H), 4.37 (d, J 

































































N-Me-L-Ser-OH (5.15). 5.14 (1.47 g, 7.0 mmol) was dissolved in MeOH (70 mL) and to 
it added Pd(OH)2 (700 mg). The resulting suspension was treated with H2 (55 psi) for 40 
h, then filtered through celite and concentrated to afford the title compound (660 mg, 




N-Me-L-Ser(OTBS)-OH (5.16). To a solution of 5.15 (660 mg, 5.55 mmol) in DMF (12 
mL) was added TBSCl (923 mg, 6.11 mmol) and imidazole (755 mg, 11.1 mmol). The 
resulting solution was allowed to stir at r.t. O/N, then concentrated. To the crude residue 
was added H2O and hexanes (1:1) and the resulting suspension stirred 4 h. The solid was 
filtered, rinsed with hexanes, and dried to give 5.16 (685 mg, 53% yield). 
1H-NMR (300 MHz; CD3OD): δ  4.09 (d, J = 4.1 Hz, 2H), 3.50 (t, J = 4.1 Hz, 1H), 2.72 





































N-Me,Fmoc-L-Ser(OTBS)-OH (5.17). To a suspension of 5.16 (375 mg, 1.61 mmol) in 
Na2CO3 (aq, 10%, 3.2 mL) and dioxane (1.3 mL) at 0 °C was added dropwise FmocOSu 
(570 mg, 1.69 mmol) as a solution in dioxane (2.1 mL). The resulting solution was 
allowed to warm to r.t. as it stirred O/N. After concentration, the crude mixture was 
diluted with water, acidified to pH 3-4 with 10% KHSO4, and the product extracted in 
EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, and 
concentrated to afford 5.17 (663 mg, 90% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.77 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 7.2 Hz, 2H), 7.36 
(dt, J = 27.2, 7.4 Hz, 4H), 4.82 (t, J = 5.9 Hz, 1H), 4.49-4.40 (m, 2H), 4.30-4.22 (m, 1H), 
4.14-4.05 (m, 2H), 3.88 (t, J = 5.1 Hz, 1H), 3.04 (d, J = 24.1 Hz, 3H), 0.86 (s, 9H), 0.08-







































































































N-Me,Bn-L-Trp-OMe (5.18). To a solution of L-Trp-OMe·HCl (500 mg, 2 mmol) in 
MeOH (20 mL) and Et3N (1.67 mL) was added PhCHO (212 µL, 2.1 mmol). The 
resulting mixture was stirred at r.t. for 1 h, then NaBH3CN (132 mg, 2.1 mmol) added. 
The reaction mixture was stirred overnight at r.t., at which time paraformaldehyde (180 
mg, 2 mmol) was added. After full dissolution (ca. 5 h), PhCHO (132 mg, 2.1 mmol) was 
added and the reaction stirred overnight. The crude reaction mixture was concentrated 
and the residue dissolved in EtOAc, filtered through celite, and concentrated. Purification 
by SiO2 chromatography (5-30% EtOAc in hexanes) afforded diprotected amine 5.18 
(300 mg, 47% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.11 (s, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.35 (t, J = 4.3 Hz, 
6H), 7.23 (t, J = 6.9 Hz, 1H), 7.14 (t, J = 6.9 Hz, 1H), 7.02 (d, J = 2.2 Hz, 1H), 3.92 (d, J 
= 13.5 Hz, 1H), 3.82 (dd, J = 9.1, 5.8 Hz, 1H), 3.72-3.68 (m, 4H), 3.42 (dd, J = 14.4, 9.1 
Hz, 1H), 3.17 (ddd, J = 14.3, 5.8, 0.6 Hz, 1H), 2.44 (s, 3H). 


































































































N-Me-L-Trp-OMe (5.19). To a degassed solution of 5.18 (300 mg, 0.93 mmol) in 
MeOH (9 mL) was added Pd(OH)2/C (150 mg). The resulting suspension was treated 
with H2 (55 psi) for 18 h, then filtered through celite and concentrated to afford 
methylamine 5.19 (215 mg, 99.5% yield), deemed sufficiently pure to carry forward 
without further purification. 
1H-NMR (300 MHz; CDCl3): δ  8.26 (s, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.36-7.33 (m, 1H), 
7.15 (tdd, J = 14.4, 6.5, 1.2 Hz, 2H), 7.04 (d, J = 2.3 Hz, 1H), 3.66 (s, 3H), 3.57 (t, J = 























































































































N-Me,Boc-L-Trp-OMe (5.20). To a solution of 5.19 (6.40 g, 27.6 mmol) in 
water/dioxane (1:1, 110 mL) was added NaOH (1.10 g, 27.6 mmol) and Boc anhydride 
(7.22 g, 33.1 mmol). The resulting solution was allowed to stir O/N at r.t., then acidified 
with HCl to pH 6-7. The product was extracted in CHCl3 and the organic phase dried 
over Na2SO4 and concentrated. Crude material was purified by SiO2 chromatography 
(25% EtOAc in hexanes) to afford 5.20 (4.50 g, 49% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.07-8.06 (m, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 
7.5 Hz, 1H), 7.16 (dt, J = 21.1, 7.3 Hz, 2H), 7.06-7.00 (broad, 1H), 5.07-4.73 (m, 1H), 
3.76 (s, 3H), 3.48-3.40 (m, 1H), 3.27-3.11 (m, 1H), 2.75 (d, J = 14.1 Hz, 3H), 1.29 (d, J = 


























































































































































L-Ser-OMe (5.21). To a solution of L-serine (50.0 g, 0.48 mol) in MeOH (450 mL) at 0 
°C was added SOCl2 (35 mL, 0.48 mol). The reaction was allowed to warm to r.t. as it 
stirred O/N. The resulting solution was concentrated, taken up in ether, filtered, and the 
solid washed with ether. The crude solid material was recrystallized in MeOH/ether to 








N-Bn,Me-L-Ser-OMe (5.22). To a solution of L-Ser-OMe·HCl (10.0 g, 64.1 mmol) in 
MeOH (500 mL) and Et3N (50.0 mL, 385 mmol) was added PhCHO (6.8 mL, 67.3 
mmol). The resulting mixture was stirred at r.t. for 1 h, then NaBH3CN (4.24 g, 67.3 
mmol) added. The reaction mixture was stirred overnight at r.t., at which time 
paraformaldehyde (5.78 g, 64.1 mmol) was added. After full dissolution (ca. 5 h), 
NaBH3CN (4.24 g, 67.3 mmol) was added and the reaction stirred overnight. The crude 
reaction mixture was concentrated and the residue dissolved in EtOAc, filtered through 
celite, and concentrated. Purification by SiO2 chromatography (2:1 hexanes:EtOAc) 
afforded diprotected amine 5.22 (7.41 g, 52% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.37-7.29 (m, 5H), 4.69 (d, J = 5.9 Hz, 1H), 3.79-3.71 
(m, 5H), 3.54 (dd, J = 8.8, 6.6 Hz, 1H), 2.78 (dd, J = 8.6, 3.0 Hz, 1H), 2.33 (s, 3H). 








































































N-Me-L-Ser-OMe (5.23). To a degassed solution of 5.22 (3.7 g, 16.6 mmol) in MeOH 
(140 mL) was added Pd(OH)2 (1.85 g). The resulting suspension was treated with H2 (55 
psi) for 18 h, then filtered through celite and concentrated to afford methylamine 5.23 
(99.5% yield), deemed sufficiently pure to carry forward without further purification. 
1H-NMR (300 MHz; CDCl3): δ  3.82-3.77 (m, 4H), 3.63 (dd, J = 10.9, 6.1 Hz, 1H), 3.28 
(t, J = 5.2 Hz, 1H), 2.43 (s, 3H). 








































3-(1H-indol-3-yl)-2-(methylamino)propan-1-ol (5.24). To a suspension of LAH (813 
mg, 21.4 mmol) in THF (20 mL) at 0°C was added methyl ester 5.19 (1.70 g, 5.35 mmol) 
dropwise. The resulting mixture was heated to reflux and stirred O/N. After cooling to 
0°C, 15% NaOH (8 mL) was added and the reaction stirred an additional 1 h at r.t. The 
suspension was filtered through celite and the filtrate dried over Na2SO4 before 
concentrating to afford 1.09 g (100% yield) of methylamine alcohol 5.24. 
1H-NMR (300 MHz; CDCl3): δ  8.76 (s, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.34 (d, J = 8.0 
Hz, 1H), 7.23-7.10 (m, 2H), 6.92 (s, 1H), 3.71 (dd, J = 11.5, 2.1 Hz, 1H), 3.47 (dd, J = 
10.9, 4.3 Hz, 1H), 2.98-2.90 (m, 3H), 2.41 (s, 3H). 

























































































N-Cbz-L-Ser-OH (5.25). To a solution of L-Ser (10.0 g, 95 mmol) in saturated aqueous 
NaHCO3 (380 mL) was added CbzCl (15 mL, 100 mmol). The resulting solution was 
stirred O/N at r.t., then acidified to ph 4 with 1M HCl. The product was extracted in 
EtOAc (3x), and the combined organic layers dried and concentrated to afford N-Cbz-L-
Ser-OH (21.78 g, 96% yield). 
1H-NMR (300 MHz; CD3OD): δ  7.38-7.28 (m, 5H), 5.10 (s, 2H), 4.27 (t, J = 4.3 Hz, 
1H), 3.91-3.80 (m, 2H). 


















































N-Cbz-L-Ser(OTBS)-OH (5.26). N-Cbz-L-Ser-OH (10.0 g, 41.8 mmol), TBSCl (6.95 g, 
46.0 mmol), and imidazole (5.68 g, 83.6 mmol) were dissolved in DMF (100 mL). The 
resulting solution was stirred at r.t. under Ar for 48 h before concentrating. The residue 
was suspended in hexanes and the product extracted into 5% aqueous NaHCO3. KHSO4 
(1M) was added to acidify the aqueous layer to pH 3, from which the product was 
extracted into EtOAc. The combined organic extracts were washed with brine, dried over 
Na2SO4, and concentrated to afford N-Cbz-L-Ser(OTBS)-OH (10.04 g, 68% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.33-7.30 (m, 5H), 5.08 (d, J = 3.4 Hz, 2H), 4.33-4.31 
(m, 1H), 4.05 (dd, J = 10.2, 2.8 Hz, 1H), 3.82 (dd, J = 10.2, 2.8 Hz, 1H), 0.82 (d, J = 2.8 
Hz, 9H), -0.02 (s, 6H). 
































































L-Trp-OMe·HCl (5.27). To a solution of L-tryptophan (25 g, 123 mmol) in MeOH (250 
mL) at 0 °C was added SOCl2 (8.9 mL, 123 mmol) dropwise. The reaction was allowed 
to warm to r.t. as it stirred O/N. Upon completion, the reaction was concentrated, then 
MeOH (2x) and ether (3x) separately added and the mixture concentrated to thoroughly 
dry the crude product. Pure L-tryptophan-OMe·HCl crystals were recovered following 
recrystallization in MeOH/ether (25.08 g, 80% yield). 
1H-NMR (300 MHz; CD3OD): δ  10.62 (bs, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 
8.1 Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.17-7.03 (m, 2H), 4.33 (dd, J = 7.4, 5.5 Hz, 1H), 






































































































N-Cbz-L-Trp-OMe (5.28). To a suspension of L-tryptophan-OMe·HCl (15 g, 58.8 
mmol) in dioxane (75 mL) at 0 °C was added 1M NaOH (60 mL). CbzCl (9.7 mL, 64.7 
mmol) was added, followed by a second portion of 1M NaOH (60 mL). The reaction 
mixture was allowed to stir for 20 minutes at 0 °C, then diluted with EtOAc. The organic 
layer was separated, washed with 1M HCl and brine, then dried and concentrated to 
afford the title compound. 
1H-NMR (300 MHz; CDCl3): δ  8.22 (bs, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.34 (bs, 6H), 
7.26-7.17 (m, 2H), 7.13-7.08 (m, 1H), 6.93 (s, 1H), 5.39 (d, J = 8.1 Hz, 1H), 5.11 (d, J = 






























































































N’-SO2Ph-N-Cbz-L-Trp-OMe (5.29). Phenylsulfonyl chloride (4.4 mL, 34.1 mmol) was 
added dropwise to a suspension of N-Cbz-L-Trp-OMe (10 g, 28.4 mmol), NaOH (3.4 g, 
85.2 mmol), and Bu4NHSO4 (483 mg, 1.42 mmol) in CH2Cl2 (140 mL). The reaction was 
allowed to stir O/N at r.t., then to it added concentrated NH4Cl and EtOAc. The organic 
layer was removed and the product further extracted into EtOAc (2x), then the combined 
organic extracts dried and concentrated to afford the title compound (13.31 g, 95% yield). 
1H-NMR (300 MHz; CDCl3): δ  8.05 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.81 
(d, J = 7.8 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.37 (sextet, J = 7.7 Hz, 9H), 7.20 (d, J = 
7.4 Hz, 1H), 5.31 (d, J = 7.9 Hz, 1H), 5.16-5.06 (m, 2H), 4.70 (q, J = 6.6 Hz, 1H), 3.62 


























































































Bromopyrroloindoline (5.30). N’-SO2Ph-N-Cbz-L-Trp-OMe (13.31 g, 27 mmol) was 
dissolved in CH2Cl2 (400 mL), and to the resulting solution added NBS (4.81 g, 27 
mmol) and PPTS (6.78 g, 27 mmol). The reaction was allowed to stir O/N at r.t. NaHCO3 
(10% aq.) and Na2S2O4 (10% aq.) were added in a 1:1 mixture, the organic layer 
removed, dried, and purified (SiO2 chromatography, 1:1 H:E) to afford the title 
compound (11.46 g, 74% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.63 (d, J = 8.1 Hz, 1H), 7.50-7.45 (m, 3H), 7.36-7.34 
(m, 8H), 7.26-7.25 (m, 2H), 7.19 (d, J = 7.4 Hz, 1H), 6.36-6.29 (bs, 1H), 5.42-5.22 
(broad, 2H), 3.90-3.84 (m, 1H), 3.69-3.52 (broad, 3H), 3.09 (dd, J = 12.8, 6.0 Hz, 1H), 






















































































































































































Methyl 3-bromo-2-(tert-butoxycarbonylamino)propanoate (5.31). To a solution of N-
Boc-Ser-OMe (2.0 g, 9.1 mmol) in THF (50 mL) at 0 °C was added CBr4 (4.54 g, 13.7 
mmol) and PPh3 (3.59 g, 13.7 mmol). The reaction was stirred at 0 °C for 10 minutes, 
then warmed to r.t. and stirred 4 h under Ar. The crude mixture was filtered through a bed 
of celite, diluted with ether, and washed with water and brine. The organic phase was 
dried over Na2SO4, filtered, and concentrated. The crude residue was purified by SiO2 
chromatography (3:1 hexanes:EtOAC) to afford bromide 5.31 (1.64 g, 64% yield). 
1H-NMR (300 MHz; CDCl3): δ  5.42-5.39 (m, 1H), 4.78-4.73 (m, 1H), 3.81 (s, 3H), 3.71 










































































Methyl 2-(benzyloxycarbonylamino)-3-hydroxypropanoate (5.32). To a solution of 
Ser-OMe·HCl (5.0 g, 32.1 mmol) in MeOH:NaHCO3 (1:1, 120 mL) was added CbzCl 
(5.75 g, 33.7 mmol). The reaction mixture was stirred at r.t. for 48 h, then 1 M HCl 
added. The crude mixture was concentrated and the resulting residue dissolved in EtOAc. 
The organic phase was washed with 1 M NaOH, dried over Na2SO4, filtered, and 
concentrated under reduced pressure to afford Cbz-amine 5.32 (8.12 g, 100% yield) as a 
clear oil, carried forward without additional purification. 
1H-NMR (300 MHz; CDCl3): δ  7.37-7.34 (m, 5H), 5.72-5.67 (m, 1H), 5.13 (s, 2H), 4.47-

















































































































































3-benzyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (5.33). To a solution of 
Cbz-Ser-OMe (7.56 g, 30.0 mmol) in dry acetone (100 mL) was added 2,2-
dimethoxypropane (40 mL), BF3·OEt2 (3.8 mL, 30.0 mmol), and Na2SO4 (10 g). The 
reaction mixture stirred overnight at r.t. under Ar, and then Et3N (12 mL) was added. The 
resulting suspension was filtered and the filtrate concentrated under reduced pressure. 
The product was extracted with ether (3 x 75 mL), washed with NaHCO3, washed with 
brine, dried over Na2SO4, and concentrated. The crude oil was purified by SiO2 
chromatography (5-50% EtOAc in hexanes) to afford 5.33 (7.20 g, 82% yield) as a 
mixture of rotamers. Crude oil was likely pure enough to carry forward without 
purification. 
1H-NMR (300 MHz; CDCl3): δ  7.36-7.30 (m, 5H), 5.20-5.02 (m, 2H), 4.52 (ddd, J = 
23.2, 6.6, 2.7 Hz, 1H), 4.19-4.07 (m, 2H), 3.69 (d, J = 40.4 Hz, 3H), 1.68 (d, J = 20.1 Hz, 








































































































Benzyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (5.34). To a 
solution of ester 5.33 (1.0 g, 3.4 mmol) in THF (12 mL) at -10 °C was added NaBH4 (517 
mg, 13.6 mmol). The resulting mixture was stirred for 30 minutes at -10 °C, then MeOH 
(5 mL) added dropwise. The reaction was allowed to warm to r.t. while it stirred 
overnight under Ar. Water was added and the resulting suspension stirred for 30 minutes, 
concentrated under reduced pressure, diluted with brine, and the product extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, and concentrated to afford alcohol 5.34 (900 mg, 100% yield), deemed 
sufficiently pure to carry forward without additional purification. 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 5H), 5.17-5.12 (m, 2H), 4.15-4.13 (m, 1H), 4.04-
3.98 (m, 2H), 3.83-3.59 (m, 3H), 3.39-3.36 (bs, 1H), 1.65-1.47 (m, 6H). 































































































































Benzyl 4-(iodomethyl)-2,2-dimethyloxazolidine-3-carboxylate (5.35). To a solution of 
Ph3P (550 mg, 2.1 mmol) and imidazole (143 mg, 2.1 mmol) in CH2Cl2 (10 mL) at 0 °C 
was added I2 (533 mg, 2.1 mmol) in 3 portions. The reaction mixture was warmed to r.t. 
for 10 minutes, then cooled to 0 °C before adding dropwise a solution of alcohol 5.34 
(450 mg, 1.7 mmol) in 5 mL CH2Cl2. The resulting solution was stirred 1 h at 0 °C, then 
allowed to warm to r.t. as it stirred an additional 1.5 h. The crude reaction mixture was 
filtered through a plug of silica with 1:1 EtOAC/Hexanes. The filtrate was concentrated 
under reduced pressure and purified by SiO2 chromatography (5-20% EtOAc in hexanes) 
to afford iodide 5.35 (30 mg, 8% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.36 (s, 5H), 5.15 (s, 2H), 4.25-4.19 (m, 1H), 4.08-4.02 
(m, 2H), 3.54-3.35 (m, 1H), 3.21-3.10 (m, 1H), 1.62 (d, J = 20.1 Hz, 3H), 1.47 (d, J = 
19.3 Hz, 3H); 13C-NMR (75 MHz; CDCl3): δ 128.9, 128.0, 67.69, 67.58, 67.0, 59.5, 58.9, 
28.1, 27.2, 24.7, 23.2, 6.8, 6.5. 











Figure 5.106a. 1H NMR spectrum of compound 5.35. 
 





























































































































Benzyl 4-(bromomethyl)-2,2-dimethyloxazolidine-3-carboxylate (5.36). To a solution 
of alcohol 5.34 (450 mg, 1.7 mmol) in THF (9 mL) at 0 °C was added CBr4 (862 mg, 2.6 
mmol) and PPh3 (681 mg, 2.6 mmol). The reaction was stirred at 0 °C for 10 minutes, 
then warmed to r.t. and stirred 4 h under Ar. The crude mixture was concentrated, diluted 
with ether, filtered through a bed of celite, and concentrated. The crude residue was 
purified by SiO2 chromatography (5-20% EtOAc in hexanes) to afford bromide 5.36 (460 
mg, 82% yield). 
1H-NMR (300 MHz; CDCl3): δ  7.35 (s, 5H), 5.15 (s, 2H), 4.20-4.15 (m, 1H), 4.12-4.07 
(m, 1H), 3.99 (ddd, J = 7.0, 5.1, 2.3 Hz, 1H), 3.68-3.49 (m, 1H), 3.30 (dt, J = 15.3, 10.0 
Hz, 1H), 1.60 (d, J = 20.2 Hz, 3H), 1.48 (d, J = 19.8 Hz, 3H). 













































































































3,5,6-trichloroindole (5.37). NCS (1.75 g, 13.2 mmol) was added in one portion to a 
solution of 5,6-dichloroindole (2.45 g, 13.2 mmol) in DMF (65 mL) at rt. The reaction 
was stirred for 3 h at rt, and brine (50 mL) was added. The mixture was extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with water (100 mL), 
brine (100 mL), dried (Na2SO4), and concentrated under reduced pressure. The residue 
was purified by flash chromatography eluting with hexanes/EtOAc (9:1) to give 1.95 g 
(67%) of 5.37 as a brown solid. 
1H NMR (300 MHz, CDCl3) δ 8.11 (bs, 1 H), 7.71 (s, 1 H), 7.49 (s, 1 H), 7.20 (d, J = 2.6 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 133.7, 127.5, 125.3, 125.1, 122.9, 119.7, 113.2, 
106.5; IR (neat) 3442, 1448,1266, 1011 cm-1; HRMS (ES/ApCl) calcd for C8H3NCl3 (M-










Figure 5.108a. 1H NMR spectrum of compound 5.37. 
 
Figure 5.108b. 13C NMR spectrum of compound 5.37. 
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5,6-dichloro-2-(2-methylbut-3-en-2-yl)-1H-indole (5.38). Solid 5.37 (1.95 g, 8.84 
mmol) was added in one portion to a solution of freshly prepared prenyl-9-BBN (26.52 
mmol) and Et3N (3.12 g, 30.94 mmol, 4.30 mL) in THF (53 mL) at rt. The reaction was 
stirred for 3 h, and then quenched with sat. NaHCO3 (50 mL). The organic layer was 
separated and the aqueous layer was extracted with Et2O (3 x 50 mL). The combined 
organic layers were washed with H2O (100 mL), brine (100 mL), and dried (Na2SO4), 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with hexanes/EtOAc (99:1) to give 1.80 g (80%) of 5.38 as a 
yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.87 (bs, 1 H), 7.59 (s, 1 H), 7.38 (s, 1 H), 6.23 (m, 1 H), 
6.01 (dd, J = 17.3, 10.6 Hz, 1 H), 5.15 (d, J = 10.6 Hz, 1 H), 5.09 (d, J = 17.3 Hz, 1 H), 
1.46 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 148.2, 145.6, 134.9, 128.5, 125.0, 123.7, 
121.1, 113.0, 112.0, 97.6, 38.5, 27.5; IR (neat) 3231, 2927, 1453, 1102 cm-1; HRMS 









Figure 5.109a. 1H NMR spectrum of compound 5.38. 
 




(5.39). A solution of Me2NH (0.78 mL, 40% solution in H2O, 6.00 mmol) and a solution 
of CH2O (0.47 mL, 37% solution in H2O, 6.00 mmol) were sequentially added to AcOH 
(2 mL) and the reaction stirred for 1 h. Neat 5.38 (1.45 g, 5.71 mmol) was added, and the 
reaction was stirred for 12 h at rt. 2N NaOH was added until pH ≈ 12. The reaction was 
extracted with Et2O (3 x 20 mL). The combined organic layers were washed with H2O 
(50 mL), brine (50 mL), and dried (Na2SO4), and concentrated under reduced pressure to 
give 1.66 g (90%) of 5.39 as a yellow oil which was used without further purification.  
1H NMR (400 MHz, CDCl3) δ 7.86 (bs, 1 H), 7.76 (s, 1 H), 7.32 (s, 1 H), 6.08 (dd, J = 
17.6, 10.0 Hz, 1 H), 5.14 (d, J = 10.0 Hz, 1 H), 5.12 (d, J = 17.6 Hz, 1 H), 3.49 (s, 2 H), 
2.16 (s, 6 H), 1.52 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 145.7, 143.4, 132.9, 130.4, 
124.9, 123.3, 120.6, 112.7, 111.8, 109.0, 54.1, 45.5, 39.5, 27.2; IR (neat) 3320, 2928, 











Figure 5.110a. 1H NMR spectrum of compound 5.39. 
 
 




(5.40). PBu3 (346 mg, 1.72 mmol, 0.43 mL) was added to a solution of 5.39 (1.0 g, 3.43 
mmol) and N-(Diphenylmethylene)glycine ethyl ester (832 mg, 3.12 mmol) in CH3CN 
(30 mL) at rt. The reaction was heated to reflux and was stirred under Ar for 12 h. The 
reaction was cooled to rt and concentrated under reduced pressure. The residue was 
purified by flash chromatography eluting with hexanes/EtOAc (4:1) to give 1.19 g of a 
yellow oil which was dissolved in CH2Cl2 (25 mL). 1N HCl was added and the reaction 
was vigorously stirred for 12 h at rt. The organic layer was separated and the aqueous 
layer was extracted with CH2Cl2 (2 x 25 mL). The combined organic layers were 
concentrated under reduced pressure. The residue was purified by flash chromatography 
eluting with MeOH/CH2Cl2 (1:99-5:95) to give 848 mg (67%) of 5.40 as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.89 (bs, 1 H), 7.59 (s, 1 H), 7.34 (s, 1 H), 6.08 (dd, J = 
17.2, 10.8 Hz, 1 H), 5.16 (d, J = 10.8 Hz, 1 H), 5.15 (d, J = 17.2 Hz, 1 H), 4.09 (comp, 2 
H), 3.73 (m, 1 H), 3.20 (dd, J = 14.8, 5.6 Hz, 1 H), 2.96 (dd, J = 14.8, 8.8 Hz, 1 H), 1.53 
(s, 6 H), 1.16 (t, J = 7.2 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 170.6, 145.6, 142.7, 
133.1, 129.9, 125.3, 123.6, 119.9, 112.9, 112.0, 107.3, 61.2, 56.0, 39.5, 31.0, 27.8, 14.3; 
IR (neat) 3368, 2973, 2927, 1729, 1463, 1199 cm-1; HRMS (TOF-) calcd for 










Figure 5.111a. 1H NMR spectrum of compound 5.40. 
 





yl)propanoic acid (5.41). 0.5M NaOH (4.5 mL, 2.25 mmol) and Boc2O (586 mg, 2.69 
mmol) were sequentially added to a solution of 5.40 (848 mg, 2.24 mmol) in dioxane (5 
mL). The reaction was stirred at rt for 3 h, and then concentrated under reduced pressure 
to remove dioxane. 10% KHSO4 was added until pH ≈ 2, and the solution was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under reduced pressure. The residue was dissolved in 2:1 THF/H2O (18 
mL), and LiOH (280 mg, 11.25 mmol) was added in one portion. The reaction stirred at rt 
for 12 h. 10% KHSO4 was added until pH ≈ 2, and the solution was extracted with 
EtOAc (3 x 25 mL). The combined organic layers were dried (Na2SO4) and concentrated 
under reduced pressure to afford 902 mg (91%) of a yellow solid which was used without 
further purification. 
1H NMR (300 MHz, CDCl3) δ 11.0 (bs, 1 H), 8.19 (m, 1 H), 6.63 (m, 1 H), 7.31 (m, 1 H), 
6.80 (bs, 1 H), 6.08 (m, 1 H), 5.18 (comp, 2 H), 4.56 (bs, 1 H), 3.37 (bs, 1 H), 3.14 (m, 1 
H), 1.52 (s, 6 H), 1.28-1.02 (comp, 9 H); 13C NMR (75 MHz, CDCl3) δ 177.3, 176.3, 
170.4, 156.6, 155.3, 145.4, 142.9, 133.0, 129.9, 129.7, 128.4, 125.0, 124.9, 123.5, 123.3, 
119.7, 119.5, 112.9, 112.8, 106.6, 106.0, 81.4, 80.3, 55.4, 54.7, 39.2, 29.8, 28.6, 28.2, 
27.8, 27.5; IR (neat) 3335, 2976, 2932, 1697, 1461 cm-1; HRMS (TOF-) calcd for 










Figure 5.112a. 1H NMR spectrum of compound 5.41. 
 




2-yl)-1H-indol-3-yl)propanoyl)-3-hydroxypyrrolidine-2-carboxylate (5.42). To a 
solution of 5.41 (280 mg, 0.63 mmol) in CH3CN (6 mL) was sequentially added HATU 
(361 mg, 0.95 mmol), iPr2NEt (327 mg, 2.54 mmol), and cis-3-hydroxy-L-proline ethyl 
ester HCl (217 mg, 1.11 mmol). The reaction was stirred at rt for 3 h, and 2N HCl (10 
mL) was added. The mixture was extracted with CH2Cl2 (3 x 25 mL), and the combined 
organic layers were dried (Na2SO4) and concentrated under reduced pressure. The residue 
was purified by flash chromatography eluting with hexanes/EtOAc (1:1) to give 252 mg 
(68%) of 5.42 as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 8.73- 8.47 (m, 1 H), 7.58-7.32 (comp, 2 H), 6.11 (m, 1 H), 
5.50 (m, 1 H), 5.17 (comp, 2 H), 4.63-3.04 (comp, 9 H), 1.57-1.14 (comp, 18 H); 13C 
NMR (75 MHz, CDCl3) δ 172.1, 169.3, 169.1, 169.0, 155.0, 154.8, 154.3, 145.7, 144.8, 
144.7, 143.7, 143.3, 142.9, 133.1, 132.7, 129.9, 129.5, 129.2, 124.9, 124.7, 123.1, 119.6, 
112.9, 112.6, 112.0, 105.9, 105.6, 79.6, 79.3, 71.7, 70.4, 70.1, 63.8, 63.3, 62.0, 61.4, 60.6, 
53.0, 52.4, 45.2, 44.4, 44.3, 39.2, 33.5, 32.6, 30.8, 30.5, 30.2, 28.3, 28.0, 27.7, 21.1, 18.4, 
14.2, 14.0; IR (neat) 3359, 2978, 2932, 1694, 1633, 1500, 1455 cm-1; HRMS (TOF-) 












Figure 5.113a. 1H NMR spectrum of compound 5.42. 
 




hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione (5.43). TFA (0.86 mL, 11.16 
mmol) was added to a solution of 5.42 (252 mg, 0.43 mmol) in CH2Cl2 (9 mL). The 
reaction was stirred for 3 h, and sat. NaHCO3 (30 mL) was added. The mixture was 
extracted with EtOAc (3 x 20 mL), and the combined organic layers were dried (Na2SO4) 
and concentrated under reduced pressure. The residue was dissolved in toluene (9 mL) 
and 2-hydroxypyridine (9 mg, 0.09 mmol) was added. The reaction was refluxed under 
Ar for 12 h, cooled to rt, and concentrated under reduced pressure. The residue was 
dissolved in CH2Cl2 (30 mL) and washed with 1N HCl (30 mL). The organic layer was 
dried (Na2SO4) and concentrated under reduced pressure to afford 156 mg (85%) of a 
beige solid which was used without further purification. 
1H NMR (300 MHz, CDCl3) δ 8.14 (s, 1 H), 7.54 (s, 1 H), 7.43 (s, 1 H), 6.10 (dd, J = 
17.4, 10.6 Hz, 1 H), 5.72 (bs, 1 H), 5.22 (d, J = 10.6 Hz, 1 H), 5.17 (d, J = 17.4 Hz, 1 H), 
4.71-2.10 (comp, 9 H), 1.55 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 167.7, 165.5, 145.0, 
144.1, 133.2, 128.8, 126.1, 124.3, 119.0, 113.6, 112.6, 104.5, 71.0, 64.7, 54.5, 44.2, 39.1, 
30.3, 27.8, 26.3; IR (neat) 3352, 2973, 1647, 1459 cm-1; HRMS (TOF+) calcd for 















Figure 5.114a. 1H NMR spectrum of compound 5.43. 
 




tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione (5.44). DEAD (419 mg soln., 40% in 
toluene, 0.44 mL, 0.96 mmol) was added to a solution of 5.43 (140 mg, 0.32 mmol) in 
CH2Cl2 (10 mL). The reaction was stirred for 5 min, and PBu3 (194 mg, 0.96 mmol) was 
added. The reaction was stirred for 3 h, and then concentrated under reduced pressure. 
The residue was purified by flash chromatography eluting with hexanes/EtOAc (1:1) to 
give 86 mg (64%) of 5.44 as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 8.72 (s, 1 H), 7.52 (s, 1 H), 7.33 (s, 1 H), 6.05 (comp, 3 
H), 5.09 (d, J = 17.3 Hz, 1 H), 5.09 (d, J = 10.6 Hz, 1 H), 4.42 (m, 1 H), 4.01 (comp, 2 
H), 3.57 (dd, J = 14.6, 4.0 Hz, 1 H), 3.15 (dd, J = 14.6, 10.6 Hz, 1 H), 2.73 (comp, 2 H), 
1.46 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 162.4, 156.8, 145.4, 144.3, 133.4, 132.8, 
128.7, 125.5, 123.7, 119.4, 119.2, 112.6, 112.4, 104.3, 60.5, 57.2, 45.7, 39.2, 30.7, 27.8; 
IR (neat) 3323, 2971, 1681, 1644, 1446 cm-1; HRMS (TOF+) calcd for C21H22N3O2Cl2 














Figure 5.115a. 1H NMR spectrum of compound 5.44. 
 
Figure 5.115b. 13C NMR spectrum of compound 5.44. 
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Preparation of Cycloadducts 5.45a and 5.45b. To a solution of 5.44 (86 mg, 0.21 
mmol) in MeOH (16 mL) at 0 °C was added 20% aqueous KOH (4 mL). The reaction 
was warmed to room temperature (rt) and was stirred for 12 h. The reaction was 
quenched with sat. NH4Cl (30 mL) and extracted with CH2Cl2 (3x30 mL). The combined 
organic layers were dried (Na2SO4) and concentrated under reduced pressure. The residue 
was triturated with CHCl3 (30 mL), and the suspension was filtered to provide 53 mg 
(60%) of 5.45a as a white amorphous solid. Concentration of the filtrate gave 25 mg 
(29%) of 5.45b as a white amorphous solid.  
Data for major isomer 5.45a: 1H NMR (300 MHz, CD3OD) δ 7.55 (s, 1 H), 7.40 (s, 1 H), 
3.57 (d, J ) 15.5 Hz, 1 H), 3.47 (m, 1 H), 2.74 (d, J ) 15.5 Hz, 1 H), 2.60 (m, 1 H), 2.20- 
1.96 (comp, 6 H), 1.35 (s, 3 H), 1.11 (s, 3 H); 13C NMR (75 MHz, CD3OD) δ 175.7, 
171.3, 144.3, 137.2, 128.1, 125.4, 123.3, 119.8, 113.1, 104.8, 68.3, 61.6, 50.8, 45.2, 36.2, 
31.7, 30.1, 28.6, 25.4, 24.9, 22.3; IR (neat) 1663, 1428 cm-1; HRMS (TOF+) calcd for 
C21H22N3O2Cl2 (M + H) 418.1084, found 418.1084.  
Data for minor isomer 5.45b: 1H NMR (300 MHz, CDCl3) δ 9.78 (s, 1 H), 7.49 (s, 1 H), 
7.33 (s, 1 H), 3.71 (d, J ) 17.8 Hz, 1 H), 3.47 (comp, 2 H), 3.25 (s, 1 H), 2.78 (d, J ) 17.8 
Hz, 1 H), 2.67 (m, 1 H), 2.18- 1.78 (comp, 6 H), 1.24 (s, 3H), 1.16 (s, 3 H); 13C NMR (75 
MHz, CD3OD /CDCl3 (1:9)) δ 173.7, 169.6, 142.6, 135.7, 127.1, 125.0, 122.9, 119.1, 
112.4, 102.9 67.2, 61.5, 45.8, 44.3, 34.8, 32.6, 29.8, 29.1, 28.4, 24.5, 23.2; IR (neat) 


















Figure 5.116a. 1H NMR spectrum of compound 5.45a. 
 
Figure 5.116b. 13C NMR spectrum of compound 5.45a. 
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Figure 5.117a. 1H NMR spectrum of compound 5.45b. 
 
Figure 5.117b. 13C NMR spectrum of compound 5.45b. 
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Synthesis of Malbrancheamide (5.46). DIBAL-H (0.70 mL, 1 M in toluene, 0.70 mmol) 
was added to a suspension of 5.45a (15 mg, 0.036 mmol) in toluene (7 mL) at rt. The 
reaction was stirred at rt for 12 h, whereupon finely powdered Na2SO4-10H2O was added 
until bubbling ceased. The mixture was filtered with a medium porosity fritted funnel 
washing with EtOAc (50 mL) and MeOH (50 mL), and the filtrate was concentrated 
under reduced pressure. The residue was purified by flash chromatography eluting with 
MeOH/ CH2Cl2 (2:98) to give 12 mg (80%) of 5.46 as a white amorphous solid. 
1H NMR (400 MHz, CD3OD) δ 7.48 (s, 1 H), 7.40 (s, 1 H), 3.43 (d, J ) 10.3 Hz, 1 H), 
3.06 (m, 1 H), 2.85 (comp, 2 H), 2.54 (m, 1 H), 2.27 (dd, J ) 10.2, 1.5 Hz, 1 H), 2.20-1.18 
(comp, 6 H), 1.43 (s, 3 H), 1.34 (s, 3 H); 13C NMR (100 MHz, CD3OD) δ 176.6, 145.1, 
137.3, 128.2, 125.3, 123.2, 119.6, 113.1, 104.7, 66.1, 59.4, 57.4, 55.4, 48.5, 35.5, 32.4, 
30.6, 30.0, 28.1, 24.2, 23.5; IR (neat) 3226, 1658, 1460 cm-1; HRMS (TOF+) calcd for 











Figure 5.118a. 1H NMR spectrum of compound 5.46. 
 
Figure 5.118b. 13C NMR spectrum of compound 5.46. 
 344 
 
Chetomin (1.12). Authentic sample purchased from Santa Cruz Biotechnology. 
1H-NMR (400 MHz; CDCl3): δ  7.66 (dd, J = 6.1, 3.0 Hz, 1H), 7.35-7.33 (m, 1H), 7.31-
7.27 (m, 2H), 7.23-7.22 (m, 2H), 7.18 (s, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.80 (d, J = 8.0 
Hz, 1H), 6.21 (s, 1H), 4.43 (s, 1H), 4.39 (d, J = 4.7 Hz, 1H), 4.35 (s, 1H), 4.31 (d, J = 3.5 
Hz, 1H), 4.28 (s, 1H), 3.87 (d, J = 15.6 Hz, 1H), 3.71 (d, J = 15.4 Hz, 1H), 3.20 (s, 3H), 
3.16 (s, 3H), 3.10 (s, 1H), 2.96 (s, 3H); 13C-NMR (101 MHz; CDCl3): δ 166.8, 165.51, 
165.48, 163.2, 148.3, 134.0, 131.4, 130.4, 127.2, 126.5, 125.0, 122.8, 120.60, 120.40, 
119.2, 111.4, 111.2, 107.7, 80.0, 76.5, 76.1, 74.7, 73.7, 73.5, 61.3, 60.7, 42.6, 28.2, 27.44, 
27.34, 27.1. 
FOR NMR FILES, SEE Tim/NMR/robot/trw-III-chetomin. 
See also (for characterization data): Fujimoto, H.; Sumino, M.; Okuyama, E.; Ishibashi, 
M. Immunomodulatory Constituents from an Ascomycete, Chaetomium Seminudum. J. 























Figure 5.119a. 1H NMR spectrum of compound 1.12. 
 















































































































































































































Biomimetic Synthesis of Alkaloids Derived
from Tryptophan: Dioxopiperazine Alkaloids
Timothy R. Welch and Robert M. Williams
4.1
Introduction
Countless secondary metabolic indole alkaloids produced in both marine and ter-
restrial fungi are derived from tryptophan. Our crude attempts to synthesize some
of the vast array of structurally diverse natural alkaloids only serves to showcase the
efficiency and elegance with which Nature is able assemble the same molecules.
Still, we strive to mimic and in turn better understand the mechanisms inside the
cell that are able to produce molecular architecture of such synthetic complexity.
Moreover, it has often been found advantageous to exploit Nature’s evolutionary
creative design of alkaloids in search of new compounds of therapeutic potential.
The rich subclass of biologically active, tryptophan-derived dioxopiperazines found
in nature has inspired medicinal chemists to use the dioxopiperazine core in
drug design efforts to mimic the interactions of natural peptides while reducing
susceptibility to metabolic amide bond cleavage. Furthermore, a dioxopiperazine
should pay a small entropic penalty upon binding to a target in comparison to an
analogous peptide, as a direct consequence of the reduced conformational mobility
inherent in the dioxopiperazine ring. In this chapter, we present a brief review of a
select group of (partly) biomimetic syntheses of tryptophan-derived dioxopiperazine
alkaloids (Figure 4.1). In most of these syntheses, a single step or key transformation
has been deemed to constitute the ‘‘biomimetic’’ aspect of that particular work. As
the actual biosynthetic pathways to most, if not all, of the alkaloid natural products
covered here are either unknown or known only in part we have attempted, where
appropriate, to point out the particular biomimetic step or transformation.
4.2
Prenylated Indole Alkaloids
Birch, Wright, and Russell first isolated brevianamide A from Penicillium brevi-
compactum in 1969 [1–3]. Several years later, Birch and coworkers determined
that brevianamide A was biosynthetically derived from tryptophan, proline, and
Biomimetic Organic Synthesis, First Edition. Edited by Erwan Poupon and Bastien Nay.

























































































Section 4.2.3 Section 4.3 Section 4.3.1
Figure 4.1 Representative molecules discussed in this chapter.
mevalonic acid through feeding experiments (Scheme 4.1) [4]. Furthermore, Birch
showed that radiolabeled brevianamide F was incorporated into 5. It was postu-
lated at the time and later supported with experimental evidence by Williams and



















































Scheme 4.1 Proposed biosynthesis of the brevianamides.
Since these early studies, Williams has developed a proposal for the biosyn-
thesis of the brevianamides, with that of brevianamide E shown in Scheme 4.2.
Derived from tryptophan and proline, 6 was proposed to undergo oxidation to
hydroxyindolenine 7. Irreversible nucleophilic ring closure was supposed to lead
to brevianamide E (8), supported by incorporation of [8-3H2]6 into 8 in significant
radiochemical yield [5].
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Scheme 4.2 Proposed biosynthesis of brevianamide E.
4.2.1
Dioxopiperazines Derived from Tryptophan and Proline
Brevianamide F (12) was first isolated in 1972 and is one of the simplest
tryptophan-derived dioxopiperazine natural products. It is readily synthesized
through amino acid coupling of N-Boc-tryptophan (9) to proline ethyl ester (10),
































Scheme 4.3 Biomimetic synthesis of brevianamide F.
Brevianamide F lacks only the reverse prenyl group found in deoxybrevianamide
E, which has been synthesized by Kametani and coworkers en route to
brevianamide E (Scheme 4.4) [6]. N-Benzyloxycarbonyl-l-proline (13) was
subjected to Schotten–Baumann conditions with dimethyl aminomalonate
to give amide 14. Debenzyloxycarbonylation of 14 followed by heating with
catalytic 2-hydroxypyridine effected cyclization to dioxopiperazine 15 in 93%
yield. Condensation with indole 16 gave a separable mixture of diastereomers,
individually hydrolyzed to the corresponding free acids (17). Heating of the desired
diastereomer in dioxane gave deoxybrevianamide E (18) and its epimer (19) in 29
and 55% yield, respectively. Irradiation of methanolic 18, containing Rose Bengal
in the presence of oxygen, followed by addition of dimethyl sulfide, resulted in the
biomimetic hydroxylation of deoxybrevianamide E, furnishing brevianamide E (8)
and 20 as a separable mixture of diastereomers.
Nineteen years later, a more efficient synthesis of brevianamide E was com-
pleted by Danishefsky and coworkers [7]. The synthesis commenced with C3
chlorination of the known phthaloylated tryptophan derivative 21, followed by
addition of fresh prenyl-9-borabicyclo[3.3.1]nonane (prenyl-9-BBN) to the resultant
3-chloroindolenine (Scheme 4.5). Hydrazinolysis in ethanol provided amino ester
348
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Scheme 4.5 Danishefsky’s total synthesis of brevianamide E.
23 in 65% yield, which was coupled to N-Boc-l-proline, deprotected, and cyclized
to afford deoxybrevianamide E (18) in 52% yield. Compound 18 was elaborated
to brevianamide E (8) and bis(epi)brevianamide E (20) in a ratio of !1 : 5 upon
treatment with dimethyldioxirane (DMDO) in a biomimetic oxidative cyclization
sequence reminiscent of the original Kametani work discussed above.
The structural similarities between deoxybrevianamide E and the then newly
isolated natural products tryprostatin A and B did not escape notice of Danishefsky
349
4.2 Prenylated Indole Alkaloids 121
and coworkers. While prenylation failed in attempts to use a reverse prenylborane
nucleophile directly as in the method used to synthesize 22 above, a solution
was found in treating chloroindolenine 24 with tri(n-butyl)prenylstannane and
BCl3 to afford the desired prenyl functionality at C2 in excellent yield (Scheme 4.6).
Phthalimide deprotection, peptide coupling, Boc-deprotection, and cyclization were























































CH2Cl2, NaHCO3 2. NH3, MeOH
83%
•
Scheme 4.6 Biomimetic total synthesis of tryprostatin B.
Danishefsky and coworkers also completed the total synthesis of the spirooxin-
dole spirotryprostatin B [8]. l-Tryptophan methyl ester was converted into the
oxindole derivative 32, followed by addition of prenyl aldehyde under basic
conditions to afford an inseparable four-component mixture of spirooxindoles
(33–36, Scheme 4.7). Peptide coupling and subsequent treatment of the mix-
ture with lithium bis(trimethylsilyl)amide (LHMDS) followed by selenylation
presumably gave phenyl selenide mixture 38. Oxidative elimination produced
a mixture from which 39 was separated and elaborated to spirotryprostatin B (40)
via Boc-deprotection and base-induced cyclization.
Danishefsky took a markedly different approach in the synthesis of spirotrypro-
statin A [9]. A potentially biomimetic Pictet–Spengler reaction of tryptophan
derivative 42 with thioaldehyde 41 as a masked isoprene equivalent gave the
desired cis-tetrahydrocarboline (43) with marginal selectivity (Scheme 4.8).
N-Bromosuccinimide (NBS)-mediated oxidative rearrangement proceeded via
intermediate 44 to the oxindole was followed by deprotection of the carbamate to
give amine 45. The modest yield of the sequence (57%) reflects the susceptibility of
the oxindole to electrophilic aromatic bromination under the spiro-rearrangement
conditions. Peptide coupling and Troc-deprotection resulted in cyclization to the
dioxopiperazine, after which oxidation and sulfoxide elimination revealed the
prenyl group to afford selectively spirotryprostatin A (48).
The synthesis of notoamide J was completed by Williams and coworkers, starting
with the Boc-protection of 7-hydroxyindole (Scheme 4.9) [10]. Chlorination at C3
was followed by reverse prenylation of the resultant 3-chloroindolenine 51 to afford
350
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Scheme 4.7 Danishefsky’s synthesis of spirotryprostatin B.
52. The corresponding gramine was prepared by treating 52 with formaldehyde and
dimethylamine, and subsequent Somei–Kametani coupling and imine hydrolysis
gave tryptophan derivative 54 in good yield. Protection of the free amine as the
Boc-carbamate and ester hydrolysis gave 55, which was coupled to proline ethyl
ester in the presence of O-(7-azabenzotriazol-1-yl)-N,N,N",N"-tetramethyluronium
hexafluorophosphate (HATU) to afford amide 56. Cyclization to dioxopiperazine
57 was followed by a biomimetic oxidation sequence accompanied by pinacol-type
rearrangement to the oxindoles notoamide J (58) and 3-epi-notoamide J (59) in a
2 : 1 separable mixture.
4.2.2
Dioxopiperazine Derived from Tryptophan and Amino Acids other than Proline
Corey and coworkers designed a succinct synthesis of okaramine N, featuring
a Pd-promoted dihydroindoloazocine formation [11]. Readily available trypto-
phan derivative 60 was reduced to indoline 61 and subsequently prenylated
via copper(I)-catalyzed alkylation with butyne 62 (Scheme 4.10). Treatment with
351



























































































































































































































































































































































































































































































































































































































































Scheme 4.10 Synthesis of the N-reverse-prenylated tryptophan derivative.
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) effected the dehydrogenation of
the indoline, and the resulting tryptophan derivative 63 was deprotected, saponified,
and reprotected as the N-Fmoc derivative (64).
The synthesis of okaramine N was completed through reductive amination of
3-methyl-buten-2-al onto l-tryptophan methyl ester, followed by coupling of the
resultant product (65) with acid 64 to form the desired tetracycle (Scheme 4.11).
Treatment of 66 with Pd(OAc)2 provided the eight-membered ring (67) in modest
yield (38%). The free amine obtained upon Fmoc cleavage underwent cyclization to
form dioxopiperazine 68 in 95% yield. A potentially biomimetic oxidative cyclization
was effected by treating 68 with N-methyltriazolinedione (MTAD), which reacted


























































Scheme 4.11 Completion of the total synthesis of okaramine N.
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Scheme 4.12 Danishefsky’s total synthesis of amauromine.
then reduction formed a hydroxylated octacycle that was directly converted into
okaramine N (69) via thermolysis in 70% yield.
Amauromine was synthesized as shown in Scheme 4.12, starting with the
bis(Boc) protection of l-tryptophan [12]. Conversion into the selenide by re-
action with N-phenylselenophthalimide (N-PSP) in the presence of pyridinium
p-toluenesulfonate (PPTS) afforded a mixture of 71 and 72 (9 : 1). Photolysis of
the mixture in the presence of prenyltri(n-butyl)tin produced a mixture of reverse
prenylated pyrrolodinoindolines, the desired major diastereomer of which was
separated by crystallization from hexanes. The Boc groups were globally cleaved
using iodotrimethylsilane (TMSI) to afford the ester (75). Coupling of 75 with
acid 74 gave the amide, which readily cyclized to the desired dioxopiperazine (76,
amauromine) upon treatment with TMSI.
Danishefsky and coworkers completed a total synthesis of gypsetin in the same
fashion as their effort on brevianamide E [7]. The reverse prenylated amine, 23,
was synthesized as shown above (Scheme 4.5). Boc protection and cleavage of the
methyl ester afforded acid 77, which was coupled to amine 23, deprotected, and
cyclized to dioxopiperazine 78 (Scheme 4.13). Treatment with DMDO effected the
biomimetic oxidative conversion into the natural product gypsetin (79).
4.2.3
Bicyclo[2.2.2]diazaoctanes
In 1970, Sammes proposed a hetero-Diels–Alder cycloaddition to be the biosyn-
thetic origin of the bicyclo[2.2.2]diazaoctane core found in brevianamides A and B
(Scheme 4.14) [13].
Support for this proposal was observed upon treating dihydroxypyrazine 82 with
dimethyl acetylenedicarboxylate (83) or with norbornadiene (84) to give cycloadducts
85 or 86, respectively (Scheme 4.15) [13].
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Scheme 4.15 Sammes’ model study of proposed cycloaddition.
Williams and coworkers expanded on the pioneering work of Sammes with
the following biosynthetic proposal for the brevianamides [5]. Deoxybrevianamide
E (18) was thought to undergo oxidation to hydroxyindolenine 7, which could
undergo a pinacol-type rearrangement to indoxyl 87 (Scheme 4.16). Subsequent
two-electron oxidation and enolization to azadiene 88, followed by an intramolecular
hetero-Diels–Alder reaction was, following from the original proposal of Sammes,
envisioned to give the natural products (+)-brevianamide A and (+)-brevianamide
356


















































































Scheme 4.16 Biosynthetic proposal for the brevianamides.
B. The pseudo-enantiomorphic relationship between the two natural products
was envisaged to arise from the equilibrium between conformers 88a and 88b,
which undergo cycloaddition to give 89 and 90, respectively. Ab initio studies
of the two transition states demonstrated that 88a is the more stable of the
two, which is consistent with the observed product ratios of 89 and 90. The
theoretical insights published by Domingo et al. lend support to the proposal
of a biosynthetic intramolecular Diels–Alder reaction of intermediate 88 [14].
Unfortunately, experimental support for this pathway has been elusive to secure
and thus it remains a speculative biogenetic construction.
The total synthesis of d,l-brevianamide B demonstrated the first congru-
ent application of a biomimetic Diels–Alder reaction used to form the bicy-
clo[2.2.2]diazaoctane core common to the series of prenylated dioxopiperazines to
be discussed in this section [15]. 9-Epi-deoxybrevianamide E (19) was converted
into the lactim ether (91) and oxidized to give the Diels–Alder precursor 92
(Scheme 4.17). Treatment with aqueous methanolic KOH induced tautomeriza-
tion to azadiene 93, which underwent a potentially biomimetic intramolecular
Diels–Alder cycloaddition to give a mixture of diastereomers (94 and 95, 2 : 1).
Oxidation, pinacol-type rearrangement, and lactim ether deprotection of the minor
diastereomer (95) afforded brevianamide B (90) in 65% overall yield from 96. This
study was one of the first to experimentally support the biogenetic origin of the
core bicyclo[2.2.2] ring system as arising via a dioxopiperazine that undergoes a net
two-electron oxidation to an azadiene moiety.
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Scheme 4.17 Application of the proposed biomimetic Diels–Alder reaction.
Williams and coworkers also applied the intramolecular Diels–Alder reaction to
the racemic synthesis of VM55599 [16]. The reverse-prenylated tryptophan deriva-
tive 97 was coupled to !-methyl-!-hydroxyproline ethyl ester 98 to afford dipeptide
99 (Scheme 4.18). N-Boc deprotection and cyclization afforded dioxopiperazine 100,
and elimination with thionyl chloride gave enamide 101. Formation of the lactim
ether (102) and treatment with aqueous KOH gave azadiene 103, which sponta-
neously suffered intramolecular Diels–Alder reaction to give a separable mixture of
all four possible racemic diastereomers (104–107, 2.6 : 3.7 : 1.0 : 1.6, respectively).
Cleavage of the lactim ether and diisobutylaluminum hydride (DIBAL-H) reduction
gave VM55599 in 73% yield from 105.
The synthesis of VM55599 allowed for assignment of the absolute stereochem-
istry of the molecule, which places the methyl group at the !-position of the
proline residue syn- to the bridging isoprene moiety [16]. In stark contrast, the
analogous methyl group of paraherquamide A is anti to the bridging isoprene
unit. Scheme 4.19 outlines a possible unified biosynthesis for VM55599 and para-
herquamide A, arising from dimethylallyl pyrophosphate (DMAPP), l-isoleucine,
and l-tryptophan. If a Diels–Alder cycloaddition is to be invoked, approach of the
isoprene moiety must occur from the same face as the methyl group on the proline
ring for synthesis of VM55599, and from the opposite face to the methyl group to
give paraherquamide A. The diastereofacial selectivity of the Diels–Alder reaction
gave a preponderance of the syn-relative stereochemistry alpha to the gem-dimethyl
group in both molecules. As VM55599 is a very minor metabolite of Penicillium
sp. IMI332995, it is plausible that cyclization of 112#114 is preferred and further
metabolization gives paraherquamide A, whereas the minor cycloaddition via 113
produces VM55599 as a dead-end shunt metabolite. As shown in Scheme 4.18
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104:105:106:107 = 2.6 : 3.7 : 1.0 : 1.6









































































Scheme 4.19 Proposed biosynthesis of paraherquamide A and VM55599.
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4.2 Prenylated Indole Alkaloids 131
above, the intrinsic diastereofacial bias of the Diels–Alder reaction is modest at
best, giving a slight excess (1.47 : 1) of cycloaddition from the same face as the
methyl group, and favoring the syn-relative stereochemistry to the extent of 2.4 : 1.
Such observations suggest that the biosynthesis may rely on protein organization
of the precyclization conformers to stereoselectively produce the syn-isomers.
A report from Liebscher and coworkers showed promise in terms of improving
the diastereoselectivity of the Diels–Alder cycloaddition, using neutral conditions
to prepare the azadiene in contrast to the basic conditions employed by Williams
[17]. Compound 118 was prepared by a Horner–Wadsworth–Emmons reaction
of aldehyde 116 with phosphonate 117 (Scheme 4.20). Treatment of 118 with
neat acetyl chloride for 20 days gave the Diels–Alder product 119 as a single







































Scheme 4.20 Liebscher’s Diels–Alder work.
The precedent set by Liebscher’s work was applied to an asymmetric total
synthesis of VM55599 [18]. The loss of stereochemistry observed at the proline
methyl group in 101 above led Williams to employ a dehydrotryptophan derivative
as the Diels–Alder azadiene precursor, allowing for the preparation of VM55599 in
an enantioselective fashion. Williams has demonstrated that the !-methylproline
residue of paraherquamide A and VM55599 are biosynthetically derived from l-Ile.
In a biomimetic construct, l-Ile was converted into optically pure !-methylproline








































































Scheme 4.21 Key dioxopiperazine synthesis.
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Scheme 4.22 Completion of the asymmetric total synthesis of ($)-VM55599.
Cleavage of the ethyl ester, peptide coupling to glycine methyl ester hydrochloride,
Boc deprotection, and cyclization gave dioxopiperazine 122 in good overall yield.
Protection of the secondary amide and subsequent condensation with aldehyde 116
gave an epimeric mixture of dioxopiperazines, which gave selectively (Z)-isomer
125 following deprotection and dehydration.
Following Liebscher’s protocol, 125 was treated with acetyl chloride for 14 days,
yielding a mixture of three diastereomers (Scheme 4.22). The reaction is thought
to proceed by initial acylation to the O-acyl lactim 126, tautomerization to azadiene
127, which suffers intramolecular Diels–Alder reaction from three of the four pos-
sible diastereomeric transition states, followed by loss of acetate to give compounds
128–131. The major diastereomer 129 was treated with excess DIBAL-H to effect
reduction to ($)-VM55599 (108). Interestingly, cycloadduct 130 was not observed
from the cycloaddition reaction. Penicillium sp. produces paraherquamide A in
large excess over VM55599 (>600 : 1), so it is surprising that this provocative bio-
genetic precursor to paraherquamide A is not observed in laboratory cycloaddition
reactions. Despite the structural differences between the laboratory and biological
Diels–Alder precursors, the intrinsic facial selectivity of the cyclization does not
appear to mimic the bias toward paraherquamide stereochemistry one would
expect given the observed product ratios of the fungal metabolites.
As many of the bicyclo[2.2.2]diazaoctane natural products differ only at the
substitution of the indole ring, a convergent approach utilizing a Fischer indole
synthesis was undertaken in an alternative racemic synthesis of brevianamide
B [19]. This work had the objective of validating other possible biosynthetic pathways
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Scheme 4.23 Concise synthesis of brevianamide B.
to reach the oxidation state of the azadiene. In the present instance, the "-ketoamide
species (138) was posed to serve as a surrogate for the possible biosynthetic oxidative
deamination of the tryptophan moiety and coupling to a proline amide species
(Scheme 4.23). Conjugate addition of carboxylate 133 to ketone 132 gave ester 134
in 76% yield. Saponification, peptide coupling with l-proline amide, and dithiane
deprotection gave a mixture of the uncyclized amide 138 and dioxopiperazine
139. Aluminum trichloride was added to the mixture to give the Diels–Alder
cycloadduct (140) in exclusively the anti-configuration, whereas mixtures of both
the syn- and anti-cycloadducts were observed in previous syntheses of VM55599
and brevianamide B discussed above. A Fischer indole synthesis was completed by
treatment of 140 with phenyl hydrazine followed by ZnCl2, affording 141 in good
yield. Oxidation and pinacol-type rearrangement of this known intermediate gave
brevianamide B. While an appealing convergent approach towards the synthesis
of other related bicyclo[2.2.2]diazaoctanes, the utility of this strategy is limited to
those natural products containing the anti-stereochemistry observed in formation
of compound 140, the remainder of which must be able to withstand the harsh
conditions of the Fischer indole synthesis.
The same biomimetic Diels–Alder disconnection was exploited in the total syn-
thesis of stephacidin A [20]. Starting with reverse prenylated tryptophan derivative
142 (prepared in eleven steps from 6-hydroxyproline), dipeptide 144 was prepared
through bis(2-oxo-3-oxazolindinyl)phosphinic chloride (BOPCl) mediated coupling
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4.2 Prenylated Indole Alkaloids 135
with cis-3-hydroxyproline ethyl ester (143, Scheme 4.24). Fmoc deprotection resulted
in the cyclization to dioxopiperazine 145, which upon treatment with tributyl phos-
phine and diethyl azodicarboxylate (DEAD) underwent Mitsunobu dehydration to
give enamide 146. Formation of the lactim ether (147) was followed by intramolec-
ular Diels–Alder reaction to give a mixture of epimers enriched with the syn-isomer
(149, 2.4 : 1). Deprotection of 149 gave stephacidin A (150) in excellent yield.
Williams found that the bicyclo[2.2.2]diazaoctane core could be accessed directly
from compound 145 by treating it with excess PBu3 and DEAD, effecting the dehy-
dration, tautomerization, and Diels–Alder reaction in one pot to afford stephacidin
































Scheme 4.25 Improved biomimetic synthesis of stephacidin A.
Myers and coworkers, in the course of their total synthesis of avrainvillamide,
discovered that synthetic ($)-152 spontaneously dimerized to stephacidin B under
several mild conditions, including addition of triethylamine or exposure to silica gel
[22, 23]. Baran and coworkers later determined that stephacidin A could be readily
converted into avrainvillamide through reduction to indoline 151 followed by
Somei oxidation (Scheme 4.26). In accord with Myers’ observations, dimerization
to stephacidin B occurred readily upon exposure to silica gel, triethylamine,
or on evaporation from dimethyl sulfoxide (DMSO) [24–26]. Myers has further
demonstrated that the observed biological activity of stephacidin B may be due to
the formation of 152 from 153 in vivo [22].
Stephacidin A is of particular biogenetic interest, as both enantiomers have
been isolated in nature: (+)-stephacidin A from Aspergillus ochraceus [27] and
from a marine-derived Aspergillus sp. [28] and ($)-stephacidin A from terrestrial
Aspergillus versicolor [29–31]. Operating under the assumption that the biosynthe-
sis of stephacidin A proceeds through a common, achiral intermediate, Williams
and coworkers have proposed notoamide S (154) as the point of divergence in the
two biosyntheses [32]. Oxidation of 154 could give achiral azadiene 155, which
is postulated to undergo intramolecular Diels–Alder reaction to give either (+)-
or ($)-stephacidin A depending on the enantiofacial selectivity of the reaction
(Scheme 4.27).
Tryptophan derivative 142 used in the above synthesis of stephacidin A was also
employed in the biomimetic total synthesis of marcfortine C (164) [33]. Pipecolic
acid derivative 156 was coupled to acid 142 to form amide 157, which underwent
cyclization to the dioxopiperazine following Fmoc-deprotection to give 158 as
364













































































































Scheme 4.27 Proposed biosynthesis of (+)- and ($)-stephacidin A through notoamide S.
an inconsequential mixture of diastereomers (Scheme 4.28). The biomimetic
Diels–Alder reaction preferred the syn-diastereomer 160 in 2.4-fold excess, as
expected. Excess DIBAL-H selectively reduced the tertiary amide of 160, and amine
salt formation followed by a biomimetic oxidative rearrangement gave marcfortine
C (164).
Malbrancheamide and malbrancheamide B were synthesized via the biomimetic
Diels–Alder reaction of enamides 165 and 166 to afford both syn-cycloadducts 167
365























































































































































































































































165: X = Cl

















































Scheme 4.29 Completion of the total syntheses of the malbrancheamides.
and 169, as well as the anti-epimers 168 and 170 (Scheme 4.29) [34]. Treatment
of the syn-cycloadducts with excess DIBAL-H gave either malbrancheamide or
malbrancheamide B.
As the malbrancheamides were the first of this family of prenylated indole
alkaloids to possess a halogenated indole ring, Williams and coworkers probed the
biosynthesis to establish the timing of the chlorination event [35]. Malbrancheamide
is proposed to arise from tryptophan, proline, and dimethylallyl diphosphate,
leading to deoxybrevianamide E (18, Scheme 4.30). Oxidation of 18 could give


































174, X = O
175, X = H2



































Scheme 4.30 Proposed biosynthesis of the malbrancheamides.
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140 4 Biomimetic Synthesis of Alkaloids Derived from Tryptophan: Dioxopiperazine Alkaloids
(IMDA) to cycloadduct 176. Reduction of the tertiary amide would provide premal-
brancheamide (177). Alternatively, 18 could suffer reduction of the tertiary amide
to 175, providing 177 directly upon cycloaddition. Premalbrancheamide is pro-
posed to undergo subsequent halogenation events to give both malbrancheamide
B and malbrancheamide. In feeding studies, labeled dioxopiperazine 176 and
premalbrancheamide (177) were added to separate cultures of Malbranchea au-
rantiaca, but interestingly only premalbrancheamide 177 was incorporated into
malbrancheamide B. This suggests that reduction of the tertiary amide must
precede Diels–Alder construction of the bicyclo[2.2.2]diazaoctane core through an
intermediate analogous to monooxopiperazine 175.
Williams has reported that–like stephacidin A and notoamide B, which are
produced in Nature as distinct enantiomers–the minor metabolite versicolamide
B is likewise produced as distinct enantiomers in different strains of Aspergillus sp.
The asymmetric syntheses of both (+)- and ($)-versicolamide B (182) have recently
been accomplished by deploying compound 145, previously used in the synthesis
of stephacidin A (Scheme 4.31). Oxaziridine oxidation of 145 and pinacol-type
rearrangement consequent to oxidation of the indole gave a 3 : 1 separable mixture
of 178 and 179 [36]. As previously reported, treatment with tributyl phosphine and
DEAD induced Mitsunobu dehydration to give enamides 180 and 181.
Treatment of 180 and 181 individually with potassium hydroxide in methanol
induced the intramolecular Diels–Alder reaction to afford either (+)- or
($)-versicolamide B (182), along with the minor anti-diastereomers (+)-183 or
($)-183 (Scheme 4.32). As previous biomimetic Diels–Alder reactions containing
indole-based azadienes display syn-selectivity (typically !2.5 : 1 syn : anti), the
exclusive selectivity for the anti-products in the versicolamide B syntheses is of
particular interest. The authors suggest that the anti-preference stems from a
stable transition state leading to the anti-cycloadduct when an oxindolic azadiene
is employed, whereas the syn- and anti-transition states arising from an indolic



















































































Scheme 4.32 Completion of the asymmetric syntheses of the versicolamides.
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While the above syntheses have differed in the approach to the azadiene, all
share a common biomimetic intramolecular Diels–Alder reaction to give the
bicyclo[2.2.2]diazaoctane core featured in the molecules presented in this section.
4.3
Non-prenylated Indole Alkaloids
Hart and coworkers have expressed interest in the biosynthesis of the fumiquina-
zoline family of alkaloid natural products, and reported a biomimetic synthesis
of ent-alantrypinone as the initial effort at a synthetic program to access more
complex, related substances [38]. l-Tryptophan methyl ester was coupled to isatoic
anhydride to afford amide 184 in good yield (Scheme 4.33). Acylation of 184 with
acyl chloride 186 (prepared in two steps from S-methyl-l-cysteine, 185) under
Schotten–Baumann conditions furnished diamide 187, which underwent cyclode-
hydration to iminobenzoxazine 188. Treatment with excess Li[Me3AlSPh] effected
the rearrangement to quinazolinone 189, and Fmoc deprotection was accompanied
by amide formation to give 190. Oxidation of 190 provided the sulfoxide, which was
converted into enamide 191 upon heating in benzene with triphenylphosphine.
Trifluoroacetic acid induced the conversion into bicycle 192, presumably through
intramolecular electrophilic attack of an intermediate N-acyliminium ion onto
indole. Conversion into the oxindole proceeded via oxidative rearrangement of 192
with NBS to give the polybrominated indolinone, which was hydrogenolyzed
over platinum on carbon to give ent-alantrypinone (193), along with ent-17-
epi-alantrypinone (194).
Three dimeric tryptophan-derived dioxopiperazines have succumbed to
biomimetic total syntheses, all completed by Movassaghi and coworkers, namely,
(+)-WIN 64821, ($)-ditryptophenaline, and (+)-11,11"-dideoxyverticillin A [39, 40].
Syntheses of the former two began with cleavage of the Boc carbamate to effect the
cyclization to dioxopiperazine 196 (Scheme 4.34) [40]. Treatment with bromine
then gave a separable mixture of two diastereomers, endo-(+)-197 and exo-($)-198.
endo-Bromide (+)-197 was carried on to (+)-WIN 64821 (201) by, first, treatment
with tris(triphenylphosphine)cobalt chloride to afford the dimerized product 199,
which was globally deprotected upon exposure to samarium diiodide. (+)-WIN
64821 was thus obtained in 75% yield. Similarly, ($)-ditryptophenaline (202) was
synthesized following methylation of exo-($)-198, dimerization, and deprotection
to give the product in 79% yield.
4.3.1
Epidithiodioxopiperazines
(+)-11,11"-Dideoxyverticillin A (211) differs from dimers 201 and 202 in that it is
likely derived from l-tryptophan and l-alanine, rather than from l-phenylalanine.
Additionally, the dioxopiperazines are bridged by a disulfide, adding a difficult
challenge to the synthetic construction of the molecule. Similar to their previous
370














































































































































































































































































































































































































































































































































































































































































































































Scheme 4.35 Biomimetic total synthesis of (+)-11,11"-dideoxyverticillin A.
work, Movassaghi and coworkers showed that cleavage of the N-Boc carbamate was
accompanied by cyclization to dioxopiperazine 204 (Scheme 4.35) [39]. Exposure of
204 to bromine produced the 3-bromopyrroloindoline, and the amides were sub-
sequently methylated upon treatment with iodomethane. Reductive dimerization
with the cobalt(I) complex as before gave the desired dimeric intermediate 206. The
dimer was oxidized with bis(pyridine)-silver(I) permanganate to octacycle 207, and
exposure to Fu’s (R)-(+)-4-pyrrolidinopyridinyl(pentamethylcyclopentadienyl)iron
(PPY) catalyst with t-butyldimethylsilyl chloride (TBSCl) gave selectively the
alanine-derived protected hemiaminals of 208. Removal of the benzenesulfonyl
groups with sodium amalgam revealed diaminodiol 209. Treatment of 209 with
K2CS3 followed by ethanolamine gave diaminotetrathiol 210, which readily oxi-
dized to (+)-11,11"-dideoxyverticillin A (211) when partitioned between aqueous
hydrochloric acid and dichloromethane and treated with potassium triiodide.
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The total synthesis of sporidesmin A was completed by Kishi and coworkers
in 1973. In a series of communications, Kishi described a novel strategy for the
synthesis of epidithiodioxopiperazines using a dithioacetal moiety as a protecting
group for the disulfide bridge [41–43]. Thus protected, the dithioacetal is stable
to acidic, basic, and reducing conditions, allowing for the introduction of thiol
groups at an early stage in a total synthesis. Synthesis of the sporidesmins be-
gan with the treatment of dioxopiperazine 212 with the dithiane derivative of
p-anisaldehyde in the presence of acid to afford dithioacetal-protected dioxopiper-
azine 213 (Scheme 4.36) [43]. Condensation with acid chloride 214 and subsequent
methoxymethyl deprotection gave compound 215. Treatment of ketone 215 with
DIBAL-H at $78 %C resulted in stereoselective reduction to the alcohol, which was
then converted into acetate 216 in 80% yield. Cyclization to the diacetate (217)
proceeded upon addition of iodosobenzene diacetate, and hydrolysis of the acetates
gave the corresponding diol. Treatment of the diol with m-chloroperbenzoic acid
(mCPBA) afforded an intermediate sulfoxide, which decomposed to the disulfide

































































































Scheme 4.36 Total synthesis of (±)-sporidesmin A.
The biosynthesis of gliotoxin is believed to proceed through the intramolecular
nucleophilic ring-opening of a phenylalanine-derived arene oxide and has been
the subject of considerable speculation and interest. Kishi and coworkers drew
inspiration from these biogenetic hypotheses in devising a brilliant total synthesis
of gliotoxin. The total synthesis of (±)-gliotoxin was completed in 1976 utilizing
the same disulfide protecting strategy as deployed above for the sporidesmins,
and was re-engineered in 1981 by the same route starting from optically pure
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Scheme 4.37 Kishi’s total synthesis of (±)- and (+)-gliotoxin.
dithioacetal 219 obtained from resolution (Scheme 4.37) [44, 45]. Coupling of 219
with t-butoxy arene oxide 220 in the presence of triton B afforded 221 and 222 in a
2 : 1 ratio. Acylation, deprotection, mixed anhydride formation, and reduction gave
alcohol 223 in 77% yield. Alcohol 223 was converted into the chloride following
mesylation, and then deprotected to reveal alcohol 224. The key stereoselective
cyclization–alkylation reaction was achieved upon addition of phenyllithium to 224
and phenoxymethyl chloride, affording cycloadduct 225 in modest yield (53%). The
primary alcohol was revealed upon removal of the benzyl ether, and the thioacetal
oxidatively removed to afford either (±)- or (+)-gliotoxin (226).
4.4
Conclusion
Dioxopiperazine alkaloids cover an astonishing array of molecular architecture
and, with that, corresponding synthetic challenges to construct such substances.
The biosynthesis of many of the natural substances touched on in this chapter has,
in some instances, been studied going back several decades, and many workers
have sought to exploit insights from Nature’s strategic bond constructions in a
synthetic laboratory context. Advances in whole genome sequencing have brought
new and invigorated interest in elucidating the biosynthesis of structurally intrigu-
ing and biomedically relevant secondary metabolites. The insights to be gained
from educated guess work on what specific compounds might lie along a pos-
sible biosynthetic pathway, traditionally accomplished by isolation and structural
375
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elucidation to map metabolite co-occurrence in conjunction with isotopically la-
beled precursor incorporation experiments, is in the process of giving way to a
much higher resolution picture of secondary metabolism in microorganisms and
plants. With the advent of powerful new genomics and proteomics tools to study
and manipulate secondary metabolite production, advances in our understanding
of Nature’s creative synthetic palette will surely explode in the coming years.
The fruits of these insights will undoubtedly be extensively exploited by synthetic
chemists working at the forefront of complex molecule synthesis. In addition, many
new natural products–the biosynthetic intermediates themselves, often isolated in
trace amounts if at all–will provide and constitute worthy new synthetic targets
and substrates for various important applications.
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The biomimetic total syntheses of both malbrancheamide and malbrancheamide B are reported. The
synthesis of the two monochloro species enabled the structure of malbrancheamide B to be unambiguously
assigned. The syntheses each feature an intramolecular Diels-Alder reaction of a 5-hydroxypyrazin-
2(1H)-one to construct the bicyclo[2.2.2]diazaoctane core, which has also been proposed as the biosynthetic
route to these compounds.
Introduction
Our research group has exhibited a long-standing interest in
the synthesis and biosynthetic study of a number of unique
prenylated indole alkaloids containing a characteristic bicyclo-
[2.2.2]diazaoctane core.1 This class of natural products includes
such highly biologically active fungal metabolites as the
paraherquamides,2 brevianamides,3 notamides,4 and stephaci-
dins,5 among others, which we have shown all arise biogeneti-
cally from tryptophan, mevalonate-derived isoprene units, and
proline or derivatives of proline.1 Sammes originally proposed
that the bicyclo[2.2.2]diazaoctane core common to all of these
natural products arises in Nature via an intramolecular hetero-
Diels-Alder reaction of a 5-hydroxypyrazin-2(1H)-one,6 and
work from this laboratory has extensively supported such a
proposal.1 In fact, we have applied such a [4+2] hetero-Diels-
Alder cycloaddition strategy to the total synthesis of several of
these prenylated indole alkaloids, including stephacidin A,7
brevianamide B,8 marcfortine C,9 notoamide B,7b and VM55599.10
Malbrancheamide (1)11 and malbrancheamide B (2) were
recently isolated from Malbranchea aurantiaca RRC1813, a† Colorado State University.
‡ The University of Michigan.
§ University of Colorado Cancer Center.
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fungus collected on bat detritus collected in a cave in Mexico
by Mata and co-workers. These new substances are the first
alkaloids in this class of prenylated indole alkaloids to contain
a halogenated indole ring (Figure 1). The lack of a tertiary amide
in the bicyclo[2.2.2]diazaoctane core also serves to characterize
the malbrancheamides. In addition to these notable structural
features, malbrancheamide has been shown to be a calmodulin
(CaM) antagonist that inhibits the activity of CaM-dependent
phosphodiesterase (PDE1) in a concentration dependent man-
ner.11 The chemotherapeutic potential of PDE1 inhibitors
includes applications in the treatment of neurodegenerative
diseases, cancers, and vascular diseases, due to the effect on
intracellular cAMP and cGMP concentrations.12 New pharma-
cological properties of malbrancheamide may be discovered
through the study of malbrancheamide, malbrancheamide B, and
other analogs, as specific PDE1 inhibitors are scarce and the
exact function of the enzyme has not been fully characterized.
Although compelling spectroscopic evidence indicated that
the structure of 1 was as shown,11 the precise structure of
malbrancheamide B (2) was less certain. Isolation and structural
characterization of 2 indicated the presence of a single chlorine
on the indole ring, and further, preliminary biosynthetic experi-
ments indicated that malbrancheamide B (2) is a putative
biosynthetic precursor to 1,13 which is thought to arise by
sequential halogenation events. However, the question as to
whether malbrancheamide B (2) was constituted as the 5-chloro
or the 6-chloro derivative was unclear from the preliminary
characterization data due to the scarce supply of the natural
material. With these issues at the forefront, we undertook the
synthesis of both natural substances to determine the exact
identity of malbrancheamide B. To this end, we envisioned that
malbrancheamide (1) and malbrancheamide B (2) would arise
from the aforementioned hetero-IMDA of the 5-hydroxypyrazin-
2(1H)-one 3, which we could access by enolization and
tautomerization of the enamide 4 (Scheme 1). Using chemistry
previously established in our laboratory,7a we planned on
assembling the enamide 4 from a reverse prenylated tryptophan
5, which could be obtained in a few steps from the correspond-
ing chlorinated indole 6.
Results and Discussion
Installation of the reverse prenyl group at the indole 2-position
was carried out using a two-step protocol developed by
Danishefsky and co-workers.14 Chlorination at the 3-position
of indoles 6a-c15 using NCS in DMF gave 7a-c (Scheme 2),
which were treated with prenyl-9-BBN in the presence of Et3N
to afford the reverse prenylated indoles 8a-c.14 The corre-
sponding gramines 9a-c were prepared by treating 8a-c with
formaldehyde and dimethylamine, and subsequent Somei-
Kametani coupling16 and imine hydrolysis gave the tryptophan
derivatives 5a-c in good yields.
The free amine moieties in 5a-c were protected as the
corresponding BOC-carbamates followed by ester hydrolysis
under standard conditions to yield acids 10a-c (Scheme 3).
Coupling of cis-3-hydroxyproline ethyl ester with the tryptophan
derivatives 10a-c in the presence of HATU delivered the
amides 11a-c as inseparable mixtures of diastereomers. Treat-
ment of 11a-c with TFA led to carbamate deprotection and
the resulting amino esters were immediately cyclized to the
corresponding diketopiperazines 12a-c after refluxing with
2-hydroxypyridine. Dehydration of 12a-c under Mitsunobu
conditions gave the enamides 4a-c, which would serve as the
respective IMDA substrates.17
Treatment of the enamides 4a-c with aqueous KOH in
MeOH gave intermediate hydroxy-azadienes by enolization and
tautomerizaion, and subsequent IMDA gave mixtures of 13a-c
and 14a-c favoring the desired syn-isomers 13a-c in ratios of
(2-1.6):1 (Scheme 4). The observed preference for the IMDA
to provide the syn-isomers 13a-c as the major products mirrors
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Pharm. Bull. 2005, 28, 1974. (b) Leisner, T. M.; Liu, M. J.; Jaffer, Z. M.;
Chernoff, J.; Parise, L. V. J. Cell Biol. 2005, 170, 465.
(13) Ding, Y.; Sherman, D. H.; Williams, R. M. Unpublished results.
(14) Schkeryantz, J. M.; Woo, J. C. G.; Siliphaivanh, P.; Depew, K. M.;
Danishefsky, S. J. J. Am. Chem. Soc. 1999, 121, 11964.
(15) For the preparation of 5,6-dichloroindole see: Bromidge, S. M.; et
al. J. Med. Chem. 1998, 41, 1598.
(16) (a) Somei, M.; Karasawa, Y.; Kaneko, C. Heterocycles 1981, 16,
941. (b) Kametani, T.; Kanaya, N.; Ihara, M. J. Chem. Soc., Perkin Trans.
1 1981, 959.
(17) Curiously, attempts to effect the one-step dehydration/IMDA reaction
sequence from 12a-c directly to 13a-c + 14a-c failed under the same
conditions used successfully for stephacidin A (ref 7a) and marcfortine C
(ref 9).
FIGURE 1. Malbrancheamide and malbrancheamide B.
SCHEME 1. Retrosynthetic Plan
SCHEME 2. Reverse Prenylated Tryptophan Derivatives
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the preference we have noted for this cycloaddition in the
past.7-9 Considering that previous optimization efforts to
improve the syn:anti ratio in related IMDAs were not productive
when a variety of solvents and temperatures were studied, we
elected to simply separate the major isomers 13a-c and continue
the total syntheses without further optimization.7-9
Completion of the syntheses required selective reduction of
the tertiary amide in the presence of the secondary amide, and
to that end, 13a-c were treated with excess DIBAL-H,18 which
cleanly provided malbrancheamide (1) from 12a (80%) and
malbrancheamide B (2) from 12c (74%) (Scheme 5). Synthetic
1 was identical in all respects (1H, 13C, HRMS) to the natural
product.11 Comparison of the 1H NMR spectrum of 15, the
5-chloro derivative, to that of natural malbrancheamide B
revealed significant differences in the aromatic region revealing
that the correct structure contained a 6-chloroindole ring.
Gratifyingly, synthetic 2 was identical in all respects (1H,
HRMS) to natural malbrancheamide B.
It is striking that the initial halogenation of the indole ring
during the biosynthesis of malbrancheamide B, occurs at the
less-activated 6-position as opposed to the more electron-rich
5-position. Studies to clone and express the putative halogenase
from M. aurantiaca are currently under investigation in these
laboratories.
In summary, the first total synthesis of malbrancheamide (1)
and malbrancheamide B (2) have been completed in twelve steps
in 5.3% and 8.2% overall yield, respectively. In addition, the
structure of malbrancheamide B (2) was confirmed though the
synthesis of both the 5-chloro and the 6-chloro regioisomers.
Experiments to establish the biosynthetic relationship between
1 and 2 and their putative progenitors are in progress and will
be reported in due course.
Experimental Section
Representative Procedure for the Hetero-Diels-Alder Reac-
tion of Enamides 4. Preparation of Cycloadducts 13a and 14a.
To a solution of 4a (86 mg, 0.21 mmol) in MeOH (16 mL) at 0 °C
was added 20% aqueous KOH (4 mL). The reaction was warmed
to room temperature (rt) and was stirred for 12 h. The reaction
was quenched with sat. NH4Cl (30 mL) and extracted with CH2-
Cl2 (3 ! 30 mL). The combined organic layers were dried (Na2-
SO4) and concentrated under reduced pressure. The residue was
triturated with CHCl3 (30 mL), and the suspension was filtered to
provide 53 mg (60%) of 13a as a white amorphous solid.
Concentration of the filtrate gave 25 mg (29%) of 14a as a white
amorphous solid. Data for major isomer 13a: 1H NMR (300 MHz,
CD3OD) ! 7.55 (s, 1 H), 7.40 (s, 1 H), 3.57 (d, J ) 15.5 Hz, 1 H),
3.47 (m, 1 H), 2.74 (d, J ) 15.5 Hz, 1 H), 2.60 (m, 1 H), 2.20-
1.96 (comp, 6 H), 1.35 (s, 3 H), 1.11 (s, 3 H); 13C NMR (75 MHz,
CD3OD) ! 175.7, 171.3, 144.3, 137.2, 128.1, 125.4, 123.3, 119.8,
113.1, 104.8, 68.3, 61.6, 50.8, 45.2, 36.2, 31.7, 30.1, 28.6, 25.4,
24.9, 22.3; IR (neat) 1663, 1428 cm-1; HRMS (TOF+) calcd for
C21H22N3O2Cl2 (M + H) 418.1084, found 418.1084. Data for minor
isomer 14a: 1H NMR (300 MHz, CDCl3) ! 9.78 (s, 1 H), 7.49 (s,
1 H), 7.33 (s, 1 H), 3.71 (d, J ) 17.8 Hz, 1 H), 3.47 (comp, 2 H),
3.25 (s, 1 H), 2.78 (d, J ) 17.8 Hz, 1 H), 2.67 (m, 1 H), 2.18-
1.78 (comp, 6 H), 1.24 (s, 3H), 1.16 (s, 3 H); 13C NMR (75 MHz,
CD3OD /CDCl3 (1:9)) ! 173.7, 169.6, 142.6, 135.7, 127.1, 125.0,
122.9, 119.1, 112.4, 102.9 67.2, 61.5, 45.8, 44.3, 34.8, 32.6, 29.8,
29.1, 28.4, 24.5, 23.2; IR (neat) 1676, 1453 cm-1; HRMS (TOF+)
calcd for C21H22N3O2Cl2 (M + H) 418.1084, found 418.1079.
Cycloadducts 13b and 14b. Prepared from 4b in to give 43%
of 13b as a white amorphous solid and 27% of 14b as a white
amorphous solid according to the representative procedure described
above for 13a and 14a. Data for major isomer 13b: 1H NMR (300
MHz, CD3OD) ! 7.54 (s, 1 H), 7.44 (s, 1 H), 7.22 (d, J ) 8.6 Hz,
1 H), 7.04 (d, J ) 8.6 Hz, 1 H), 3.68 (d, J ) 15.4 Hz, 1 H), 3.55-
3.40 (comp, 2 H), 2.77 (d, J ) 15.4 Hz, 1 H), 2.76 (m, 1 H), 2.61
(m, 1 H), 2.25-1.92 (comp, 5 H), 1.37 (s, 3 H), 1.12 (s, 3 H); 13C
NMR (100 MHz, CD3OD) ! 175.8, 171.4, 143.4, 136.8, 129.2,
125.2, 122.1, 118.2, 112.8, 104.5, 68.3, 61.6, 50.8, 45.2, 36.2, 31.7,
30.1, 28.7, 25.5, 25.0, 22.4; IR (neat) 1678, 1441 cm-1; HRMS(18) Fukuyama, T.; Liu, G. J. Am. Chem. Soc. 1996, 118, 7426-7427.
SCHEME 3. Enamide Diels-Alder Precursors
SCHEME 4. Hetero-IMDA Reactions
SCHEME 5. Amide Reductions
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(TOF+) calcd for C21H23N3O2Cl (M + H) 384.1473, found
384.1460. Data for minor isomer 14b: 1H NMR (300 MHz, CD3-
OD) ! 7.91 (s, 1 H), 7.41 (d, J ) 2.0 Hz, 1 H), 7.23 (d, J ) 8.6
Hz, 1 H), 7.01 (dd, J ) 8.6, 2.0 Hz, 1H), 3.71 (d, J ) 17.6 Hz,
1H), 3.53 (comp, 2 H), 2.90 (d, J ) 17.6 Hz, 1 H), 2.70 (m, 1 H),
2.23-1.89 (comp, 6 H), 1.34 (s, 3 H), 1.27 (s, 3 H); 13C NMR
(100 MHz, CD3OD) ! 175.4, 171.7, 143.4, 136.8, 129.7, 125.3,
122.1, 118.1, 112.8, 103.8, 68.6, 62.7, 47.3, 45.2, 35.9, 33.3, 30.8,
29.9, 28.7, 25.4, 24.8, 23.8; IR (neat) 1675, 1461 cm-1; HRMS
(TOF+) calcd for C21H23N3O2Cl (M + H) 384.1473, found
384.1468.
Cycloadducts 13c and 14c. Prepared from 4c in to give 55%
of 13c as a white amorphous solid and 31% of 14c as a white
amorphous solid according to the representative procedure described
above for 13a and 14a; data for major isomer 13c: 1H NMR (400
MHz, DMSO-d6) ! 8.75 (s, 1 H), 7.40-6.98 (comp, 3 H), 3.42 (d,
J ) 15.3 Hz, 1 H), 3.30 (comp, 2 H), 2.68 (d, J ) 15.3 Hz, 1 H),
2.50 (comp, 1 H), 2.10-1.70 (comp, 6 H), 1.27 (s, 3 H), 0.99 (s,
3 H); 13C NMR (100 MHz, DMSO-d6) ! 173.0, 168.4, 142.0, 136.8,
125.3, 125.2, 118.9, 118.5, 110.4, 103.8, 66.0, 59.6, 48.9, 43.6,
34.6, 30.0, 28.7, 27.9, 24.0, 23.7, 21.6; IR (neat) 1671, 1409 cm-1;
HRMS (TOF+) calcd for C21H23N3O2Cl (M+H) 384.1473, found
384.1470. Data for minor isomer 14c: 1H NMR (400 MHz, CD3-
OD/CDCl3 (1:9)) ! 9.58 (s, 1 H), 7.33 (d, J ) 8.4 Hz, 1 H), 7.23
(d, J ) 1.8 Hz, 1 H), 6.97 (dd, J ) 8.4, 1.8 Hz, 1 H), 3.75 (d, J )
17.8 Hz, 1 H), 3.47 (comp, 2 H), 3.30 (bs, 1 H), 2.84 (d, J ) 17.8
Hz, 1 H), 2.70 (m, 1 H), 2.23-1.77 (comp, 6 H), 1.25 (s, 3 H),
1.18 (s, 3 H); 13C NMR (100 MHz, DMSO-d6) ! 172.43, 169.0,
142.0, 136.8, 125.8, 125.3, 119.0, 118.5, 110.4, 103.1, 79.2, 66.4,
60.5, 45.4, 43.7, 34.2, 31.6, 28.6, 27.7, 24.0, 22.5; IR (neat) 1672,
1410 cm-1; HRMS (TOF+) calcd for C21H23N3O2Cl (M + H)
384.1473, found 384.1468.
Representative Procedure for the Selective Reduction of
Tertiary Amides with Excess DIBAL-H. Synthesis of Mal-
brancheamide (1). DIBAL-H (0.70 mL, 1 M in toluene, 0.70
mmol) was added to a suspension of 13a (15 mg, 0.036 mmol) in
toluene (7 mL) at rt. The reaction was stirred at rt for 12 h,
whereupon finely powdered Na2SO4‚10H2O was added until
bubbling ceased. The mixture was filtered with a medium porosity
fritted funnel washing with EtOAc (50 mL) and MeOH (50 mL),
and the filtrate was concentrated under reduced pressure. The
residue was purified by flash chromatography eluting with MeOH/
CH2Cl2 (2:98) to give 12 mg (80%) of 1 as a white amorphous
solid: 1H NMR (400 MHz, CD3OD) ! 7.48 (s, 1 H), 7.40 (s, 1 H),
3.43 (d, J ) 10.3 Hz, 1 H), 3.06 (m, 1 H), 2.85 (comp, 2 H), 2.54
(m, 1 H), 2.27 (dd, J ) 10.2, 1.5 Hz, 1 H), 2.20-1.18 (comp, 6
H), 1.43 (s, 3 H), 1.34 (s, 3 H); 13C NMR (100 MHz, CD3OD) !
176.6, 145.1, 137.3, 128.2, 125.3, 123.2, 119.6, 113.1, 104.7, 66.1,
59.4, 57.4, 55.4, 48.5, 35.5, 32.4, 30.6, 30.0, 28.1, 24.2, 23.5; IR
(neat) 3226, 1658, 1460 cm-1; HRMS (TOF+) calcd for C21H24N3-
OCl2 (M + H) 404.1291, found 404.1290.
Isomalbrancheamide B (15). Prepared from 13b in 68% yield
as a white amorphous solid according to the representative
procedure described above for 1: 1H NMR (400 MHz, DMSO-d6)
! 8.39 (s, 1 H), 7.33 (s, 1 H), 7.26 (d, J ) 8.5 Hz, 1 H), 7.01 (d,
J ) 8.5 Hz, 1 H), 3.33 (d, J ) 7.2 Hz, 1 H), 3.26 (d, J ) 9.9 Hz,
1 H), 2.76 (s, 2 H), 2.42 (m, 1 H), 2.15-1.73 (comp, 7 H), 1.33 (s,
3 H), 1.27 (s, 3 H); 13C NMR (100 MHz, DMSO-d6) ! 173.1. 143.4,
134.9, 127.7, 122.8, 120.4, 116.7, 112.1, 103.4, 64.1, 58.6, 55.3,
53.9, 47.0, 34.0, 31.1, 30.0, 28.7, 26.6, 23.7, 22.5; IR (neat) 3311,
1637, 1458 cm-1; HRMS (TOF+) calcd for C21H25N3OCl (M +
H) 370.1680, found 370.1675.
Malbrancheamide B (2). Prepared from 13c in 74% yield as a
white amorphous solid according to the representative procedure
described above for 1: 1H NMR (400 MHz, DMSO-d6) ! 8.41 (s,
1 H), 7.32 (d, J ) 8.4 Hz, 1 H), 7.27 (d, J ) 1.7 Hz, 1 H), 6.95
(dd, J ) 8.4, 1.7 Hz, 1 H), 3.36 (s, 1 H), 3.27 (d, J ) 10.0 Hz, 1
H), 2.95 (m, 1 H), 2.76 (s, 2 H), 2.43 (m, 1 H), 2.13 (d, J ) 9.9
Hz, 1 H), 2.10-1.70 (comp, 6 H), 1.32 (s, 3 H), 1.26 (s, 3 H); 13C
NMR (100 MHz, DMSO-d6) ! 173.1, 142.6, 136.8, 125.3, 125.2,
118.7, 118.5, 110.3, 103.7, 64.1, 58.5, 55.3, 53.9, 47.0, 34.0, 31.1,
30.0, 28.7, 26.6, 23.7, 22.5; IR (neat) 3297, 1652, 1457 cm-1;
HRMS (TOF+) calcd for C21H25N3OCl (M + H) 370.1680, found
370.1670.
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B. Research Plan: Targeting STAT5 in Prostate Cancer Cells with DNA Binding Polyamides 
 
I. Specific Aims 
  
 Prostate cancer was responsible for approximately 33720 deaths in 2011.1 While patients with 
metastatic prostate cancer typically respond to surgical or medicinal androgen deprivation initially, all will 
eventually progress to an androgen independent state termed castration-resistant prostate cancer 
(CRPC). The progression of prostate cancer cells to the androgen independent phenotype occurs 
concomitantly with an increase in the constitutive activation of the transcription factors androgen receptor 
(AR) and signal transducer and activator of transcription 5 (STAT5).2 AR is established as a relevant 
target for the treatment of CRPC, and several therapies targeting the AR signaling pathway are available 
or in development.3,4 While the exact role of STAT5 in CRPC is not as well defined, it appears to be 
equally important to prostate cancer cell growth and survival, as evidenced by the following: (1) STAT5 is 
overactive in 95% of CRPCs,5 (2) STAT5 activity is associated with highly aggressive (high Gleason 
grade) prostate cancers,6,7 and (3) inhibition of STAT5 by siRNA results in massive apoptotic cell death in 
human prostate cancer cell lines.8 STAT5 represents a promising target for the treatment of CRPC, a 
disease for which no effective therapy currently exists. To date, no small molecule inhibitors of STAT5 
transcriptional activity have been reported. 
 
 Our long term goal is to develop small molecule inhibitors of STAT5 function for the treatment of 
malignancies displaying aberrant STAT5 activity. The overall objective of this proposal is to determine the 
therapeutic potential of DNA binding pyrrole-imidazole polyamides that target STAT5 for the treatment of 
CRPC. We hypothesize that polyamides can be designed to downregulate the expression of a subset of 
genes required for CRPC cell survival. Polyamides containing N-methylpyrrole (Py) and N-
methylimidazole (Im) comprise the only known class of programmable small molecules capable of 
binding specific DNA sequences.9,10 Previous studies from the Dervan group have shown that polyamides 
are cell permeable,11-13 access nuclear chromatin,14-16 inhibit specific protein–DNA interfaces,17 and 
modulate gene expression in cell culture.18-23 Polyamides represent a promising approach toward the 
pursuit of small molecule inhibitors of STAT5 transcription for the treatment of CRPC. The specific aims 
proposed below will determine the suitability of this approach while contributing to the overall 
understanding of STAT5 signaling in prostate cancer. 
 
AIM 1. Synthesize a series of Py/Im polyamides designed to target the STAT5 response 
element and evaluate their DNA binding interactions in vitro. Polyamides designed to 
target the consensus STAT5 binding sequence 5’-TTCNNNGAA-3’† will be synthesized by 
solid phase methodology. DNA binding interactions of the polyamides will be evaluated in vitro 
using melting temperature analysis and electrophoretic mobility shift assay (EMSA).  
 
AIM 2. Examine nuclear localization and characterize gene regulatory potency of polyamides. 
Laser-scanning confocal microscopy will be used to examine cellular uptake and localization 
of high-affinity polyamides in several cancer cell lines. The expression of STAT5 regulated 
oncogenes BCL-2,24-27 BCL-XL,28,29 and CYCLIN-D12,8,30 in prostate cancer cells will be 
examined following polyamide treatment using quantitative real-time RT-PCR (qRT-PCR). The 
global effects of polyamides that are shown to modify gene expression will then be studied 
                                                            
† Abbreviations for degenerate nucleotides: N = any base; W = A or T. 
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with chromatin immunoprecipitation coupled with sequencing (ChIP-seq) and mRNA 
sequencing (RNA-seq). 
 
AIM 3. Investigate polyamide induced apoptosis in prostate cancer cell lines and in mice 
bearing xenograft tumors. General cell death will be analyzed following polyamide treatment 
in both normal and prostate cancer cell lines. Polyamide effects on C4-2 tumor growth will be 
studied in a murine model at the Caltech Animal Facility. 
  
 The aims in this proposal represent a new approach toward the development of inhibitors of STAT5 
regulated gene expression. The proposed experiments will provide thorough and systematic 
understanding of the activity, mechanism, and specificity of polyamides in prostate cancer. If successful, 
the proposed research could produce the first known specific inhibitors of STAT5 regulated gene 
expression for the treatment of CRPC. 
 
II. Background and Significance 
 
 A limited set of transcription factors has been 
implicated in a large number of diverse oncogenic 
signaling pathways.31 Selective inhibition of a single 
transcription factor would thus influence the expression 
of numerous upstream oncogenes, many of which are 
currently individually targeted by discrete inhibitors. 
Signal transducer and activator of transcription (STAT) 
proteins are overactive in a variety of cancers, promote 
cancer cell survival and proliferation, and are 
susceptible to inhibition, making them ideal targets for 
cancer therapy.32-34 STATs are latent cytoplasmic 
proteins that, once activated by tyrosine kinase 
phosphorylation, dimerize, traffic to the nucleus, and 
bind specific response elements of target gene 
promoters (Figure 1).32,35-37 In normal cells, STAT 
activation has a role in cell survival, angiogenesis, 
immune function, and in controlling cell growth.38,39 
However, disregulation of this activity can contribute to 
tumor cell growth and proliferation.32,40 
 
 Persistent activity of STAT5, a member of the 
STAT family of proteins, is associated with prostate 
cancer,5,6,8,41,42 lung, head, and neck cancers,43 and 
several types of leukemia44-47 and lymphomas.35,48 The 
link to prostate cancer is particularly strong, with 95% 
of castration-resistant prostate cancers (CRPC) 
displaying constitutive STAT5 activity.5 Active STAT5 in prostate cancer predicts early disease recurrence 
and is associated with high Gleason grade prostate cancers characterized by an aggressive phenotype 
and poor patient outcome.6,7 Furthermore, active STAT5 has been shown to increase the motility of 
prostate cancer cells, enhancing the intrinsic ability of the disease to metastasize.49 STAT5 is a generic 
term for two highly homologous protein isoforms, 94-kDa STAT5a and 92-kDa STAT5b.50 Both isoforms 
share a conserved DNA binding domain that permits binding of STAT5 to consensus motifs (5’-
TTCNNNGAA-3’) found in target gene promoters, including the oncogenes encoding anti-apoptotic (BCL-
XL, BCL-2) and pro-proliferative (Cyclin-D1) proteins.2,8,24-30,51 STAT5 binding to this consensus motif 
Figure 1. Canonical STAT5 signaling pathway. 
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found at non-canonical recognition sites has additionally been shown to activate several novel and 
potentially oncogenic genes, including TNFRSF13b, MKP-1, and C3ar1.52 
 
  Numerous studies have shown that inhibition of STAT5 results in massive apoptotic cell death in 
human prostate cancer cell lines, regardless of the inhibitory method employed (adenoviral expression of 
dominant-negative mutants of STAT5, siRNA, or antisense oligonucleotides).2,8,41,53 STAT5 inhibition by 
antisense oligonucleotides has specifically been shown to suppress the expression of Cyclin-D1 and 
BCL-XL in LNCaP, C4-2, and DU145 prostate cancer cell lines at both the mRNA and protein levels, 
resulting in increased apoptotic death and decreased cell growth.2,8 In mouse xenograft models, the 
progression of CRPC was delayed significantly by STAT5 inhibition with antisense oligonucleotides.2 
These findings imply prostate cancers depend on persistent STAT5 activation for cell growth and survival. 
Chemotherapeutic small molecules targeting STAT5 signaling could thus have a substantial impact on 
the treatment of CRPC, a disease for which no effective pharmacological therapy currently exists. STAT5 
inhibitors published to date indiscriminately downregulate STAT5 regulated transcription and lack 
practical therapeutic potential. Herein, we describe a new, promising approach for the selective inhibition 
of STAT5 mediated gene expression in prostate cancer, using DNA binding polyamides to disrupt the 
STAT5–DNA interface. 
 
 Polyamides containing N-methylpyrrole (Py) and N-methylimidazole (Im) comprise a class of 
programmable small molecules that can be designed to bind specific DNA sequences with affinities 
Figure 2. Molecular recognition of the minor groove of DNA by a hairpin polyamide. (A) Model of an eight ring 
hairpin polyamide (ImImPyPy-(R)H2N-!-PyPyPyPy-"-IPA) bound to a 5’-TGGAAA-3’ sequence. Putative 
hydrogen bonds are represented by dashed lines. (B) X-ray crystal structure of a cyclic polyamide (blue) in 
complex with dsDNA (0.95Å resolution). (C) Ball-and-stick model of the polyamide in 2A. Closed and open 
circles represent N-methylimidazole and N-methylpyrrole monomers, respectively. Diamonds, "-alanine; triangle 
with positive charge, triamine linker; curved line substituted with positive charge, #-amino-substituted !-turn. The 
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comparable to native DNA binding proteins.9 Sequence specificity of Py/Im polyamides is determined by 
side-by-side pairing of the heterocyclic amino acids to form distinct hydrogen bonds to nucleotides in the 
minor groove of DNA (Figure 2).54 Im/Py pairs distinguish G!C from C!G, whereas Py/Py pairs 
degenerately bind A!T and T!A.10 Hairpin polyamides designed as such have been shown to bind DNA 
with high affinities,55 inhibit interactions with DNA binding proteins,17 bind chromatin,14-16 and traffic to 
the nucleus in a variety of cell types.11-13 Recently, analyses have shown that 8-ring cyclic polyamides 
allosterically perturb the DNA helix through a 4Å widening of the minor groove and consequent major 
groove compression.56 This significant change provides a mechanistic basis for disruption of protein–
DNA interfaces by hairpin polyamides.  
 
 To evaluate the specific inhibition of STAT5 mediated gene expression by cell permeable, 
sequence specific DNA binding polyamides, we propose the synthesis, biochemical evaluation, and 
biological study of a small library of Py/Im polyamides designed to specifically disrupt the interactions of 
STAT5 with regulatory regions of pro-proliferative and anti-apoptotic genes. 
 
III. Preliminary Studies 
  
 This proposal builds upon known chemical and biological 
techniques developed in the Dervan group. The study highlighted here 
shows precedence for the use of polyamides in the modulation of 
endogenous gene expression (Figure 3). In the study, hypoxia 
inducible factor (HIF-1#) binding to the sequence 5’-WWWCGW-3’ 
found in the vascular endothelial growth factor (VEGF) hypoxia 
response element (HRE) was perturbed by a hairpin polyamide.21,22 
The polyamide reduced occupancy of HIF-1# at the VEGF HRE and 
suppressed VEGF mRNA expression. Only a subset of genes induced 
by deferoxamine (DFO)—a small molecule used to mimic hypoxia in 
cells—was inhibited by polyamide, whereas HIF-1# siRNA and the 
DNA-binding natural product echinomycin inhibited most of the DFO 
induced transcripts. This demonstrated the relative selectivity of Py/Im 
polyamides compared to other methods used to perturb HIF-1# 
activity. 
 
 A second investigation key to the design of this proposal was detailed in a series of publications from 
the Dervan group in which the nuclear localization of a library of over 120 polyamide-fluorophore 
conjugates was described.11-13 Cellular uptake profiles of the polyamides were assayed in 13 cell lines 
using confocal microscopy. The reported nuclear uptake trends suggest the following structural features 
to be conducive to uptake: an eight-ring hairpin or cyclic core, a positive charge on the amino substituent 
of the !-aminobutyric acid (GABA) turn, and either a conjugated fluorescein fluorophore (FITC) or 
isophthalic acid (IPA) moiety on the hairpin tail. Polyamides targeting 5’-WGWWGW-3’ and 5’-
WGGWWW-3’ similar to those proposed below were shown to have strong nuclear localization in PC-3 
and LNCaP prostate cancer cell lines.11,12 
 
 The transition from cell culture work to murine models is an important next step in Py/Im polyamide 
research that is focused on biomedical applications of the technology. Recent studies undertaken in the 
Dervan laboratory have provided basic pharmacokinetic analyses of polyamides in C57/BL6 wild type 
mice.57 Micromolar blood levels of Py/Im polyamides were achieved for multiple hours following a single 
injection of the compound subcutaneously or intraperitoneally. An example is shown in Figure 4a (a 
representative HPLC trace) and 4B (a representative pharmacokinetic profile for a hairpin Py/Im 
polyamide). Decline in hairpin polyamide concentration was observed over the course of multiple hours, 
Figure 3. Polyamide mediated 
inhibition of HIF-1 DNA binding 
to the HRE suppresses VEGF 
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with a peak concentration noted between 1-3h depending on route of administration. Compound 
plasma levels were below detection level 24h after the injection. The polyamide was well tolerated by 
the animals. Multiple administrations (i.p. or s.c. at 120 nmol per injection per animal) did not result in 
any significant reduction in body weight. Weight loss is a commonly used criterion for health 























 The Dervan group has recently gained broad experience with xenograft experimentation in 
immunocompromised mice, encompassing the engraftment of human cancer cell lines A549, LNCaP, 
U251, and T47D. FITC-labeled polyamides injected subcutaneously on the flank opposite the tumor 
were shown by confocal microscopy to access the tumor derived cell nuclei. Moreover, gene 
expression changes have been observed in engrafted A549 tumors following polyamide treatment.58  
 
 The studies outlined above demonstrate the validity of targeting the transcription factor–DNA interface 
as a means of modulating gene expression. Furthermore, evaluation of nuclear uptake trends allows for 
the rational design of new polyamides that are structurally optimized for nuclear localization. The Dervan 
group has also recently developed a gram-scale synthesis of hairpin polyamides and shown that 
polyamides are bioavailable in mice, eliminating two major obstacles in the evaluation of polyamides in 
animal models.59,60 Tumor engraftment protocols, established tolerable dosing conditions, and general 
animal care and handling expertise found in the Dervan group will be invaluable during in vivo testing of 
the proposed STAT5-targeting polyamides. We are confident the methods established by these studies 
can be extended to the proposed research and will increase the probability of success.  
 
IV. Research Design and Methods  
 
 An estimated timeline for completion of the specific aims is given in Figure 5. The proficiency of the 
Dervan group with these techniques coupled with the outstanding equipment, facilities, and expertise 
found at Caltech will provide strong support for the success of this research project. We are confident that 
the proposed objectives will be thoroughly pursued during the planned three year period.  
A B
C D
Figure 4. Pharmacokinetic data for 
hairpin polyamide 1 in C57/BL6 
wild type mice. (A) HPLC analysis 
of a blood sample collected retro-
orbitally 1.5 h post intraperitoneal 
(i.p.) injection of 1. Plasma was 
isolated by centrifugation and pre-
cleared from protein by methanol 
precipitation. (4 = internal reference 
standard). (B) Plasma levels of 1 
as a percent of reference standard 
4 following i.p. or subcutaneous 
(s.c.) injection. (C, D)  Weight of 
four individual mice in response to 
polyamide dosing regimen. 120 
nmol doses were administered 
either i.p. (C) or s.c. (D) at intervals 
denoted by arrows in the plot. The 
solid red line indicates the 15% 
weight loss mark considered an 
endpoint criterion for the mice. 
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AIM 1. Synthesize a series of Py/Im polyamides designed to target the STAT5 response element 
and evaluate their DNA binding interactions in vitro. 
 
 Three oncogenes shown in the 
literature to be functionally activated 
by STAT5 and to contain a STAT5 
binding site characterized at the 
sequence level were selected as 
targets for polyamide inhibition 
(Table 1). The three degenerate 
base pairs found in the middle of the 
consensus STAT5 binding 
sequence (5’-TTCNNNGAA-3’) represent the great degree of diversity of the binding sequences on target 
genes, allowing for the design of polyamides with greater DNA site sequence specificity than the native 
transcription factor. Three polyamides (Figure 6) are proposed to bind the sequences 5’-WGWWGW-3’ 
(1, found in BCL-XL), 5’-WWCGGW-3’ (2, found in BCL-XL), and 5’-WGGWWW-3’ (3, found in BCL-2 and 
CYCLIN-D1).27,30 Polyamide 3 is also expected to bind non-canonical STAT5 binding sites found in MKP-
1, TNFRSF13b, and C3ar1.52 Mismatch controls will be prepared for each compound by substituting a Py 
for an Im (structures not shown). Polyamides 1-3 and the three mismatch controls will be synthesized 
using solid-phase methodology established in the Dervan laboratory.18,61,62 Preparative reverse-phase 
high performance liquid chromatography (RP-HPLC) will be used to purify crude reaction products. 
Chemical purity of polyamides will be determined by analytical HPLC and the chemical composition of 
each confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF). 
 The ability of synthesized polyamides 1-3 to bind DNA will be determined using melting temperature 
(Tm) analysis. The degree to which both match and mismatch polyamides stabilize 14 base pair DNA 
duplexes containing the appropriate match sequence will be measured. Previous results have shown a 
correlation between the increase in Tm of DNA duplexes and DNA binding affinity.63-65 Polyamides 
Gene Function STAT5 Binding Sequence 
BCL-XL anti-apoptotic 5’-GCATTTCGGAGAAGACG-3’ 
BCL-2 anti-apoptotic 5’-CAAGTTCCAGGAAAGCG-3’ 
CYCLIN-D1 pro-proliferative 5’-GGCGTTCTTGGAAATGC-3’ 
Table 1. Promoter sequences for selected genes demonstrated to 
be STAT5 dependent. The consensus sequence is 
specified in bold. 
Figure 6. Proposed library of polyamide inhibitors of STAT5. Structural abbreviations are defined in 
Figure 2. 
IPA + +
W G G W W W
W C C W W W
IPA + + IPA + +
W W C G G W
W W G C C W
W G W W G W
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identified to bind DNA with high affinity will be subjected to electrophoretic mobility shift assay (EMSA) to 
evaluate their ability to disrupt STAT5 binding to their cognate sequences. Published protocols from the 
Dervan laboratory will be followed using commercially available STAT5 and 32P-labelled oligonucleotides 
purchased from Abcam and Integrated DNA Technologies, respectively.19-21,63 
 
AIM 2. Examine nuclear localization and characterize gene regulatory potency of polyamides. 
 
 Fluorescent (FITC) derivatives of polyamides 1-3 will be evaluated in cell culture to examine their 
uptake and localization properties. Cells treated with varying concentrations of fluorescent polyamides will 
be examined using confocal microscopy as previously described.11-13 Several prostate cancer cell lines 
will be studied to establish general cellular uptake trends, including LNCaP, C4-2, DU145, and PC-3 
(Table 2). All have been previously used in the Dervan laboratory or are commercially available and will 
be cultured and propagated according to recommended American Type Culture Collection (ATCC) 
procedures. 
 
 Polyamides will then be screened for the ability to suppress gene expression in cells by quantitative 
real-time RT-PCR (qRT-PCR).22 Specifically, we will examine the mRNA expression profiles of STAT5 
regulated genes BCL-XL, BCL-2, and CYCLIN-D1 in the presence of polyamides following induction of 
STAT5 activity by interleukin 3 (IL-3) in four different prostate cancer cell lines. A reduction in IL-3 induced 
expression is expected if a polyamide disrupts STAT5 activation of the gene under investigation. 
Mismatch polyamides will serve as a negative control, while STAT5 siRNA known to inhibit expression of  
all three target genes will be used as a positive control for comparison.8 Since constitutive STAT5 
activation is most prevalent in cells expressing an 
androgen independent phenotype, cell lines for 
this experiment were selected based on 
androgen dependence (Table 2). Polyamide 
binding is expected to impart a greater change on 
gene expression in androgen independent cell 
lines C4-2 and DU145 than on androgen 
sensitive LNCaP cells. PC-3 cells do not express 
STAT5 and are included as a negative control for 
STAT5 regulated gene expression.  
 
 The global effects of polyamide treatment on prostate cancer cells will be investigated through 
chromatin-immunoprecipitation coupled with sequencing (ChIP-seq) and cellular mRNA sequencing 
(RNA-seq). To probe the mechanism of polyamide induced gene suppression in prostate cancer cells, 
ChIP-seq will be conducted to assess STAT5 occupancy in nuclear chromatin. In the absence of 
polyamide or in the presence of the mismatched control, amplification of DNA isolated from anti-STAT5 
antibody (purchased from Santa Cruz) pull-down is expected, demonstrating normal STAT5–DNA 
binding. A decrease in pull-down efficiency from polyamide treated cells would support an inhibitory 
mechanism in which displacement of STAT5 is attributable to polyamide binding to gene promoters. 
Isolated DNA will be submitted to high throughput sequencing using the Illumina Genome Analyzer at 
Caltech. Sequencing results mapped to the human genome will be compared between the untreated, 
mismatch control, and match polyamide experiments to identify specific genomic sites susceptible to 
polyamide-mediated STAT5 displacement. A consensus polyamide binding site will also be 
characterized, providing valuable insight as to the sequence specificity of the polyamide. The global effect 
of polyamides on gene expression can be evaluated using RNA-seq. STAT5 activity will be induced in 
cells with IL-3, then either (1) left untreated, or treated with (2) mismatch polyamide, (3) polyamide, or (4) 
STAT5 siRNA. Total mRNA will be isolated from each experiment, sequenced, and scanned for a 2-fold 









LNCaP sensitive + ATCC 
C4-2 independent + UroCor Labs 
DU145 independent + ATCC 
PC-3 independent - ATCC 
Table 2. Proposed prostate cancer cell lines. 
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a subset of STAT5 regulated genes will be supported if fewer IL-3 induced transcripts are affected by 
polyamide than by siRNA. A sequence specific mechanism of polyamide mediated perturbation is also 
supported if the mismatch control suppresses fewer induced gene transcripts than the matched 
polyamide. 
 
AIM 3. Investigate polyamide induced apoptosis in prostate cancer cell lines and in mice bearing 
xenograft tumors. 
 
 The effect on cell apoptosis of the proposed polyamides will be evaluated in each of the prostate 
cancer cell lines mentioned above. Cells will be incubated with varying concentrations of polyamide, then 
the effect on cell cycle population analyzed by flow cytometry, caspase-3 activity, and cleaved poly ADP 
ribose polymerase (PARP) expression.2,53 Polyamide induced apoptosis would be characterized by dose-
dependent increases in the fraction of cells in the sub-G0/G1 phases of the cell cycle, caspase-3 activity, 
and in the expression of cleaved PARP. STAT5-negative PC-3 cells will serve as a necessary negative 
control. The selectivity of polyamide induction of apoptosis in cancerous versus normal cell lines will be 
determined by comparing these results to those found in an analogous experiment on HUVEC and NHDF 
cell lines.  
 
 Polyamide effects on the C4-2 cell line will be further studied in an in vivo murine model. All 
experiments are to be conducted at the Caltech Animal Facility following the experimental procedures 
outlined in the IACUC protocol of the Dervan laboratory (#1638-11, date of approval: 9/21/11). Male 
immunocompromised mice will be injected subcutaneously (s.c.) with up to 107 C4-2 cells in PBS. 
Following a 1-2 week tumor engraftment period, Py/Im polyamides will be injected intraperitoneally (i.p.) 
at doses not exceeding 40 mg/kg over the course of up to 12 weeks. The animals will be injected with 
polyamide up to three times a week with a resting period of at least onea day between injections. A 
vehicle-treated reference control group will be maintained throughout the experiment. Recent 
investigations conducted in the Dervan laboratory showed that micromolar concentrations of polyamide in 
murine blood could be achieved following i.p. injection of polyamides with varying sequences.57,58 Tumor 
volume will be monitored at least once a week using caliper measurements. Retro-orbital blood samples 
will be collected weekly and levels of tumor-specific secreted factor PSA measured by enzyme-linked 
immunosorbent assay (ELISA). After four weeks of polyamide treatment, the mice will be sacrificed by 
asphyxiation (CO2 chamber, 60%). Tumors will be excised and sectioned for histological blood vessel 
quantification. RNA-seq experiments will further be conducted to determine global polyamide effects on 
the tumor transcriptome in comparison to the vehicle treated group. 
  
Potential Problems with this Proposal 
 
 Three possible problems with this proposal are presented and addressed. 
 
(i) The proposed polyamides are not sufficiently specific to be considered therapeutic candidates for the 
selective inhibition of STAT5 in the context of the human genome. 
 
 The human genome likely contains over a million potential binding sites for a compound that targets 
six base pair sequences. However, many of these sites are inaccessible in the context of nuclear 
chromatin. Boyle and coworkers have shown using DNase I hypersensitivity maps that only 2.1% of the 
genome is accessible in CD4+ T-cells.66 Moreover, polyamide binding at non-promoter sequences of 
accessible DNA does not affect transcription, as RNA polymerase dislodges polyamides from DNA during 
transcription.67 Despite the prevalence of six base pair sequences targeted by 8-ring polyamides in the 
genome, the HIF-1 studied mentioned above shows that polyamides have a relatively small effect on 
global gene expression. 
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(ii) The STAT family of proteins share a similar DNA binding domain, so polyamides designed to target a 
six base pair STAT5 sequence will invariably target other members of the family of transcription 
factors. 
  
STAT5 and STAT3 site sequences share the most 
homology (5’-TTCNNNGAA-3’ and 5’-TTCCNGGAA-3’, 
respectively) among the STAT family.68 Polyamides 1 and 2 
target STAT consensus sequences with at least two 
mismatched sites and are expected to be selective for 
STAT5 over STAT3. Polyamide 3 matches the STAT3 
consensus when N=W and will likely inhibit some binding of 
both STAT3 and STAT5 to the cognate sequence. 
Comparison of the gene regulatory activity of polyamides 1-3 
will allow us to analyze selectivity of the proposed 
polyamides. Binding specificity could be improved by 
expanding the Py/Im core to target seven or eight base pair 
sequences (Figure 7).  However, disruption of STAT3 
activated gene expression would not necessarily be an 
undesired consequence of polyamide binding, as constitutive STAT3 activity has also been implicated in 
the malignant phenotype of numerous cancers.32 For this reason, polyamide 3 was deliberately included 
in this proposal.  
 
(iii) Inhibition of STAT5 target gene expression is not selective for cancer cells. 
 
 CRPC tumors are dependent upon persistent STAT5 activity for malignant cell growth and survival. It 
has been suggested that even partial inhibition of STAT5 mediated transcription would be fatal to tumor 
cells as a consequence of this increased STAT5 dependence.32 Normal cells could plausibly survive with 
low levels of active STAT5 or utilize other survival pathways. Indeed, even STAT5 null mice remain 
viable, despite impaired mammary gland development and abnormalities in hematopoiesis.36,69 
Conversely, disruption of STAT5 signaling in tumor cells causes massive apoptosis. Aim 3 will provide a 




 The primary aim of this proposal is the development of a small library of polyamides designed to 
inhibit the binding of STAT5 to its cognate promoter site sequences. We hypothesize that the disruption of 
STAT5 binding events should suppress gene expression necessary for tumor cell growth and survival, 
resulting in apoptosis of CRPC cells. Inhibition of STAT5 transcriptional activity at the protein–DNA 
interface represents a new approach toward the treatment of CRPC. Accordingly, extensive 
experimentation has been proposed to fully elucidate the binding affinities and specificities of polyamides 
1-3 for the cognate DNA sequences, to determine if the polyamides are able to traffic to the nucleus, and 
to quantify the effect of polyamide treatment on gene expression in prostate cancer cells. The ability of 
polyamides to reduce the viability of cancer cells will then be examined in cell lines and in mice bearing 
xenograft tumors. Results of these studies will reveal the therapeutic potential of polyamides in the 
treatment of CRPC and contribute to the understanding of STAT5 signaling in prostate cancer cells.  
 
 
Figure 7. Polyamide modifications: 
extended hairpins targeting 7 bp 
sequences of CYCLIN-D1 promoter. 
IPA + +
IPA + +
G W W C W W G G W W
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LIST OF ABBREVIATIONS 
 
Ac2O    Acetic anhydride 
AcCl    Acetyl Chloride 
AcOH    Acetic acid   
AIBN    Azobisisobutyronitrile 
AQN    Anthraquinone 
ATP    Adenosine-5’-triphosphate 
9-BBN    9-Borabicyclo[3.3.1]nonane 
Bn    Benzyl 
BnBr    Benzyl bromide 
Boc    tert-Butoxycarbonyl 
Boc2O    Di-tert-butyldicarbonate  
BOMCl   Benzyloxymethyl chloride 
BOP (Benzotriazol-1-yloxy)tris(dimethylamino) phophonium 
hexafluorophosphate 
CbzCl    Benzyl chloroformate 
cod    1,5-Cyclooctadiene 
CREB    cAMP response element-binding 
d    Day 
Davis’s oxaziridine  2-(Phenylsulfonyl)-3-phenyloxaziridine 
DEAD    Diethyl azodicarboxylate 
Dess-Martin or DMP  Triacetoxy o-iodoxybenzoic acid 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DHQD    Dihydroquinidine 
DIBAL-H   Diisobutylaluminium hydride 
DMAP    4-(Dimethylamino)-pyridine 
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DMDO   Dimethyldioxirane 
DME    Dimethoxyethane 
DMF    Dimethylformamide 
DMS    Dimethylsulfide 
DMSO    Dimethyl sulfoxide 
dppf    1,1’-Bis(diphenylphosphino)ferrocene 
DTBMP   2,6-di-tert-butyl-4-methylpyridine 
EDCI    N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
ee    Enantiomeric excess 
e.r.    Enantiomeric ratio 
Et3N    Triethylamine 
EtOAc    Ethyl Acetate 
Et2O    Diethyl ether 
EtOH    Ethanol 
Fmoc    Fluorenylmethyloxycarbonyl 
FmocOSu 9-Fluorenylmethyl N-succinimidyl carbonate, N-(9-
fluorenylmethoxycarbonyloxy)succinimide 
GSH    Glutathione 
h    Hour 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HIF-1 Hypoxia-inducible factor 1 
hν Irradiation with light 
iBu    Isobutyl 
iPr    Isopropyl 
iPr2NEt   N,N-Diisopropylethylamine 
Imid    Imidazole 
KOtBu    Potassium tert-butoxide 
LDA    Lithium N,N-diisopropylamide 
LHMDS            Lithium bis(trimethylsilyl)amide 
mCPBA   m-Chloroperbenzoic acid 
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Me    Methyl 
MeCN    Acetonitrile 
MeI    Methyl iodide 
MeOH    Methanol 
min    Minute 
MOMCl   Methyl chloromethyl ether 
MRSA    Methicillin-resistant Staphylococcus aureus 
MsCl    Methanesulfonyl chloride 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NaHMDS   Sodium bis(trimethylsilyl)amide 
NBS    N-Bromosuccinimide 
NCS    N-Chlorosuccinimide 
NIS    N-Iodosuccinimide 
nBuLi    n-Butyllithium 
N-PSP    Diphenyl diselenide 
O/N    Overnight 
Pd(OAc)2   Palladium(II) acetate 
Pd/C    Palladium on carbon 
Ph    Phenyl 
PhI(OAc)2   Iodobenzene diacetate 
PhMe    Toluene 
PPTS    Pyridinium p-toluenesulfonate 
PPY (R)-(+)-4-pyrrolidinopyridinyl(pentamethylcyclo-
pentadienyl)iron 
Py. or Pyr.   Pyridine 
No Rxn   No reaction was observed 
RT or r.t.   Room temperature 
Sat’d    Saturated aqueous solution 
T3P    Propane phosphonic acid anhydride 
TBAF    Tetrabutyl ammonium fluoride 
TBDMSCl or TBSCl  tert-Butyldimethylsilyl chloride 
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TBDPS   tert-Butyldiphenylsilyl 
TBSOTf   tert-Butyldimethylsilyl trifluoromethanesulfonate 
Teoc    2-(trimethylsilyl)ethoxycarbonyl 
TES    Triethylsilyl 
Tf    Trifluoromethanesulfonate 
TFA    Trifluoroacetic acid 
TFAA    Trifluoroacetic anhydride 
Tf2O    Trifluoromethanesulfonyl anhydride 
THF    Tetrahydrofuran 
TIPS    Triisopropylsilyl 
TLC    Thin layer chromatography 
TMS    Trimethylsilyl 
TMSOTf   Trimethylsilyl trifluoromethylsulfonate 
Tr    Trityl (triphenylmethyl) 
Triton B   Benzyltrimethylammonium hydroxide 
pTsOH or pTSA p-Toluenesulfonic acid 
µw  Microwave irradiation 
V-70  2,2’-Azobis(4-methoxy-2,4-dimethyl valeronitrile) 
VRE  Vancomycin-resistant Enterococcus 
	  
